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bAckgRounD
Average life expectancy at birth in the Organisation for Economic Co-operation and De-
velopment (OECD) countries increased from 77.1 in 2000 to 80.2 years in 20121. While 
life expectancy is increasing, expenditures on health increased as well during the past 
decade and not only in absolute terms. In 2000, countries spent on health on average 
7.7% of gross domestic product (GDP) and this increased to 9.3% of GDP in 2012. In 
OECD countries, most health expenditures are public expenditures (on average 72.2%). 
In 2012, the Netherlands spent 11.8% of GDP on health which was 70,514 billion, life 
expectancy was 81.2 years. Due to the development of new medical technologies and 
ageing of the population, health care expenditures in general2 and for cancer in particu-
lar3 are likely to increase further.
Most health expenditures are publicly financed. However, health expenditures are 
not the only public expenditures and expenditures on health have to compete with 
spending on for example social security, education, and infrastructure. In addition, 
although patients demand access to all health care programmes available, the scarcity 
of resources necessitates that political choices have to be made4. These choices are 
not limited to choices between different areas of public spending. Also within health 
care, choices have to be made since, for example, money spent on patients with cancer 
cannot be spent on patients with cardiovascular diseases or elderly care. 
Given that health is such an important matter for every human and that political deci-
sions usually have far-reaching consequences for individuals, the allocation of resources 
requires careful consideration preferably based on transparent and unbiased data. Cost 
in relation to the expected outcomes are most important in health technology assess-
ment (HTA)5. HTA is a policy approach that examines the short- and long-term social 
consequences of the application or use of a health technology4,6. Health technologies 
include drugs, procedures, devices, and health programmes7,8. The main dimensions of 
HTA are presented in Figure 1.1 and include organisational, clinical, economic, and pa-
tient-related aspects6. Organisational aspects of health technologies include the uptake 
(i.e. whether a technology is adopted in daily practice), accessibility (i.e. whether the 
technology is available for patients who may benefit), and utilisation (i.e. how many pa-
tients receive the technology, by which regimen and in what frequency). Clinical aspects 
include the efficacy, effectiveness and safety of a technology. Economic aspects include 
costs, including budget impact, and cost-effectiveness of health technologies. Finally, 
patient-related aspects involve social impact, ethics and patient related outcomes. For a 
long time, HTA was mainly based on evidence from randomised controlled trials (RCTs). 
However, more recently, there is growing interest in HTA based on real-world data7.
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DATA fRom RAnDomisED conTRoLLED TRiALs 
VERsus REAL-WoRLD DATA
RCTs are considered the golden standard for establishing efficacy since these stud-
ies demonstrate whether the treatment works and is safe under optimal and highly 
controlled circumstances7. Although RCTs ensure internal validity by ensuring optimal 
and highly controlled circumstances, the results are not generalisable to the context of 
care in daily practice (i.e. external validity). Technologies may not be adopted, adopted 
under different circumstances or applied to patients who do not fulfil the inclusion cri-
teria of studies9. As a consequence, efficacy as demonstrated in RCTs will most certainly 
differ from effectiveness in daily  practice10,11. Since RCT data might not be sufficient for 
making decisions in daily practice, real-world evidence is increasingly requested7. 
Real-world data are not collected through conventional RCTs but from real-world  prac-
tice (i.e. not under controlled circumstances)7. Population based disease registries may 
provide a convenient way to collect real-world data12,13. Real-world data allow studying 
the organisational, clinical, economic and patient-related aspects of HTA. For example, 
evidence can be obtained on the uptake, accessibility and utilisation under daily practice 
circumstances. Furthermore, real-world data provide generalisable effectiveness and 
cost-effectiveness estimates of technologies. While findings from real-world data are of 
more practical value to health care decision makers, using real-world data also imposes 
methodological challenges due to the absence of random treatment assignment and 
uncontrolled circumstances. As a consequence, the evidence base regarding the actual 
added value of real-world data compared to RCTs is currently inconclusive. This thesis 
evaluates the added value of real-world evidence for health care decision makers.
figure 1.1 The dimensions of health technology assessment 
Health technology assessment
Organisational
aspects
e.g.
- Uptake
- Accessibility
- Utilisation
Clinical 
aspects
e.g.
- Efficacy
- Effectiveness
- Safety
Economic 
aspects
e.g.
- Cost
- Cost-effectiveness
Patient-related 
aspects
e.g.
- Social impact
- Ethics
- Patient-related 
outcomes
Adapted from Draborg et al.6
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cAncER AnD hAEmAToLogicAL mALignAnciEs
The study of the main dimensions of HTA is especially relevant for disease areas with 
high treatment costs, rapid introduction of innovative technologies and rising incidence 
rates. In developed countries, cancer is a disease area that fulfils these criteria and 
delivering high quality and accessible care for patients with cancer is a challenge for 
decision makers3. First, cancer is a severe, often fatal disease and has a major impact 
on many people. Decisions regarding reimbursement of cancer treatment have far 
reaching consequences and are constantly the subject of public debate14. Second, the 
economic burden of cancer is high and expected to increase. In the European Union 
the economic burden of cancer was calculated to be €126 billion in 2009, €51 billion 
of which were health care costs15. Spending on cancer care is expected to increase due 
to ageing, improved diagnostics and treatment advances. For example, conventional 
chemotherapy, introduced during the second half of the twentieth century, improved 
the outcomes of patients with cancer and a much greater step forward is expected from 
the introduction of immunotherapy (i.e. therapies that stimulate the immune system 
to destroy tumours) and targeted therapies (i.e. therapies that target critical molecular 
pathways of tumours)16. However, these treatment advances are also associated with 
higher cost. For example in the Netherlands, the costs for expensive inpatient cancer 
drugs were €376 million in 2011 and increased to €675 million in 201417. 
Malignancies of blood, bone marrow and lymph nodes, the so called haematologi-
cal malignancies are a likely target for HTA. The previously mentioned criteria show an 
enormous development in technology and survival. Many patients with haematological 
malignancies are cured but, treatment also aims for prolonging survival without cure, 
especially in older people. Incidence for most haematological malignancies increases 
with age; the median age at diagnosis is above 65 years18. Although haematological ma-
lignancies are more prevalent among the elderly, very few RCTs focus on older patients. 
For example in non-Hodgkin lymphoma, only 10% of the RCTs focused on older patients 
and in 25% of the RCTs, patients were excluded if they were older than 65 years19. As 
a consequence, and for reasons discussed earlier, efficacy evidence from RCTs and 
economic evaluations based on RCT data in haematology will not provide sufficiently 
relevant information for health care decision makers. Data from real-world studies are 
eagerly awaited for health care decision makers. Therefore, haematological malignan-
cies was selected as case study for evaluating the  added value of real-world evidence.
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ThE PhARos-REgisTRy
Real-world data of patients with haematological malignancies were available from the 
Population-based Haematological Registry for Observational Studies (PHAROS-regis-
try)20,21. This Dutch registry was initiated in 2010 for three haematological malignancies: 
chronic lymphocytic leukaemia, non-Hodgkin lymphoma and multiple myeloma. Newly 
diagnosed patients were included from three Dutch regions; these regions cover 40% 
of the Netherlands21. Detailed real-world data of the PHAROS-registry (i.e. patient and 
disease characteristics, diagnostics, treatments, response to treatment and health 
care utilisation) supplemented the data of the Netherlands Cancer Registry (i.e. date 
of birth, sex and date of incidence)22 The PHAROS-registry was set up to measure and 
improve the quality of haematological care and to provide a basis for assessing the 
cost-effectiveness of new treatments in a real-world setting. 
objEcTiVEs
This thesis evaluates the added value of real-world evidence for health care decision 
makers regarding organisational, clinical and economic aspects of HTA. As a start, the 
shortcomings of evidence derived from RCTs are explored. Further insights in the added 
value of real-world evidence are obtained by addressing the different aspects of HTA 
using real-world data. Practical guidance is provided for how to best use real-world 
data. The main potentials, including the development of a full disease model, as well as 
the methodological challenges are described in detail. 
This thesis addresses the following research questions:
1) What are the shortcomings of evidence from randomised controlled trials for health 
care decision makers?
2) What is the added value of real-world evidence for health care decision makers 
regarding 
 A) organisational aspects of health technology assessment?
 B) clinical aspects of health technology assessment? 
 C) economic aspects of health technology assessment? 
3) What are the main methodological challenges for using real-world data to inform 
health care decision makers?
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ouTLinE
This thesis consists of three parts. Part 1 includes Chapter 2 and reports on the limi-
tations of RCT evidence for health care decision makers. A cost-effectiveness analysis 
based on RCT data for a novel treatment is presented. This study illustrates the difficul-
ties in determining value for money for health care decision makers based on RCT data. 
Part 2 focuses on the organisational, clinical and economic aspects of HTA using real-
world data and consist of the Chapters 3, 4, and 5. Chapter 3 reports on the uptake, 
accessibility and utilisation of an expensive drug (i.e. bortezomib) in the Netherlands. 
This chapter illustrates how organisational aspects of HTA can be investigated with real-
world data. Chapter 4 illustrates how economic aspects of HTA can be studied with 
real-world data and describes a real-world study on the costs of treatment (i.e. stem 
cell transplantations). In this chapter, a comparison between the costs in daily clinical 
practice and reimbursement is made. Both clinical and economic aspects of HTA are ad-
dressed in Chapter 5. In this chapter, the real-world effectiveness and cost-effectiveness 
of an expensive drug is presented on both RCT and real-world data. 
Part 3 of this thesis provides practical guidance on using real-world data and highlights 
the methodological challenges for obtaining real-world evidence. Chapter 6 illustrates 
how real-world data can be used for HTA and describes methodological challenges and 
possible solutions for using real-world data. One of the potentials of real-world data is 
to develop full disease models and to study treatment sequences. This is illustrated in 
Chapter 7 and Chapter 8. 
Finally, Chapter 9 discusses the main findings regarding organisational, clinical and 
economic aspect of HTA and the added value of real-world evidence for health care 
decision makers.

Chapter 2
Lenalidomide for the treatment of low- or intermediate-1 
risk myelodysplastic syndromes associated with deletion 
5q cytogenetic abnormality: an evidence review of the 
NICE submission from Celgene.
Blommestein HM, Armstrong N, Ryder S, Deshpande S, Worthy G, Noake C, 
Riemsma R, Kleijnen J, Severens JL, Al MJ
PharmacoEconomics. 2015 Aug 28. [Epub ahead of print]
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AbsTRAcT 
The National Institute for Health and Care Excellence (NICE) invited the manufacturer of 
lenalidomide (Celgene) to submit evidence of the clinical and cost-effectiveness of the 
drug for treating adults with myelodysplastic syndromes (MDS) associated with deletion 
5q cytogenetic abnormality, as part of the Institute’s single technology appraisal (STA) 
process. Kleijnen Systematic Reviews Ltd (KSR), in collaboration with Erasmus University 
Rotterdam, was commissioned to act as the Evidence Review Group (ERG). This paper 
describes the company’s submission, the ERG review, and the NICE’s subsequent deci-
sions. 
The ERG reviewed the evidence for clinical and cost-effectiveness of the technology, 
as submitted by the manufacturer to the NICE. The ERG searched for relevant additional 
evidence and validated the manufacturer’s decision analytic model to examine the 
robustness of the cost-effectiveness results. 
Clinical effectiveness was obtained from a three-arm, European randomised phase III 
trial among red blood cell (RBC) transfusion-dependent patients with low-/intermedi-
ate-1 risk del5q31 MDS. The primary endpoint was RBC independence for ≥26 weeks, 
and was reached by a higher proportion of patients in the lenalidomide 10 and 5mg 
groups compared with placebo (56.1 and 42.6 vs 5.9%, respectively; both p<0.001). 
The option of dose adjustments after 16 weeks due to dose-limiting toxicities or lack of 
response made long-term effectiveness estimates, unreliable, e.g. overall survival (OS). 
The de novo model of the manufacturer included a Markov state-transition cost-utility 
model implemented in Microsoft Excel. The base case incremental cost-effectiveness 
ratio (ICER) of the manufacturer was £56,965. The ERG assessment indicated that the 
modelling structure represented the course of the disease; however, a few errors were 
identified and some of the input parameters were challenged. In response to the ap-
praisal documentation, the company revised the economic model, which increased the 
ICER to £68,125 per quality-adjusted life-year. The NICE Appraisal Committee (AC) did 
not recommend lenalidomide as a cost-effective treatment. Subsequently, the manu-
facturer submitted a Patient Access Scheme (PAS) that provided lenalidomide free of 
charge for patients who remained on treatment after 26 cycles. This PAS improved the 
ICER to £25,300, although the AC considered the proportion of patients who received 
treatment beyond 26 cycles, and hence the ICER to be uncertain. 
Nevertheless, the AC accepted a commitment from the manufacturer to publish, 
once available, data on the proportion of patients eligible for the PAS and believed 
this provided reassurance that lenalidomide was a cost-effective treatment for low- or 
intermediate-1 risk MDS patients. 
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inTRoDucTion
The National Institute for Health and Care Excellence (NICE) is an independent organisa-
tion providing national guidance on promoting good health and preventing and treating 
ill health23. The single technology appraisal (STA) process is designed to provide recom-
mendations and guidance on a single product, device or other technology with a single 
indication. The process covers new technologies and enables the NICE to produce guid-
ance shortly after the technology is introduced in the United Kingdom (UK). The NICE 
Appraisal Committee (AC) obtains relevant evidence from several sources: the manu-
facturer’s submission (MS), a report from the appointed independent Evidence Review 
Group (ERG) and advice from consultees (i.e. experts and other stakeholders). The MS 
includes a written report and a mathematical model that describe the clinical and cost-
effectiveness of the technology under investigation. The ERG, an external organisation 
independent of the NICE, reviews the MS and produces a report. After consideration 
of all the relevant evidence, the AC formulates preliminary guidance in the form of the 
Appraisal Consultation Document (ACD) as to whether to recommend the intervention. 
The stakeholders are invited to comment on this ACD and the submitted evidence. A 
subsequent ACD may be produced or a Final Appraisal Determination (FAD) issued. The 
submission of a Patient Access Scheme (PAS) is allowed in order to allow the NICE to 
recommend treatments that would otherwise not have been found to be cost-effective. 
The PAS is a means of reducing the price of the drug by some means, e.g. simple dis-
count or other formula, and has to be agreed by the Department of Health. This paper 
presents a summary of the ERG report and the development of NICE guidance based 
on the findings of the AC for the STA of lenalidomide for treating myelodysplastic syn-
dromes (MDS) associated with deletion 5q (del5q) cytogenetic abnormality. Full details 
of all the relevant appraisal documents can be found on the NICE website24. This is one 
in a series of STA summaries being published in Pharmacoeconomics25-30. 
ThE DEcision PRobLEm
MDS are a heterogeneous group of haematological disorders in which the bone marrow 
functions abnormally, causing peripheral blood cytopenia due to insufficient produc-
tion of mature blood cells31. MDS can affect red blood cells (RBCs), white blood cells 
(WBCs) and platelets, resulting in anaemia, increase in bleeding, infection and disease 
transformation to acute myeloid leukaemia (AML)32. The quality of life of patients with 
MDS is impaired due to symptoms such as fatigue and dyspnoea as well as treatments 
involving hospitalisations with drug administration and blood transfusions. As reported 
in 2003, the incidence is approximately 4 per 100,000 population but rises to >30 per 
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100,000 in the over 70 years age group33. In the UK, there are approximately 11,200 
patients diagnosed with MDS34, a condition that is mainly caused by cytogenetic abnor-
malities found in marrow cells. The most common cytogenetic abnormality, present in 
approximately 15% of patients with MDS, is del5q35. 
Currently, there is no active treatment available for patients with MDS del5q since 
stem cell transplantations or treatment with azacitidine are not recommended for 
this patient group33. Patients receive best supportive care (BSC), which includes blood 
transfusions to control symptoms associated with bone marrow failure and antibiotics 
to treat or prevent infection. In addition, growth factors such as erythropoietin and/or 
granulocyte colony-stimulating factors to stimulate the production of RBCs and WBCs 
are prescribed. 
Lenalidomide was already available in the UK for the treatment of relapsed refrac-
tory multiple myeloma. In 2013 the European Medicines Agency extended the market 
authorisation of lenalidomide to include patients with transfusion-dependent anaemia 
due to low- or intermediate-1 risk MDS associated with del5q when other therapeutic 
options were insufficient or inadequate36. Lenalidomide is an oral therapy that aims to 
reverse transfusion dependence. 
NICE developed a scope for the assessment of lenalidomide, which specified that the 
clinical and cost-effectiveness of this drug should be established, relative to BSC for the 
treatment of patients with transfusion-dependent anaemia due to low- or intermedi-
ate-1 risk MDS associated with del5q cytogenetic abnormality with or without other 
cytogenetic abnormalities. 
ThE inDEPEnDEnT ERg REViEW
Kleijnen Systematic Reviews Ltd (KSR), in collaboration with Erasmus University Rot-
terdam, acted as the ERG. The ERG reviewed the evidence on the product’s clinical and 
cost-effectiveness among low- or intermediate-1 risk MDS del5q patients as submitted 
by the manufacturer (Celgene). The review embodied three aims:
- to assess whether the MS conformed to the methodological guidelines issued by the 
NICE23
- to assess whether the manufacturer’s interpretation and analysis of the evidence 
was appropriate
- to indicate the presence of other sources of evidence or alternative interpretations 
of the evidence that could help to inform NICE guidance
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The ERG critically reviewed the MS, conducted additional searches, explored the impact 
of assumptions on the incremental cost-effectiveness ratio (ICER), revised the economic 
model and explored additional scenario analyses. The ERG review detailed here relates 
to the evidence contained in the original MS and additional information submitted by 
the manufacturer in response to the clarification questions and ACD which included a 
PAS. 
clinical evidence
The MS included a systematic review of the literature on the clinical effectiveness 
of lenalidomide. Evidence on the efficacy of lenalidomide was extracted from the 
MDS-004 trial, a phase III, multicentre, randomised, double blind, placebo controlled 
study37. Adult patients with low- or intermediate-1 risk MDS with del5q, with or with-
out additional cytogenetic abnormalities and RBC transfusion-dependent anaemia 
(N=205) were randomly assigned to three arms: lenalidomide 10 mg on days 1–21, 
lenalidomide 5 mg on days 1–28, or placebo on days 1–28 for each 4-week cycle. BSC 
included blood transfusions that were provided to all transfusion-dependent patients 
as required. If dose-limiting toxicities occurred, the dose of lenalidomide was reduced. 
Crossover was allowed at 16 weeks if at least a minor erythroid response (i.e. a 50% 
decrease in transfusion requirements) was not achieved, and all but 11 patients on the 
placebo arm crossed over to lenalidomide 5 mg. Before crossover at 16 weeks, two 
patients (3%) in the placebo group, two (2.9%) in the lenalidomide 5 mg group and 
none in the lenalidomide 10 mg group progressed to AML. The primary endpoint was 
RBC transfusion independence for ≥26 weeks, which was reached in 56.1, 42.6, and 
5.9% of patients in the lenalidomide 10 mg, lenalidomide 5 mg and placebo groups, 
respectively. Transfusion-independent rates in both lenalidomide groups were different 
compared with placebo (p< 0.001). Median duration of transfusion independence was 
not reached in either lenalidomide group after a median follow up of 1.55 years. Of the 
patients who initially received placebo and crossed over to lenalidomide 5 mg, 30.4% 
progressed to AML, compared with 23.2% in the 5 mg group and 21.7% in the 10 mg 
group. Median overall survival (OS) was not statistically significantly different between 
the groups, and ranged from 35.5 to 44.5 months. 
Significantly higher proportions of treatment-emergent adverse events (AEs) were 
reported among patients treated with lenalidomide compared with placebo-treated 
patients. At least one drug-related AE was reported in 42% of the placebo group, 87% 
in the lenalidomide 5 mg group and 90% in the lenalidomide 10 mg group. The most 
frequent drug-related AEs were neutropenia (15% in the placebo group and 74% in each 
lenalidomide group) and thrombocytopenia (2% in the placebo group and 32 and 36% 
in the 5 mg and 10 mg groups, respectively). 
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Health-related quality of life (HRQoL) outcomes were assessed during the MDS-004 trial 
using the Functional Assessment of Cancer Therapy-Anemia (FACT-An) questionnaire, 
which was administered at baseline, and weeks 12, 24, 36 and 48. The EQ-5D was ad-
ministered at baseline only. Compared with placebo, treatment with lenalidomide was 
associated with improvements in HRQoL (FACT-An scores) during the initial 12 weeks of 
therapy. Improved HRQoL was maintained in patients who remained on double-blind 
treatment with lenalidomide. Among patients who switched from placebo to the le-
nalidomide 5 mg group, improved HRQoL was observed. 
critique of the clinical evidence and interpretation
According to the ERG, some of the literature searches of the manufacturer were unnec-
essarily restrictive. For AEs, other study designs could have been included and longer-
term data could have been sought. It was also not clear how studies were identified 
for inclusion. Nevertheless, the ERG was unaware of any relevant trials that had been 
missed, and agreed with the manufacturer that the MDS-004 trial was most likely the 
best source of clinical evidence for the effectiveness of lenalidomide versus BSC. 
Data extraction from the MDS-004 trial was reported for the intention-to-treat (ITT) 
population (N=205) as well as for the modified ITT (mITT) population (N=139). The 
primary reason for exclusion from the mITT was an inadequate bone marrow sample, 
preventing confirmation of the diagnosis of low- or intermediate-1 risk MDS del5q. The 
manufacturer considered the ITT to match more closely with the daily practice popula-
tion as defined in the NICE scope; therefore the rates from this population were used 
in the health economic model. Response rates for lenalidomide were based on the 
lenalidomide 10 mg group (60.9%) while the response rate in the model was 7.5% for 
the placebo group. Nevertheless, the ITT population included patients not fulfilling the 
inclusion criteria, i.e. del5q mutation and bone marrow morphology. 
Although serious infections were explicitly mentioned as a relevant outcome in the 
NICE scope, reporting on this outcome in the MS was minimal. Additional data were 
obtained from the clinical study report and showed that serious infections occurred in 
the lenalidomide groups twice as often as in the placebo group. 
Due to the crossover design after 16 weeks and dose reductions of the trial, the 
chances of detecting attributable prolonged survival or acceleration of leukaemia pro-
gression were limited. 
cost-effectiveness 
The manufacturer submitted a de novo economic evaluation on the cost-effectiveness 
of lenalidomide compared with BSC in low- or intermediate-1 risk MDS del5q patients 
who are transfusion-dependent. An Excel-based Markov model was developed with 
14 health states that reflected transfusion requirements, iron chelation, progression 
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to AML and complications associated with both transfusion dependency and iron 
chelation therapy. Patients responding to treatment became transfusion-independent 
while non-responders remained transfusion-dependent. As a simplifying assumption, 
all trial patients who responded, regardless of timing, were classed as responders from 
cycle 1 onwards. Transition probabilities for OS and progression to AML were assumed 
to be different for transfusion-dependent and -independent patients, and estimated 
based on the initial response for lenalidomide and BSC of the MDS-004 trial. Response 
rates for iron chelation therapy and iron overload complication rates were based on the 
literature38,39. 
Lenalidomide treatment (plus BSC) is compared with BSC, which was also the com-
parator in the MDS-004 trial. However, BSC in the trial consisted of blood transfusions 
only (plus chelation therapy when iron overload occurred) whereas BSC in the UK may 
also include the provision of erythropoietin stimulating agents (ESA) or ESA plus gran-
ulocyte-colony stimulating factors (G-CSF). The proportion of patients receiving ESA in 
the model was calculated from the proportion of UK patients in the MDS-004 trial who 
received ESA prior to the trial, i.e. 28%. Of the side effects associated with lenalidomide, 
only neutropenia and thrombocytopenia were included in the model since only these 
were considered serious enough by the manufacturer to warrant inclusion while also 
being different between the placebo and lenalidomide arms in the trial. Iron chelation is 
initiated to avoid complications associated with iron overload for transfusion-dependent 
patients. In the de novo model, patients received either desferrioxamine or deferasirox 
as iron chelation therapy. Since the number of patients included in the trial was in-
sufficient to obtain transition probabilities for AML mortality, transition probabilities 
were obtained from the adverse risk group in the article by Wahlin et al.40. No half-cycle 
correction was applied. The model had a National Health Service (NHS) perspective and 
time horizon of 20 years. Costs and effects were discounted at an annual rate of 3.5%. 
During the MDS-004 trial, quality of life was measured using the FACT-An at baseline 
and in weeks 12, 24, 36 and 48. However, the EQ-5D was measured at baseline only 
(i.e. when all patients were still transfusion-dependent) and therefore, EQ-5D data for 
transfusion-independent patients were not available. Therefore, utility values were 
obtained from the study by Szende et al.41. 
Drug acquisition prices were obtained from the British National Formulary (6 March 
2013), while the frequency of monitoring associated with the initiation of lenalidomide 
treatment was based on the summary of product characteristics. Monitoring visits were 
assumed to occur with a general practitioner (GP). Costs for lenalidomide were based 
on the dosing observed in the MDS-004 trial and manufacturer’s price quotations. 
An arbitrary standard error of 10% of the mean was assigned to those cost estimates 
without a standard error.
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The base case ICER (cost per quality-adjusted life-year (QALY) gained) was £56,965 per 
QALY gained (Table 2.1). The probabilistic sensitivity analysis (PSA) showed a 0% prob-
ability of the ICER being below £30,000 per QALY gained. Sensitivity analysis revealed 
that utility values, the proportion of patients experiencing dose interruptions, and the 
curve fitting for progression to AML and overall mortality were key parameters. Table 2.1 
shows the revised base case cost-effectiveness analysis, incorporating corrections and 
amendments identified by the ERG and AC. 
critique of the cost-effectiveness evidence and interpretation
The economic model described in the MS was considered, by the ERG, to meet the NICE 
reference case to a reasonable extent and was in line with the decision problem speci-
fied in the scope. However, the manufacturer’s description of the model did not match 
their own presented figure. The illogical (e.g. from health-state chelation failure to no 
chelation cardiac disease) and missing transitions (e.g. from health-state transfusion-
dependent chelation to transfusion-independent) were corrected by the ERG. 
The ERG challenged some of the assumptions of the manufacturer and therefore made 
the following adjustments in the ERG base case.
- A half-cycle correction was implemented since the first few cycles showed a very 
significant redistribution of patients over the various health states.
- Deferiprone, a third option for chelation therapy, was included in the model 
(Table 2.1). This slightly changed the costs per cycle for chelation therapy (from 
£1,383 to £1,332) but also influenced the QALYs since adding this third option in-
creases the proportion of patients receiving oral instead of intravenous chelation 
therapy (from 71 to 94.3%). 
- Standard errors without a standard deviation estimate were increased from 10 
to 20% of the mean for adverse events and complications. The standard errors of 
10% were considered too small by the ERG since more variation for costs is usually 
observed. 
- A programming error for the initial response rate for BSC was corrected.
- The effect of G-CSF, in addition to ESA, for non-responders to BSC was added. The 
initial response rate was used in the model of the manufacturer. G-CSF is only added 
to ESA for patients who initially do not respond to ESA. As a consequence, the model 
of the manufacturer did not include the effect of G-CSF for non-responders to BSC.
The revised base case ICER was £62,674 per QALY gained. The PSA results showed a 0% 
probability that the ICER was below £30,000 per QALY gained.
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Remaining concerns
Utilities were obtained from a study that included broad health state descriptions cov-
ering a range of health problems42. The manufacturer assumed that these descriptions 
adequately described the difference between the transfusion-independent and -depen-
dent health states. However, this was challenged by the ERG. In addition, the ERG raised 
questions on the assumption of similar utility values for transfusion-dependent and 
AML health states. The latter was accepted by the ERG since the impact of the utility 
value assigned to AML was minimal. Moreover, a reasonable alternative for health state 
utility values was unavailable. 
While the ERG was not entirely convinced that the definition of BSC fully reflects BSC 
within the NHS, the model outcomes were not very sensitive to changes in the propor-
tion of ESA use. 
Additional scenarios were explored by the ERG and these revealed that utility and 
cost parameters related to AML, complications and AEs have little to no effect on the 
ICER. The assumption that monitoring occurred with a GP was challenged by the ERG 
and therefore adjusted to monitoring by a haematologist in an additional scenario 
analysis together with revised progression rates to AML (Table 2.1).
conclusion of the Evidence Review group (ERg) report (before 
implementation of the Patient Access scheme [PAs])
According to the ERG there were two main problems with the clinical effectiveness data 
obtained from the MDS-004 trial and described by the manufacturer in the MS. First, 
the possibility of crossover after 16 weeks meant that most long-term effectiveness 
data were unreliable. Second, data were reported for two populations -the ITT and 
mITT- and it is not clear how differences between these populations influenced results. 
The manufacturer base case ICER was £56,965 per QALY gained, while the ERG base 
case, correcting for the various issues identified, estimated an ICER of £62,674 per QALY 
gained.
ERg research recommendations
The ERG concluded that further comparisons of lenalidomide and BSC are required in 
terms of long-term effectiveness, OS, AML progression and incidence of adverse events. 
The study on which utilities for the transfusion-related health states was based did not 
conform to the NICE reference case. In order to increase the robustness of the health 
economic outcome, a quality-of-life study among MDS patients would be of great value. 
Ideally, such a study would ask transfusion-dependent patients, as well as patients who 
have become transfusion-independent, to fill out the EQ-5D, after which outcomes 
would be valued using the UK tariff, which is based on the general population43.
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kEy mEThoDoLogicAL issuEs
Long-term effectiveness, including survival and progression to AML, was compromised 
by the crossover design of the trial at 16 weeks. The manufacturer stated that survival 
of patients with MDS is strongly related to transfusion dependency. In order to perform 
a life-time cost-effectiveness analysis, the model linked OS and progression to AML to 
transfusion dependency. Therefore, separate time-to-event curves for people who were 
transfusion-dependent or -independent at 8 weeks were estimated from the data of the 
MDS-004 trial. 
The relationship between survival and transfusion dependency was supported both 
by data from the MDS-004 trial (achieving transfusion independence was associated 
with a significant reduction in the risk of death (hazard ratio 0.53; 95% CI 0.31-0.90; 
p=0.019]) and the literature44,45. 
Utility values used in the model were not obtained according to NICE guidelines and, 
consequently, the committee needed to decide whether these were acceptable. The 
STA described here highlights the difficulties of relying on a single RCT with a cross-over 
design after 16 weeks. The key issue for a decision maker is whether or not these clinical 
and economic uncertainties cast sufficient doubt on any patient gain from taking the 
drug. 
nATionAL insTiTuTE foR hEALTh AnD cARE 
ExcELLEncE guiDAncE
key issues considered by the appraisal committee
Regarding effectiveness, the committee concluded that, on the basis of evidence on 
transfusion independence and HRQoL, lenalidomide is a clinically effective treatment for 
people with MDS associated with a del5q cytogenetic abnormality although uncertainty 
about whether lenalidomide improved survival remained. The committee concluded 
that the serious adverse events associated with lenalidomide could be partly managed 
by a reduction in dose. 
According to the committee, cost-effectiveness estimates from the model were un-
certain due to uncertainty in the survival estimates. In addition, there was uncertainty 
as to whether lenalidomide changed the rate of progression to AML. The committee ac-
cepted the utility values reported by Szende et al.41 after consulting the patient expert. 
In addition, the committee agreed with the adjustments of the ERG and considered that 
if the model applied similar rates of progression to AML for both treatment groups then 
the ICER would most plausibly exceed £70,000 per QALY gained. 
26 Chapter 2
Preliminary guidance (first appraisal consultation document [AcD])
After considering the initial evidence submitted by the manufacturer, the ERG report 
and the testimony of experts and other stakeholders, the AC concluded that lenalido-
mide could not be recommended for treating transfusion-dependent anaemia caused 
by low- or intermediate-1 risk MDS associated with a del5q cytogenetic abnormality 
when other treatments fail. 
Response to preliminary guidance (first AcD) and additional analysis 
submitted by the manufacturer
The manufacturer performed a systematic literature review (July 2013) to better 
highlight the association between transfusion independence and survival. The AZA-001 
trial46, which demonstrated improved survival after becoming transfusion-independent, 
was considered most convincing by the ERG. Overall, the committee concluded that 
while the strength of the relationship over time was uncertain, it was reasonable for 
the model to include a benefit in OS for patients treated with lenalidomide compared 
with BSC. Based on the additional submitted evidence47, the AC also concluded that 
progression to AML curves should be similar for both lenalidomide and BSC.
final guidance october 2013
Despite the additional analysis of the manufacturer, the committee did not change 
the guidance of the first ACD. In the FAD, they concluded that lenalidomide could 
not be recommended for treating transfusion-dependent anaemia caused by low- or 
intermediate-1 risk MDS associated with del5q cytogenetic abnormality when other 
therapeutic options were insufficient or inadequate. Given the uncertainties, the com-
mittee concluded that the most plausible ICER was above £70,000 per QALY.
PATiEnT AccEss schEmE
The proposed PAs 
The October 2013 FAD for lenalidomide was withdrawn after the submission of an 
approved PAS by the manufacturer. Under the PAS, the manufacturer would provide 
lenalidomide at no cost to the NHS for patients with transfusion-dependent low- or 
intermediate-1 risk MDS with isolated del5q abnormality who continued with lenalido-
mide treatment beyond 26 cycles. This PAS is similar to the existing PAS of lenalidomide 
for patients with multiple myeloma. The PAS therefore reduces the long-term drug costs 
for patients who receive more than 26 cycles of lenalidomide. A revised version of the 
model was submitted and reviewed by the ERG. The deterministic ICER with the PAS 
was £25,544. Minor adjustments to the sensitivity analysis were made by the ERG as 
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these were also made earlier in the ERG defined base case. At a threshold of £20,000 
per QALY, 26.2% of simulations were cost-effective and at a threshold of £30,000, 66.6% 
of simulations were cost-effective. The ERG reviewed the proposed PAS and economic 
model. No additional issues apart from those stated earlier were identified. 
Preliminary guidance (second AcD)
The main concerns raised by the AC were uncertainties with regard to the ICER. These 
uncertainties included patient survival, the proportion of patients eligible for the PAS, 
and the timing of the PAS rebate. These did not only influence the point estimate but 
also the cloud of possible outcomes around the ICER. For patient survival, the commit-
tee concluded that, despite uncertainty regarding the strength of the relationship, it 
was reasonable to assume a relationship between transfusion independence and OS. 
Therefore, it was plausible that lenalidomide indirectly improved survival by reducing 
transfusion dependence. The committee stated that treatment interruptions were not 
accounted for in the PAS and that the proportion of people surviving beyond 26 cycles 
in clinical practice was uncertain. Due to the nature of the PAS, cost reductions were ob-
tained from patients receiving treatment after 26 cycles. If this proportion is uncertain 
in daily practice, the potential cost savings from the PAS are also subject to uncertainty. 
As a consequence, the ICER could be much higher. As a response to the concerns related 
to the PAS, the manufacturer included treatment interruptions, leading to a longer 
period of time before the PAS comes into effect (26 cycles plus 16 days updated the 
ICER to £25,300). Additional evidence was provided by the manufacturer based on the 
MDS-004 trial and real-world data that supported the proportion of patients on ac-
tive treatment currently used in the model (31.9%). They also conducted an additional 
analysis on the proportion of patients eligible for the PAS, i.e. the proportion of patients 
on active treatment after 26 cycles. This showed that when 27% or more patients reach 
26 cycles of treatment, lenalidomide remains cost-effective at a threshold of £30,000 
per QALY. 
final guidance
After considering the available evidence from the manufacturer, the ERG, expert tes-
timony, and other consultees, the NICE AC decided to recommend lenalidomide for 
treating low- or intermediate-1 risk MDS associated with an isolated del5q cytogenetic 
abnormality when other therapeutic options were insufficient or inadequate. The com-
mittee agreed that the ICER was uncertain but accepted that a commitment from the 
manufacturer to publish data on the proportion of patients receiving treatment beyond 
26 cycles provided reassurance that lenalidomide was a cost-effective use of NHS re-
sources. 
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concLusions
The STA presented here describes the first treatment alternative for MDS del5q patients. 
Clinical evidence was obtained from a single randomised phase III trial with a crossover 
design after 16 weeks. The AC decided to accept lenalidomide as treatment for low- and 
intermediate-1 risk MDS del5q patients although the crossover design of the trial as well 
as the PAS increased the uncertainty of the ICER. A commitment from the manufacturer 
to collect data provided reassurance that the uncertainties surrounding the ICER can be 
reassessed when the guidance is reviewed. Nevertheless, the AC stated that if lenalido-
mide was not a cost-effective use of NHS resources, the foregone health benefits to 
other NHS patients until the review cannot be regained. This appraisal illustrated that 
the AC can accept a treatment as cost-effective under the acceptance of a commitment 
of the manufacturer to collect and publish data. This case study saw a PAS accepted by 
the Ministry of Health after the initial FAD. While lenalidomide for treating MDS patients 
with del5q cytogenetic abnormalities was initially not recommended, the PAS reduced 
the ICER substantially from approximately £68,100 to £25,300 per QALY. This changed 
the recommendation from the AC. The generalisability of the cost-effectiveness results 
to other countries depends on whether such a PAS is also introduced in these countries 
as well as the transferability of underlying utility and survival estimates. 
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Chapter 3
Access to expensive cancer drugs in Dutch daily practice: 
should we be concerned?
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AbsTRAcT
background: To investigate whether equal access to bortezomib has been achieved 
under the Dutch policy regulations that guarantee equal access to expensive inpatient 
drugs. 
methods: We investigated accessibility to bortezomib treatment at national and re-
gional levels by i) conducting interviews with stakeholders in the Dutch healthcare 
system to explore prescription barriers and ii) tabulating sales data from 2004-2009 
and trial participation rates. 
Results: Interviews revealed awareness of the high treatment costs, although prescrip-
tion barriers were not encountered. National use of bortezomib increased slowly 
(treating 2% of patients in 2004 to 17% in 2009), indicating a long adjustment period. 
Furthermore, use remains below the rate estimated by the professional association 
of haematologists (27%). Regional differences were found for both daily practice use 
(e.g. ranging from 13-27% in 2009) and clinical trial participation (e.g. ranging from 
1-12% in 2006). 
conclusion: Our results were somewhat conflicting: interviews did not reveal any 
prescription barriers, but quantitative methods showed regional differences, signs of 
underutilisation, and access inequality. Investigating use and accessibility, based on 
data triangulation, provides valuable feedback which can enhance evidence-based 
decision making for both physicians and policymakers. This could improve appropri-
ate and efficient use and ensure equal access to expensive drugs.
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inTRoDucTion
Increasing healthcare expenditures may result in limited and unequal access, par-
ticularly with regard to new and innovative cancer drugs with high acquisition costs. 
Policymakers have to make reimbursement decisions considering both rapid and equal 
accessibility to promising drugs as well as the scarcity of resources. Usually, guaran-
teeing rapid access means making decisions while available evidence on clinical- and 
cost-effectiveness is limited48. One way of dealing with the need for rapid access and 
limited evidence is the ‘coverage with evidence development’ policy; reimbursement 
under the condition that additional research will be conducted48,49. 
Such policies have been implemented in several countries for surgical procedures, 
medical devices and pharmaceuticals49. Over the last decade, a coverage with evidence 
development policy was also initiated in the Netherlands, partly triggered by signs of 
underutilisation and ‘zip code prescribing’ of trastuzumab50. Early access to expensive 
inpatient drugs is linked with the obligation to gather data on appropriate drug use and 
cost-effectiveness in daily practice51. Drugs meeting the criteria of added therapeutic 
value and expected budget impact of at least 2.5 million were temporarily included 
in the policy of 2006-2012. Four years after inclusion, a reassessment will determine 
whether or not additional financing should continue to exist. At the time we conducted 
our study, hospitals received 80% of its acquisition costs if a drug was included52. 
Currently more than 30, mostly cancer, drugs are included in this policy. One of these 
drugs is bortezomib, used for treating multiple myeloma (MM). MM is the second 
most common haematological cancer. The five-year prevalence in Western Europe 
is 31,056 while the annual age-standardised incidence rate is 3.2 per 100,000 (IARC 
GLOBOCAN 2008). Bortezomib obtained European Medicines Agency (EMA) approval 
in 2004 by demonstrating superior efficacy compared with chemotherapy for the treat-
ment of advanced MM53-55; it was included on the Dutch expensive drug list in 2006. 
Advances in MM treatment in the past decade significantly increased overall survival 
(44.8 vs 29.9 months56), which was largely due to the introduction of autologous stem 
cell transplantation and new therapeutic agents including thalidomide, lenalidomide, 
and bortezomib56,57. While thalidomide is relatively inexpensive, bortezomib and 
lenalidomide are expensive drugs. Both are incorporated in professional guidelines58. 
However, the orphan status granted to lenalidomide results in 100% reimbursement for 
lenalidomide compared with an 80% of reimbursement for bortezomib during our study 
period. Consequently, accessibility might be an issue, especially for bortezomib. Previ-
ous research studied accessibility and use of expensive drugs in the Netherlands59,60; 
however, it remains unclear whether the Dutch policy actually guarantees equal access 
to expensive inpatient drugs. We investigated whether equal access to bortezomib has 
been achieved in the Netherlands. We analysed bortezomib use patterns by means 
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of aggregate sales data and conducted interviews to shed light on perceived or real 
prescription barriers. 
mATERiALs AnD mEThoDs
We took a two-pronged approach. First, seven in-depth interviews were conducted to 
qualitatively investigate the existence of accessibility issues and prescription barriers. 
Interviewees were representatives of stakeholders in the Dutch healthcare system: i) 
a representative of the Dutch Healthcare Authority (NZa), ii) a representative of the 
Healthcare Inspectorate (IGZ), iii) a hospital director of finance, iv) four haematologists 
from hospitals varying in size and country location (the North-West, East, South-West, 
and South). Respondents were selected based on their involvement and knowledge of 
expensive inpatient drug regulations (NZa and IGZ) or geographical location and type of 
hospital (haematologists and director of finance). All semi-structured interviews were 
recorded and analysed according to the steps of Creswell61, including transcription, cod-
ing, interpretation, and description. 
Second, we quantitatively investigated the use of bortezomib in daily practice. Because 
data on bortezomib use at the individual patient level are not available, we combined 
Dutch sales data (excluding use in clinical trials) from 2004-2009 from the manufacturer, 
Janssen Pharmaceutical Companies of Johnson & Johnson, with incidence and preva-
figure 3.1 Flowchart of data input, intermediate and final outcomes
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lence data from the Netherlands Cancer Registry22. Figure 3.1 provides the flowchart 
of data used, intermediate and final outcomes and the underlying assumptions. To 
estimate the number of treated patients ((A) in Figure 3.1), the number of vials sold was 
divided by the average number of vials used per patient. The average number of vials 
per patient (18.24) was based on a Dutch observational study of 72 bortezomib patients 
treated in daily practice from 2004-200862. 
To investigate bortezomib use across regions, we used the regional division of the 
nationwide Netherlands Cancer Registry distinguishing eight Comprehensive Cancer 
Centres22. Since these regions differ in size, prescription rates were expressed relative to 
the number of patients per region. We assumed that equal accessibility to bortezomib 
would be achieved if the proportion of vials used per region was similar to their propor-
tion of national incidence or prevalence. Regional shares in incidence were calculated 
over the years 1989-2009. For example, the share in incidence in 2009 for Compre-
hensive Cancer Centre Amsterdam (IKA) was 18.8%. We calculated this percentage by 
dividing the incidence of IKA (201) by the national incidence (1069). 
Because prevalence numbers were only available for IKA (462 patients in 2004) for 
one year, we estimated other regional prevalence (B) from their relative shares in 
incidence. Hereby we assumed i) IKA to be representative for the other regions and ii) 
the share in incidence per region is equal to the share in prevalence (e.g. if IKA has 19% 
of the incidence it will also have 19% of the prevalence), and (iii) an annually increas-
ing prevalence of 2.5% (average annual increase over the years 1989-200922) per year 
because of rises in incidence57. Detailed additional information about incidence and 
prevalence estimates per year is available from the authors upon request.
To obtain a regionally comparable percentage of treated patients (C), we divided 
the estimated number of treated patients (A) by the estimated prevalence (B). To put 
regional percentages in perspective, we compared our computed use with the expected 
percentage of MM patients eligible for bortezomib treatment as estimated by the Dutch 
professional association of haematologists (the Dutch-Belgian Cooperative Trial Group 
for Haematology and Oncology (HOVON)). HOVON estimated that about 1600 patients 
would be eligible for MM treatment per year. Of these patients, one-third would not 
qualify for treatment with either bortezomib or lenalidomide due to age, the patient’s 
condition or preferences. As result, 1070 patients are eligible for advanced therapy 
each year.52 Since patients treated with bortezomib might also be eligible for treatment 
with lenalidomide and vice versa, HOVON assumed that the number of patients treated 
with each drug would be similar (50%). To compare the HOVON estimation with the 
proportion of patients treated with bortezomib per region, we divided the 535 eligible 
patients (i.e. 1070 divided by 2) by HOVON’s estimated prevalence (i.e. 2000 patients), 
resulting in an estimation of 27% patients. Furthermore, since bortezomib was a novel 
treatment, clinical trials were conducted during our years of investigation. Because 
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MM patients are often included in clinical trials, relatively high or low trial participa-
tion could distort our computed daily practice use and identified regional differences. 
Therefore, we selected the two largest clinical studies including bortezomib during our 
investigated time period and studied trial participation at the regional level. Calculation 
methods were similar: we divided the number of patients included in trials by regional 
prevalence to obtain regional trial participation rates for the years 2005-2009. We then 
combined trial participation with regional daily practice use to compare similarities and 
differences across regions.
REsuLTs
interview results
Interviewees of the NZa and IGZ did not reveal any accessibility issues for expensive 
drugs. The IGZ representative, however, admitted that the body had no active role in 
investigating such issues. Hospitals regulate financial management in various ways. As 
a result, it may differ per hospital who is responsible for the budget and who is making 
the financial decisions. According to the interviewed physicians, their financial depart-
ment divided the total hospital budget by department, whereas physicians organised 
the division and implementation of the budget within departments. These assumptions 
were verified and confirmed by the hospital financial manager. Based on these results, 
we concluded that in the studied hospitals financial management, of both treatment 
decisions and organisation of care, was the physicians’ responsibility. 
Generally, all physicians agreed that access to bortezomib is guaranteed in the Nether-
lands for patients in need. The existence of strict quantitative restrictions was explicitly 
denied. Physicians adhered to professional guidelines, as far as treatment is concerned, 
which were frequently mentioned as important. Consultation with colleagues and 
patient characteristics also seemed to be important factors in the decision (how) to 
treat. Apart from some variation immediately after the introduction of bortezomib, 
respondents believed that all eligible patients had equal access. 
The Dutch policy of 2006-2012 aimed to facilitate prescription and guarantee access 
while maintaining incentive for efficiency. According to haematologists, the effects of 
this policy were two-sided. An additional budget of 80% facilitated prescription but the 
remaining 20%, financed from the general hospital budget, could hinder prescription. 
The policy was therefore perceived as ambiguous: while the government relieved the 
high financial burden, the remainder still had to be financed from the general hospital 
budget. The situation stimulated local initiatives to manage access to expensive drugs, 
resulting in a local expensive drug committee to judge appropriate use and structures 
for consultations with more experienced physicians. Although expensive drugs were 
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perceived as a high financial burden, according to the respondents, budget played no 
role in treatment choices. 
Data results
Daily practice use.
Figure 3.2 presents the percentage of patients treated with bortezomib from 2004-2009 
irrespective of treatment line. As mentioned in the method section, HOVON estimated 
that 27% of MM patients are eligible for bortezomib treatment in daily practice. This is 
presented as a horizontal line in Figure 3.2. Figure 3.2 reveals relatively low use in 2004 
and 2005 for all regions, which was expected since bortezomib was then an innovative 
treatment and not included on the expensive drug list until 2006. Three regions did not 
use bortezomib in 2004; all regions used it in 2005. Differences across regions exist in 
all years with no stable pattern; sometimes regions switched from a high prescription 
rank in 2005 and 2006 to a low one in 2008. In 2008, two years after inclusion on the ex-
pensive drug list, differences between the regions decreased. In 2009, Comprehensive 
Cancer Centre East (IKO) was the highest prescribing region and Comprehensive Cancer 
Centre South (IKZ) the lowest, revealing that in one region 24% of patients received 
figure 3.2 Percentage of daily practice multiple myeloma patients treated with bortezomib per 
region from 2004-2009
1
2
4
10
14
16
0
5
4
9
16
18
5
7
17
13
10
16
5 5
7
9
13
18
0
3
5
16
14
24
2 2
6
11
16 17
1
1
3
7
13 13
0
4
9 9
12 13
2
4
7
10
14
17
0
5
10
15
20
25
30
2004 2005 2006 2007 2008 2009
Pe
rc
en
ta
ge
 o
f m
ul
tip
le
 m
ye
lo
m
a 
pa
tie
nt
s t
re
at
ed
 in
 d
ai
ly
 
pr
ac
tic
e
Year
IKA
IKL
IKMN
IKNO
IKO
IKR
IKW
IKZ
Total NL
IKA: Comprehensive Cancer Centre Amsterdam
IKL: Comprehensive Cancer Centre Limburg
IKMN: Comprehensive Cancer Centre Netherlands Central
IKNO: Comprehensive Cancer Centre North East
IKO: Comprehensive Cancer Centre East
IKR: Comprehensive Cancer Centre Rotterdam
IKW: Comprehensive Cancer Centre West
IKZ: Comprehensive Cancer Centre South
38 Chapter 3
bortezomib while in another only 13% received bortezomib. In all regions the prescrip-
tion rate was below the 27% of eligible patients as estimated by HOVON. 
Use in trials. 
Figure 3.3 shows the participation in the HOVON 6563 and HOVON 8664 studies per 
region in the 2005-2009 period. We observed different trial participation rates and, as 
Figure 3.3 illustrates, trial participation increased from 2005-2007, and decreased in 
2008 to almost no participation in 2009. A comparison of Figures 3.2 and 3.3 reveals 
that the percentage of patients treated in trials is lower than daily practice use of bort-
ezomib. 
Finally, Figure 3.4 presents the regional percentages of treated patients aggregated 
over the years 2005-2009. Comprehensive Cancer Centre Netherlands Central (IKMN) 
had the highest daily practice use and trial participation (19% were either treated with 
bortezomib or included in one of the larger trials); IKZ had the lowest (10%). Figure 3.4 
also shows that although differences remain, the fluctuation reduced over time. In 
general, regions with above average daily practice use also had above average trial 
participation rates.
figure 3.3 Percentage of multiple myeloma patients treated in clinical trials (HOVON 65 and HO-
VON 86) per region from 2005-2009
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Discussion
The aim of our study was to investigate whether bortezomib treatment conformed to 
policy regulations that were designed to guarantee equal access to expensive inpatient 
drugs in the Netherlands. Interviews revealed that physicians feel some financial pres-
sure but do not experience prescription barriers and believe that access to expensive 
cancer drugs is guaranteed. In addition, at that time there were no signs of accessibility 
issues among IGZ and NZa. Our results, however, also showed that (i) after the introduc-
tion of bortezomib, it took one to two years before the drug was prescribed regularly in 
all regions; (ii) the percentage of patients treated is below the expected 27% of eligible 
patients; and (iii) there are unexplained regional differences. 
In order to investigate accessibility issues and compare regional use levels we had 
to make several assumptions, especially to calculate the percentage of MM patients 
treated with bortezomib. While the regions defined by the Netherlands Cancer Registry 
vary in size, population and available hospital facilities, we expect the baseline patient 
characteristics to be comparable across regions. Since accurate prevalence numbers 
were unavailable, we assumed prevalence could be obtained from the distribution of 
incidence after verifying that the regional distribution of incidence was stable over a 
long period with a maximum deviation of only 3%. Some uncertainty surrounding total 
figure 3.4 Percentage of multiple myeloma patients treated in daily practice and clinical trials 
2005-2009
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prevalence, however, remains. Although these assumptions influence the percentage of 
patients treated, we believe our conclusion of low prescription rates will not be effected. 
Levels of use would only be closer to HOVON’s expected use of 27% if the prevalence of 
multiple myeloma was much lower (i.e. less than 1700 patients). Considering incidence 
is 1100 patients per year, prevalence of less than 1700 seems highly unlikely.
Nevertheless, the share in incidence per region was remarkably stable, confirming 
a stable division between the regions over time. If prescription rates per region were 
similar, we expected the regions to be accountable for a similar share in bortezomib 
as their share in incidence. Therefore, regional variation was definitely established, 
although violations of our assumptions could enlarge or reduce the differences. 
Observed regional variation, in both daily practice and trial use, indicates either 
differences in prescription behaviour or referral of patients to, for example, more ex-
perienced hospitals. Because we used sales data aggregated per hospital, we cannot 
distinguish between patients living in the region and patients referred to the region. 
Both causes – prescription behaviour and patient referral – limit accessibility. IKZ may 
have been especially sensitive to regional border crossing because it is the only region 
without an academic hospital. In this region, use and trial participation is low while 
relatively high numbers are observed in its neighbouring region (i.e. IKMN). Bortezo-
mib administration, however, does not require specialised skills or hospital facilities, 
implying that expertise may have been a valid reason for referral immediately after the 
introduction in 2004, but should be of minor importance in subsequent years. 
We studied treatment patterns at an aggregated level, hence neglected other treat-
ment options such as thalidomide and lenalidomide. Because thalidomide is relatively 
inexpensive in the Netherlands, accessibility should not be an issue. Lenalidomide was 
accepted for reimbursement at the end of 2007 in Dutch daily practice, creating a 
competitive alternative treatment option for the years 2008 and 2009 in our analyses. 
However, lenalidomide does not compensate the low levels of bortezomib prescription. 
In 2007, 75 patients were treated with lenalidomide and this number increased to 452 
and 671 in 2008 and 2009, respectively52,65. 
Regional differences and under-provision have been previously reported in the 
Netherlands. Large regional differences and under-provision of trastuzumab in the 
Netherlands were, according to the Dutch Breast Cancer Association50, mainly due to 
cost. After the accessibility issues of trastuzumab, the Dutch policy for expensive drugs 
was revised in 2006. Although bortezomib has been on the market since 2004, it was 
not until it was admitted to the expensive drug list in 2006 that its use in daily practice 
doubled compared with the previous year. The increase might indicate that the imple-
mented policy facilitated prescription. Other developments occurred simultaneously, 
however, including changes in professional guidelines that recommended bortezomib 
in earlier treatment phases. The relatively low use in the first years might have been 
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caused by a long adjustment period of physicians who needed to be familiarised with a 
new drug65,66. Bortezomib was, apart from the re-introduction of thalidomide, the first 
new innovative treatment option for multiple myeloma patients in four decades. It is 
important that physicians and policymakers are aware of such lags in the regular use 
of a new innovative and effective drug. Their implementation should receive more at-
tention to accelerate diffusion by, for example, providing feedback about daily practice 
use. Groot et al.59 showed that the use of bortezomib in 2005 was almost three times 
higher in Sweden and France compared with the Netherlands. Furthermore, Dutch use 
in 2007 was a little less than 35 mg per 100,000 inhabitants while the European aver-
age (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, 
Spain, Sweden, Switzerland and the UK) was above 50 mg per 100,000 inhabitants60. 
Our results also showed that use was below HOVON’s expected rate. Despite financial 
assistance, use and accessibility issues might thus still exist. 
It remains subject to further research whether observed regional differences are 
due to physician prescription behaviour or referral to more experienced or wealthier 
hospitals. Differences seem to have decreased compared with previous outcomes of 
the trastuzumab study in 2005, which might be a result of the changes in the policy 
regulations. However, we should note that the trastuzumab study analysed patients 
with breast cancer, whose prevalence is much higher than multiple myeloma. Wagelaar 
et al.67 studied accessibility of two expensive drugs in the Netherlands, bortezomib 
and trastuzumab, mainly by investigating whether prescription was in accordance with 
guidelines at the individual patient level. Medical files were examined and interviews 
were conducted with physicians, members of hospital boards of directors, and patients. 
They concluded that guidelines were strictly followed and that recommendations by the 
professional association and patient characteristics determined treatment decisions. Al-
though the budget of 80% was insufficient according to their respondents, accessibility 
was not an issue. Interestingly, while their results align with our interview results, they 
are in contrast with our quantitative findings and our research shows that differences in 
accessibility might not be revealed by using a qualitative research method only. 
In 2012, changes in the regulations increased the additional earmarked budget to full 
coverage of the ‘add-on’ diagnoses-related group (i.e. 100% reimbursement of expen-
sive drugs but hospitals and insurers negotiate on the price of the ‘add-on’). Although 
hospital resources remain scarce, this might improve access and reduce remaining 
regional differences. It will be interesting to closely follow the consequences of this new 
policy. 
We investigated equality in access to bortezomib in the context of Dutch policy regula-
tions for expensive drugs. Use of bortezomib has increased over time although regional 
differences are still present. We obtained different conclusions using two methods. 
While interviews did not reveal absolute prescription barriers, regional differences and 
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possibly underutilisation were observed by comparing sales data with incidence and 
prevalence data. It seems that appropriate drug use and thus also accessibility depends 
on various factors, regulatory and organisational characteristics of a healthcare system 
being two important ones. An evaluation of health policies should therefore be based 
on mixed methods and data triangulation. Such an evaluation provides insight and 
valuable feedback that can enhance evidence-based decision making for both health-
care providers and policymakers. This could improve appropriate drug use and ensure 
equal access to healthcare. In the end, efficient and equitable use of scarce resources 
increases society’s benefits from a healthcare system.
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AbsTRAcT
Haematopoietic stem cell transplantation (SCT) is an expensive lifesaving procedure, 
which is increasingly performed in patients with haematological diseases. Develop-
ments in the protocol for SCT have resulted in cost estimates that require updating.
We aimed to calculate actual costs for SCT and to identify major cost drivers by means 
of a daily practice cost study. We randomly selected 191 patients, treated at three uni-
versity hospitals, who underwent an autologous (auto) SCT or allogeneic (allo) SCT in 
2007, 2008 or 2009. Allo-SCT included sibling (sib) donors, matched unrelated donors 
(MUD) and umbilical cord blood (UCB). Resource use was collected from the hospital 
registration systems and medical files. The total costs included selection and harvesting 
of stem cells, transplantation and 1-year follow-up. 
The average costs per patient were €45,670 for auto-SCT and €101,919 for sibling allo-
SCT. The costs of transplantations from unrelated donors were much higher: €171,478 
for allo-SCT-MUD and €254,689 for allo-SCT-UCB. Hospital inpatient days together 
with laboratory and other activities were the main cost drivers across all types of SCT. 
Besides, donor search costs were a large cost component in allo-SCT-sib (18 %) and allo-
SCT-MUD (12%). Real-world costs were above routine reimbursement and appropriate 
financing is necessary to guarantee the continuation of SCT. 
The costs calculated in this study provide reliable up-to-date input for cost-effective-
ness studies and budget revision. 
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inTRoDucTion
Autologous (auto) and allogeneic (allo) haematopoietic stem cell transplantations (SCT) 
are effective, often lifesaving, treatments for patients with haematological diseases, 
which are increasingly applied68,69. Auto-SCT includes the reinfusion of earlier-harvested 
patient-derived stem cells to restore bone marrow function after intensive chemother-
apy with or without radiotherapy. The complication rate is low and treatment-related 
mortality is generally below 5%. In contrast, allo-SCT implies the infusion of stem cells 
from an allogeneic donor. The stem cells may be obtained from a family donor, includ-
ing a matched sibling (sib) or haploidentical family donor, a matched unrelated donor 
(MUD) or from umbilical cord blood (UCB). Donor T cells have a major antitumour effect 
but may also attack healthy tissues of the patient; graft-versus-host disease (GVHD). 
GVHD increases the complication rate and treatment-related mortality of allo-SCT, 
which may increase up to 25–30%, depending on a number of factors69,70. Since allo-SCT 
is increasingly applied and transplants are costly procedures, an increasing demand on 
health care systems are noted in several countries. 
In 2008, more than 800 patients received either an autologous or allogeneic SCT in 
the Netherlands71. As one of the first European countries, the Netherlands introduced 
managed competition and a diagnosis related group (DRG) financing system. The DRG 
system detailed hospital care into so-called “care products”, which price is negotiated 
between health providers and insurers. DRGs include all actions necessary to diagnose 
and treat the patient in the hospital. Additional reimbursement is only provided for 
expensive inpatient drugs. Due to the implementation of managed competition, hospi-
tals increasingly face financial responsibility and an urgent need for information about 
real-world costs is created. Prices of specific care products, such as SCT, are currently 
considered unsuitable for negotiations and are therefore centrally regulated. Adequate 
price data were not available, so outdated reimbursement rates were used for SCT. 
Besides, auto-SCT was only reimbursed for leukaemia patients. 
Although the cost of SCT has been studied previously72-75, up-to-date estimates of av-
erage costs are currently unavailable. New indications for SCT have emerged and recent 
medical developments such as the increasing use of peripheral blood and cord blood 
grafts affected current transplantation procedures68. Furthermore, although advances 
in the prevention and treatment of graft-versus host disease improve survival, they also 
increase medical costs. The aim of this multicentre study was to calculate the real-world 
costs of auto-SCT and allo-SCT for haematological diseases. We aim to identify the major 
cost drivers and compare real-world costs with reimbursement.
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mATERiALs AnD mEThoDs
study population
The study population consisted of patients with haematological diseases who under-
went a SCT in 2007, 2008 or 2009. We randomly selected adult patients from three 
Dutch university hospitals. As cord blood SCT was performed in only one of the three 
hospitals, the patients included for this type of SCT were from a single institution. Pa-
tient characteristics such as age, sex, and diagnosis were obtained.
Treatment
A complete transplantation consisted of three phases: selection and harvesting of stem 
cells, transplantation and the ensuing 1-year follow-up. During the first phase, patients 
were prepared for transplantation. Stem cells were harvested from the patients, or a 
donor search procedure was initiated. The second phase, in which the transplantation 
was actually performed, began on the first hospital admission day and continued until 
discharge. The second phase was followed by a 1-year follow-up for all patients that 
included monitoring and ongoing support.
Perspective and costs
We took an institutional perspective and incorporated all treatment-related hospital 
costs. Data were obtained from hospital registration systems that included detailed 
information about all relevant inpatient treatment activities. By relying on the hospital 
registration systems, the data gathering corresponded to the principles of the new 
revised system of activity-based costing. In addition, we collected information from 
medical files. Data included all relevant treatment activities. These activities were 
subcategorised into seven cost groups: inpatient days, daycare treatment, outpatient 
visits, intensive care admission, medication, blood products and laboratory and other 
activities (e.g. imaging, laboratory tests, radiation and injections). Two additional cost 
categories were added to the selection and harvesting phase of allo-SCT: donor search 
costs and human leucocyte antigen (HLA) typing. Donor search costs were based on the 
total costs of two hospitals divided by the number of allo-SCT-MUD and allo-SCT-UCB. 
We matched treatment activities to national prices defined by the health authority that 
included hospital costs and specialist fees76. Costs of inpatient days (€712), daycare 
(€224), outpatient days (€148) and intensive care (€2,100) were obtained from Gaultney 
et al.77 who updated the specific prices for haematological departments of Tan et al.78. 
Medication costs for patients at two institutions were available. From these patients, 
we selected a random sample of 78 patients to calculate medication costs during each 
of the three phases. Costs were calculated per unit, based on the Dutch Pharmaceutical 
Advisory Committee (Z-index 2009–2010) and multiplied by the total dosage given. 
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Analysis
Average and median transplantation costs per patient were calculated for each phase 
and per cost category. The main cost drivers for each type of SCT were identified by cal-
culating the proportion of total costs of each cost group. In order to reduce the number 
of categories, costs for blood products and medication were merged. We investigated 
the correlation between the cost groups and total average SCT costs. The analyses were 
performed using Microsoft Excel 2010 and STATA SE, version 11.2.
REsuLTs
Patients
We included 191 randomly selected patients who received an auto-SCT or allo-SCT in 
one of three hospitals in 2007–2009. The characteristics of the patients included are 
presented in Table 4.1. Mean and median age for auto-SCT and allo-SCT-sib were simi-
lar. Patients receiving allo-SCTMUD were significantly younger (p<0.018) compared to 
patients receiving auto-SCT or allo-SCT-sib. Table 4.1 shows that multiple myeloma was 
the most common diagnosis for auto-SCT followed by acute leukaemia and non-Hodgkin 
lymphoma. Most patients receiving allo-SCT were diagnosed with acute leukaemia. The 
average number of admission days for auto-SCT, allo-SCT-sib and allo-SCT-MUD patients 
was similar in the transplantation phase. In contrast, the average number of admission 
Table 4.1 Patient characteristics 
 
 
Type of scT
Autoa Allo-sibb Allo-muDc Allo-ucbd
N=68 N=59 N=43 N=21
Patient characteristics     
Average age (years) 51 51 45 47
Median age (years) 53 53 47 52
[range] [19 - 66] [19 - 67] [18 - 66] [21 - 66]
Sex (male) 57% 36% 67% 48%
     
Diagnosis     
Aplastic anaemia  3.3%  9.5%
Acute lymphoblastic leukaemia 4.4% 6.7% 19.0% 28.6%
Acute myeloblastic leukaemia 26.5% 50.0% 47.6% 38.1%
Chronic lymphoblastic leukaemia  3.3% 7.1% 14.3%
50 Chapter 4 Real-world costs of stem cell transplantations 51
4
days for allo-SCT-UCB patients was significantly higher (p<0.01). From Table 4.1, it can 
be concluded that the range of admission days was large.
Average and median cost
Table 4.2 presents the average and median cost for autologous and allogeneic SCT. The 
average cost was €45,668 for auto-SCT. The transplantation phase was the most ex-
pensive phase (€21,124). Total median cost (€34,688) was below the average cost. The 
average total cost for allo-SCT-sib was €101,923. In contrast with auto-SCT, the trans-
plantation phase was the least expensive phase (€24,894). The total average costs of 
SCT from an unrelated donor were much higher, €171,482 for allo-SCT-MUD compared 
to allo-SCT-sib and on account of the increased costs during selection and harvesting 
and follow-up. The total average and median costs for allo-SCT-UCB were €254,690 and 
€167,289, respectively. Compared to allo-SCT-MUD, costs during the transplantation 
and follow-up were much higher.
cost categories
Table 4.3 presents the average costs by category during the three phases for each type 
of SCT.  Inpatient days were a large cost category in all phases and for each type of SCT. 
Table 4.1 Patient characteristics  (continued)
 
 
Type of scT
Autoa Allo-sibb Allo-muDc Allo-ucbd
N=68 N=59 N=43 N=21
Chronic myeloblastic leukaemia  1.7% 9.5%  
Hodgkin lymphoma 4.4% 1.7%   
Multiple myeloma 38.2% 21.7% 4.8% 4.8%
Non-Hodgkin lymphoma 20.6% 5.0% 4.8% 4.8%
Othere 4.4% 3.3% 7.1%  
Unknown 1.5% 3.3%   
     
Admission days for scT phase              
Average
20.7 19.6 19.1 42.4
Median 20.5 17 15 40
[range] [6 - 48] [2 - 62] [7 - 59] [20 - 88]
a Auto: Autologous stem cell transplantation
b Allo-sib Allogeneic sibling stem cell transplantation
c Allo-MUD: Allogeneic matched unrelated donor stem cell transplantation
d Allo-UCB: Allogeneic umbilical cord blood stem cell transplantation
e Other diseases including Mantle cell lymphoma, Ewings sarcoma, Autoimmune diseases, Polycythaemia vera, 
Prolymphocytic leukaemia, Myelodysplastic syndromes, Primary myelofibrosis
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Table 4.3 Average costs (€) per patient for three phases per transplantation type
cost category Phase Total
selection/
harvesting
Transplantation
follow-up
(1-year)
cost (€)
Auto-scTa     
   Inpatient days 6,408 14,869 2,143  
   Daycare 128 0 326  
   Outpatient days 479 27 2,422  
   Intensive care days 0 0 0  
   Medication 1,342 2,386 362  
   Bloodproducts 720 1,794 1,230  
   Laboratory and other 
activities
2,858 2,048 6,126  
      Total auto-scT   45,668
    
Allo-scT-sibb     
   Inpatient days 10,169 14,858 13,887  
   Daycare 436 28 809  
   Outpatient days 809 41 5,125  
   Intensive care days 378 0 2,387  
   HLA typing 9,968    
   Medication 1,661 4,171 5,469  
   Bloodproducts 2,223 1,105 3,733  
   Laboratory and other 
activities
5,836 4,691 14,139  
      Total allo-scT-sib    101,923
    
Allo-scT-muDc     
   Inpatient days 12,610 13,688 33,370  
   Daycare 235 0 567  
   Outpatient days 882 42 5,553  
   Intensive care days 132 657 5,333  
   Donorsearch 30,456    
   HLA typing 9,968    
   Medication 2,778 8,688 8,640  
   Bloodproducts 2,661 2,048 5,542  
   Laboratory and other 
activities
5,154 3,458 19,020  
      Total allo-scT-muD    171,482
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For the selection and harvesting phase, there was a large difference between auto-SCT 
and allo-SCT and between SCT from related or unrelated donors. This difference is to 
a large extent related to the additional cost categories for allo-SCT, HLA typing (€9,968 
and donor search cost (€30,456), which were applied to allo-SCT-MUD and allo-SCT-
UCB. During the 1-year follow-up phase, the categories inpatient days and laboratory 
and other activities were the largest cost categories. We investigated the correlation 
between cost components, patient characteristics and total cost. Inpatient hospital 
visits were significantly correlated with total cost (p<0.001). None of the patient charac-
teristics had a significant impact on total cost.
cost drivers
Figure 4.1 shows the percentage of each cost category in the average costs per pa-
tient for the three successive phases of auto and allo-SCT. From Figure 4.1, it can be 
concluded that inpatient days were the main cost driver in auto-SCT, allo-SCT-sib, and 
allo-SCT-MUD. In allo-SCT-UCB, the cost category laboratory and other activities was a 
major cost driver and responsible for more than 30% of the costs. However, inpatient 
days were the second largest cost driver and responsible for nearly 30% of the total 
Table 4.3 Average costs (€) per patient for three phases per transplantation type (continued)
cost category Phase cost (€)
selection/
harvesting
Transplantation
follow-up
(1-year)
Total
    
Allo-scT-ucbd     
   Inpatient days 10,002 30,480 34,598  
   Daycare 395 0 2,300  
   Outpatient days 869 21 7,580  
   Intensive care days 0 2,400 6,838  
   Donorsearch 30,456    
   HLA typing 9,968    
   Medication 3,946 4,596 13,762  
   Bloodproducts 2,362 6,089 10,863  
   Laboratory and other 
activities
7,400 12,691 57,074  
      Total allo-scT-ucb    254,690
a Auto-SCT: Autologous stem cell transplantation
b Allo-SCT-sib: Allogeneic stem cell transplantation sibling donor
c Allo-SCT-MUD: Allogeneic stem cell transplantation matched unrelated donor
d Allo-SCT-UCB: Allogeneic stem cell transplantation umbilical cord blood
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costs. While Table 4.3 showed that costs for medication and blood products differed for 
each transplantation type, Figure 4.1 reveals that their contribution in the total costs 
was almost identical for each type of SCT, around 18%.
Discussion
This multicentre study calculated the cost per stem cell transplant in daily practice. 
The average cost of auto-SCT were lower than that of allo-SCT, while costs of allo-SCT 
increased depending on donor type, especially because of increased donor search costs 
of €30,456 associated with an unrelated donor as compared to a sibling donor. While 
the costs of the selection and harvesting phase of allo-SCT-UCB and allo-SCT-MUD were 
similar, the costs of the second and third phases of allo-SCT-UCB were much higher due 
to more inpatient days and laboratory and other activities. The admission period during 
allo-SCT-UCB transplantation compared to allo-SCT-MUD was on average twice as long 
because of delayed peripheral blood cell recovery. These higher costs of allo-SCT-UCB are 
predominantly related to the type of transplant, most likely explained by the significant 
lower number of haematopoietic progenitor cells present in those grafts. Compared 
to allo-SCT-MUD, regular (cheap) laboratory activities (e.g. haemoglobin, leukocytes, 
figure 4.1 Cost drivers for autologous and allogeneic stem cell transplantations
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albumin and protein) as well as expensive laboratory tests (e.g. cytomegalovirus detec-
tion with DNA/RNA amplification) were conducted frequently and much more often in 
allo-SCT-UCB. Allo-SCT-UCB was and is a new innovative treatment performed only in 
designated hospitals like one of the hospitals included in our study. Treatment strictly 
followed protocol including extensive laboratory testing. In addition, data on drug use 
revealed much more anti-viral prescription probably providing another reason why 
much more laboratory tests were performed during follow-up. 
Comparing our results with those of previous studies is difficult due to developments in 
treatment protocols, different cost analysis methods and country-specific factors which 
influence the context in which transplantations are performed. However, similarities 
between previous studies were found. In 2001, a prospective Norwegian cost study74 
calculated the cost of bone marrow allo-SCT to be $106,825 (€95,212 in 2010 after 
converting and inflation). Their average is comparable to the average costs for allo-SCT 
from a sibling donor in our study (€101,923). However, their study did not differentiate 
between sibling and unrelated donor transplantations. According to our results, the dif-
ference between these two types of transplantations is substantial. Another multicentre 
cost study was conducted in Norway among patients with malignant lymphoma and 
multiple myeloma receiving auto-SCT75. Their cost analysis included two transplantation 
phases that seem similar to the selection and harvesting and transplantation phase of 
our study. The average cost per patient was $32,160 (€28,664 in 2010 after converting 
and inflation) and comparable to our results for auto-SCT (€33,059). Majhail et al.79 
presented the median cost of allo-SCT-sib and allo-SCT-UCB for myeloablative and non-
myeloablative regimens in USA. While the results of Majhail et al.79 for allo-SCT-sib are 
comparable with our results, there is a large difference between the costs for allo-SCT 
using UCB as a source of stem cells. It should be mentioned that Majhail et al.79 excluded 
graft acquisition costs and calculated the median cost for the first 100 days only. The 
follow-up phase in our study is 365 days and to a large extent responsible for the high 
average costs associated with UCB as a graft for allo-SCT. 
Our results confirm earlier findings of hospital inpatient days as the major cost driver 
for auto and allo-SCT, and these inpatient days are probably related to post-transplant 
complications79-82. Apart from hospital inpatient days, we also identified laboratory and 
other activities as a large cost driver. The contribution of total average costs of medication 
and blood products was around 18% irrespective of the type of SCT. For reimbursement 
decisions, economic evaluations are frequently conducted as they serve as a means 
to compare the effects and cost of several treatment strategies. As SCT is a preferred 
treatment option for many indications within haematology, our real-world cost study 
provides important input for evaluations of treatment strategies available to haemato-
logical disorders. Since we have presented the entire treatment cost of transplantation 
separately for three phases, our results can be easily adapted to the required input 
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parameters in future economic evaluations depending on variations in the protocol for 
the SCT procedure. Furthermore, our estimates can be used to assess whether changes 
to the protocol can result in cost-savings. For example, strategies to decrease the num-
ber of hospital days could reduce overall costs and should be explored. Real-world cost 
studies are also useful as they can be used to compare the actual treatment costs to the 
reimbursement rates83  in use at the moment we conducted our study. For auto-SCT, 
reimbursement (€44,883) and actual costs (€45,668) were similar. However, hospitals 
were only reimbursed for auto-SCT if the procedure was conducted among leukaemia 
patients. The actual cost of allo-sib-SCT was €101,923, which was much higher than the 
Dutch reimbursement rate of €67,501  Reimbursement rates in use while we conducted 
our study did not differentiate between MUD and UCB, while according to our results, 
the difference between both types of SCT was substantial. Both real-world costs of allo-
SCT-MUD (€171,482) and allo-SCT-UCB (€254,690) were higher than the reimbursement 
rate (€145,756). While reimbursement rates should cover all hospital activities, our 
results revealed a large difference between reimbursement and actual hospital costs. 
Depending on the type of SCT and the type of patient, the shortage varied between less 
than €1,000 to more than €100,000 per patient. Similar findings were obtained from 
Norwegian DRG financing systems74,75. Inadequate reimbursement may make transplan-
tations a high financial burden since this type of care is concentrated in a few hospitals. 
This might impact patient access to care as it could lead to hospitals feeling compelled 
to refuse treatment or provide treatment at the expense of other patients’ treatment. 
Our study results provided reliable cost calculations for the Dutch government and the 
reimbursement authorities. After negotiations between haematologists and the Dutch 
reimbursement agency, reimbursement was adjusted for 2012 based on our results. 
Future studies are warranted to calculate costs and investigate whether differences 
between reimbursement and costs are a consistent problem.
Our multicentre study randomly selected patients from three Dutch hospitals. These 
three hospitals together are responsible for more than 40% of all transplantations in the 
Netherlands71. By including multiple representative hospitals across the Netherlands, 
we aimed to reduce the hospital variation and establish representative average cost. 
Results showed a broad range for costs and admission days. Considering the strong 
positive relationship between admission days and post-transplant complications, we 
included patients with and without complications. Besides, the average number of 
admission days is an important indicator of the total costs. By presenting the average 
number of admission days per transplantation, we ensure the applicability of our results 
to other hospitals and settings. 
Almost all hospitals in the Netherlands participate in the Dutch-Belgian Cooperative 
Study Group for Haematological Malignancies, HOVON, a foundation of professionals 
originally initiated for conducting clinical trials. The group further developed guidelines 
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for patients outside the context of trials and is the major political spokesman for hae-
matooncology.
Collaboration is often sought with other groups such as the EORTC and national 
groups in Europe and beyond. Within HOVON, the working group for haematopoietic 
stem cell transplantations has made consensus statements for stem cell transplantation 
indications and for all supportive care requirements, all in accordance with international 
standards of the Joint Accreditation Committee-ISCT Europe (JACIE). Therefore, our 
results are not only valid for the Netherlands but applicable to other countries which 
follow the JACIE standards. 
We obtained real-world data from the hospital registration systems, medical patient 
files, and electronic information systems. Our results depend on the completeness of 
registration, and unregistered hospital activities were not included in our study. This 
might have caused a slight underestimation of actual cost. On the other hand, while 
we aimed to select only activities related to the SCT procedure, we cannot guarantee 
that all activities were fully related to the transplantation process, especially during 
follow-up. These problems are inherent to real-world cost studies, and since we found 
no unrelated activities, the effect on our results seemed negligible.
concLusion
In conclusion, auto-SCT and allo-SCT are costly procedures for which hospital inpatient 
days are the main cost driver across all types of SCT. There was a discrepancy between 
real-world cost and reimbursement, and based on our data, reimbursement rates 
changed. Costs calculated in this study provide reliable input for cost-effectiveness 
studies and can be adapted to the required input parameters. 
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AbsTRAcT
objectives: On the basis of two population-based registries, our study aims to calculate 
the real-world cost-effectiveness of rituximab maintenance compared with observa-
tion in relapsed or refractory follicular lymphoma patients who responded to second-
line chemotherapy. 
methods: Data were obtained from the EORTC20981 trial, the Netherlands Cancer 
Registry and two population-based registries. A Markov model was developed to 
calculate cost per life year gained (LYG) and quality-adjusted life years (QALYs) for 
three scenarios. 
Results: Our real-world patients were (62 years) 6 to 7 years older and had higher 
complete response rates to second-line chemotherapy than the trial population. Dif-
ferences between the real-world rituximab and observation group were observed for 
second-line chemotherapy and disease progression. Groups were more balanced af-
ter using propensity matching. Relying entirely on updated trial results (scenario1) in 
combination with local cost data resulted in ratios of €11,259 per LYG and €12,655 per 
QALY. For scenario2, consisting of trial efficacy and matched real-world costs, ratios 
of €21,202 per LYG and €23,821 per QALY were calculated. Using real-world matched 
evidence (scenario3) for both effectiveness and costs showed ratios of €10,591 per 
LYG and €11,245 per QALY. 
conclusion: Although differences in real-world and trial population were found, using 
real-world data as well as results from long-term trial follow-up showed favourable 
ICERs for rituximab maintenance. Nevertheless, results showed that caution is 
required with data synthesis, interpretation and generalisability of results. As dif-
ferent scenarios provide answers to different questions, we recommend healthcare 
decision-makers to recognise the importance of calculating several cost-effectiveness 
scenarios.
Cost-effectiveness of rituximab 61
5
inTRoDucTion
Follicular lymphoma (FL) is the largest subtype of indolent non-Hodgkin lymphoma. In 
general, FL is incurable, and for decades, median overall survival (OS) was estimated to 
be between 8 and 10 years84. However, in the past decade, improved median OS has 
been observed, for example for stage IV, median OS was 12.7 years85, while median OS 
was more than 18 years for grade 1 to 2 FL86. Rituximab (MabThera®, F.Hoffmann-La 
Roche Ltd) is a chimeric murine/human anti CD20 monoclonal antibody capable of kill-
ing CD20-positive lymphoma cells. In FL, adding rituximab to chemotherapy improves 
event-free survival87,88, progression-free survival (PFS) and OS88-90 in first-line. Moreover, 
although OS was not significantly different, rituximab maintenance prolongs PFS in 
first-87 and second-line91,92 FL patients. As a consequence, rituximab maintenance is 
registered in Europe since 2006 and locally reimbursed in the Netherlands for patients 
with relapsed or refractory FL responding to re-induction therapy. In 2010, this was 
expanded to patients responding to chemotherapy, irrespective of treatment line. 
While the efficacy of rituximab maintenance has been established, policymakers have 
to decide whether reimbursement of rituximab maintenance is value for money. While 
randomised controlled trials (RCTs) are the golden standard for establishing efficacy, the 
data so generated do not necessarily reflect real life7. Therefore, healthcare decision-
makers are increasingly interested in real-world data. Nevertheless, data are scarce, al-
most always retrospectively gathered, and experiences of a cohort study demonstrated 
data synthesis was mostly inevitable to obtain valid cost-effectiveness results93. 
On the basis of two population-based registries, our study aims to calculate the 
real-world cost-effectiveness of rituximab maintenance compared with observation in 
relapsed or refractory FL patients who responded to second-line chemotherapy in the 
Dutch setting. Three scenarios were identified to illustrate the impact of data synthesis 
and explore how each scenario may fulfil the information need of decision makers. 
To our knowledge, our study is the first conducting outcomes research for rituximab 
maintenance on the basis of population-based registries. 
mATERiALs AnD mEThoDs
Data sources
Data were obtained from multiple sources: long-term follow-up of the EORTC20981 trial, 
primary data from the Netherlands Cancer Registry and two population-based registries 
collecting data on patient characteristics, treatment and healthcare utilisation20,94. The 
Population-based HAematological Registry for Observational Studies (PHAROS)20,21, 
located in the north-west and south-west of the Netherlands, aims to cover 40% of the 
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Dutch population and collects real-world data from medical records. HemoBase94 is a 
multidisciplinary Web-based electronic patient record in the north-eastern part of the 
Netherlands in which data are entered in the database by physicians and laboratory 
employees. 
Patients
We applied the criteria for maintenance treatment and selected indolent FL patients 
who received at least two lines of chemotherapy and responded to their second-line 
in 2004 to 2011. In addition, patients receiving rituximab maintenance after a stable 
disease or unknown response to second-line chemotherapy were included in the de-
scription of the real-world patient population. The included patients were divided in 
two groups: the maintenance and observation group. As real-world patients were not 
randomly assigned to rituximab or observation, we corrected for observed differences 
in patient characteristics with the statistical matching technique of propensity scores 
where each patient received a score that reflects the probability of being in the treat-
ment group given certain pre-treatment characteristics95. Propensity scores for ritux-
imab maintenance were estimated using logistic regression with rituximab treatment as 
the dependent variable and age, years since diagnosis, B-symptoms, FLIPI score, stage 
and response to re-induction therapy as independent variables. Nearest neighbour 
matching was used where each person in the treatment group is matched to a patient 
in the observation group with the closest propensity score to them. The final matched 
population was used for both effectiveness and cost calculations. 
cost-effectiveness scenarios 
Longer follow-up available from the EORTC trial and real-world evidence enabled us to 
calculate the incremental cost-effectiveness ratio (ICER) from a healthcare perspective 
for three different scenarios: 
1. Effectiveness based on trial efficacy; costs based on treatment protocol EORTC2098191.
2. Effectiveness based on trial efficacy; costs based on matched real-world patients.
3. Effectiveness based on real-world evidence; costs based on matched real-world 
patients.
model structure
A Markov model to calculate cost per life year gained (LYG) and quality-adjusted life 
years (QALYs) was developed in Microsoft Excel (2010) with a lifetime horizon of 20 
years and one month cycle length. This cycle length is the time interval at which patients 
may switch health states. For scenario1 and scenario2, the model included three health 
states: progression-free survival (PFS), after progression survival (APS) and death. All 
patients in the model began in the PFS health state and remained in that state until 
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relapse/progression (APS state) or death, whichever occurred first. Per cycle (1 month), 
we calculated the transition between the health states, that is, the proportion of patients 
per health state. Patients entering the APS state either remain in APS or die. As data on 
PFS were initially not collected in PHAROS, time-till-next-treatment (TTNT) instead of 
PFS was calculated in scenario3. The structure of the model was similar except that 
the PFS state became the maintenance/observation (MOB) state, while the APS state 
became the next treatment (NT) state. 
model input – effects and utilities
Effects included both LYG and QALYs. Efficacy of rituximab maintenance therapy and 
transition probabilities for scenario1 and scenario2 were obtained from the EORTC20981 
trial91,92, while effectiveness in scenario3 was obtained from matched real-world data. 
Extrapolation was performed by fitting parametric distributions to the observed survival 
times. According to Dutch guidelines, the annual discount rate of future effects was 
1.5%96. Utility values, 0.88 for PFS, 0.78 for APS and 0 for Death, were obtained from an 
observational study in the United Kingdom among 215 patients with FL97. 
model input – cost and prices
We included direct medical costs including hospital inpatient days, day treatment, 
outpatient days and medication. For scenario1, healthcare use including treatment dos-
ages, follow-up treatments and adverse events was obtained from the EORTC20981 trial. 
Hospital visits were not registered and were therefore based on the treatment protocol. 
For scenario2 and scenario3, resource use was obtained from the registries. All costs are 
in euros (2012) and discounted at 4% annually according to Dutch guidelines96. Costs 
of inpatient days (€548), day care (€177), outpatient days (€116) and intensive care 
(€2,100) were obtained from Franken et al.62, while prices for drugs were derived from 
the national reference lists (medicijnkosten.nl) and multiplied with dosages according 
to the treatment protocol of the EORTC20981 trial91. To derive average costs for adverse 
events in scenario1, costs for neutropenia (€1,290) and infection (€1,096)98 were multi-
plied with the proportion of patients experiencing these adverse events92. For scenario2 
and scenario3, costs for adverse events were incorporated in the hospital visits. Average 
treatment costs upon relapse were based on post progression treatments in the third 
treatment line. It was assumed patients had one day treatment per cycle in scenario1. 
sensitivity analyses
Probabilistic sensitivity analyses were performed to explore the robustness of results. 
Input parameters varied simultaneously by running 5000 simulations, wherein resource 
use followed gamma distributions and utilities followed beta distributions. To investi-
gate the effect on the ICER, three scenarios were introduced: A) zero discount rates, B) 
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using unmatched real-world resource use and C) using unmatched real-world resource 
use and effectiveness.
REsuLTs
Table 5.1 shows the patient characteristics of the real-world population, the propensity 
matched groups obtained from the real-world data and the characteristics of the pa-
tients included in the EORTC20981 trial. 
Real-world data
The two registries provided data of 3581 patients. After selecting patients responding to 
second-line chemotherapy (N = 113), 62 were only observed and 51 received rituximab 
maintenance. Median age in our real-world patient groups was around 62 years [Range: 
31–92] and similar in both groups. In daily practice, a higher proportion of patients 
treated with rituximab maintenance received rituximab in the re-induction therapy (92% 
vs. 73%). Besides, disease progression was faster in the observation group; 73% reached 
the observation phase within 2 years from diagnosis, while 49% reached maintenance 
within 2 years from diagnosis. Compared with the EORTC20981 trial, real-world patients 
were 6 to 7 years older, and rituximab was prescribed more often in the re-induction 
therapy. Interestingly, rituximab maintenance in daily practice was also prescribed to 
patients with unknown or SD response to re-induction therapy.
Propensity score matching
Using logistic regression with rituximab treatment as the dependent variable and age, 
years since diagnosis, B-symptoms, FLIPI score, stage and response to re-induction 
therapy as independent variables, propensity scores, that is, the chance of receiving 
rituximab treatment, were calculated for patients without missing observations for age, 
years since diagnosis, B-symptoms, stage and  response to re-induction therapy. The av-
erage probability of receiving maintenance treatment was 0.56 in the rituximab group, 
while the probability was 0.34 for patients in the observation group. This difference 
illustrated that real-world patients in both groups were not identical and patients in 
the rituximab group had, based on their characteristics, a higher chance (0.56 vs. 0.34) 
of receiving rituximab treatment. To create comparable groups, patients treated with 
rituximab maintenance were matched to patients from the observation group based 
on their chance of receiving rituximab, that is, their propensity score. More balanced 
groups were created after using propensity score matching, as shown in Table 5.1. 
For example, the proportion of patients with B-symptoms is similar as well as the re-
induction therapy in line 2 and time since diagnosis. In addition, while patients receiv-
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ing rituximab maintenance after a stable disease or unknown response to second-line 
chemotherapy were included in the initial real-world patient population, these patients 
were not included in the propensity matched real-world population. After matching, av-
erage propensity scores were similar in both real-world groups (0.56, SD 0.19), meaning 
the chance of rituximab maintenance was, based on the patient characteristics, similar 
in both groups. However, this balance reduces the number of patients especially in the 
observation groups, that is, 23 patients remained with weights between 1 and 5. These 
weights present the number of times patients in the observation group were matched 
to a patient in the rituximab maintenance group.
healthcare use
Table 5.2 shows the healthcare utilisation in daily practice. Real-world average prescrip-
tion of rituximab (366 mg/m2) and the number of cycles (6) were similar to averages 
of the EORTC study, 375 mg/m2 and 6, respectively. However, real-world rituximab was 
prescribed once every 2 instead of 3 months. Hospital visits for the matched observa-
tion group were reduced. This reduction was partly caused by four patients with relative 
high levels of healthcare utilisation, very low propensity scores (mean 0.083) and who 
died within 5 months after their observation phase started.
Table 5.2 Real-world rituximab prescription and health care use 
health care use n mean (sD) median Range
Rituximab
Prescription rate (mg/m²) 28 366 (39) 374 [250-459]
Total prescription per patient (mg) 28 3542 (1776) 3345 [700-6800]
Total days maintenance 26 491 (207) 553 [91-763]
Number of cycles 29 6 (3) 7 [1-11]
Days per cycle 26 70 (16) 75 [21-90]
Real-world hospital visits per month
observation during mob
Outpatient visits 56 0.76 (0.69) 1 [0-2.66]
Day treatment 50 0.13 (0.3) 0 [0-1.31]
Inpatient days 50 0.61 (1.63) 0 [0-7.41]
maintenance during mob
Outpatient visits 44 0.51 (0.47) 0 [0-2.63]
Day treatment 44 0.3 (0.26) 0 [0-1.37]
Inpatient days 34 0.19 (0.49) 0 [0-2.67]
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cost-effectiveness results 
Table 5.3 shows the input parameters and assumptions for the cost-effectiveness of 
the three scenarios. PFS, TTNT as well as OS were modelled with lognormal parametric 
distributions.
The results on costs and effects of the three models are presented in Table 5.4. The 
ICERs for scenario1 were €11,259 per LYG and €12,655 per QALY and almost identi-
cal to the results for scenario3; €10,591 and €11,245 per LYG and QALY, respectively. 
Cost-effectiveness ratios for scenario2 were €21,202 per LYG and €23,821 per QALY. The 
scenario analyses are shown in Table 5.5. ScenarioA shows the impact of the discount 
Table 5.2 Real-world rituximab prescription and health care use  (continued)
health care use n mean (sD) median Range
observation nT
Outpatient visits 23 0.67 (0.68) 1 [0-2.4]
Day treatment 23 0.18 (0.26) 0 [0-1.12]
Inpatient days 23 1.39 (2.52) 0 [0-9.96]
maintenance nT
Outpatient visits 9 1.39 (1.41) 1 [0-4.18]
Day treatment 8 0.63 (0.56) 1 [0-1.72]
Inpatient days 8 1.67 (2.8) 0 [0-6.21]
Propensity matched hospital visits per month   
observation during mob
Outpatient visits 41 0.62 (0.65) 0 [0-2.66]
Day treatment 37 0.18 (0.41) 0 [0-1.31]
Inpatient days 34 0.14 (0.58) 0 [0-3.28]
maintenance during mob
Outpatient visits 39 0.55 (0.48) 0 [0.02-2.63]
Day treatment 40 0.31 (0.27) 0 [0-1.37]
Inpatient days 31 0.21 (0.51) 0 [0-2.67]
observation during nT
Outpatient visits 9 0.3 (0.38) 0 [0-0.95]
Day treatment 9 0.17 (0.17) 0 [0-0.4]
Inpatient days 9 0.39 (0.72) 0 [0-1.65]
maintenance during nT
Outpatient visits 7 1.79 (1.35) 2 [0.37-4.18]
Day treatment 7 0.72 (0.54) 1 [0.13-1.72]
Inpatient days 7 1.91 (2.93) 0 [0-6.21]
MOB: Maintenance or Observation health state, NT: Next treatment
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Table 5.3 input parameters for cost-effectiveness base case scenarios
Parameter scenario1 scenario2 scenario3
general Parameters    
Effectiveness Trial Trial Real-world
Discount rate (costs) 4% 4% 4%
Discount rate (efficacy) 1.5% 1.5% 1.5%
Time horizon of analysis (years) 20 20 20
PFS/MOB Parametric distribution Lognormal Lognormal Lognormal
Overall survival parametric distribution Lognormal Lognormal Lognormal
length of cycle (days) 30.4 30.4 30.4
cost of Drug
Rituximab 100 mg € 274 274 274
Rituximab 500 mg € 1,369 1,369 1,369
Demographic
Average age of cohorts 54 60 60
Body weight (kg) 78 76 76
Height (cm) 170 174 174
Rituximab (3-monthly cycles maintenance 2 years at 375mg/m2)
Number of cycles per month 0.33 0.44 0.44
Treatment duration maximum months 24 24 24
Average dose per administration 697 596 596
Rituximab arm (maintenance phase) 
Drug costs rituximab per month € 639 € 714 € 715
Cost of monitoring and administering per month € 75
€ 223 € 223
Cost of adverse events per month € 238
observation arm (maintenance phase)
Drug costs per month 0 0 0
Cost of monitoring and administering per month € 55
€ 1721 € 1721
Cost of adverse events per month € 96
After progression treatment costs
Rituximab arm, costs per month € 786 € 1,992 € 1,992
Observation arm, costs per month € 752 € 1,332 € 1,332
utilities
Progression-free health state 0.859 0.859 0.859
After progression health state 0.798 0.798 0.798
1Costs per month including monitoring and administration as well as costs of adverse events.
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rate is marginal. ScenarioB and scenarioC show that using unmatched population-based 
resource, use and costs lead to different cost-effectiveness outcomes.
Discussion
Using both real-world data and results from long-term trial follow-up showed favour-
able ICERs for rituximab maintenance compared with observation in patients with FL 
who responded to second-line chemotherapy. We compared real-world patients from 
the registries to the population in the EORTC20981 trial and observed differences, for 
example real-world patients were older while simultaneously, the proportion of com-
plete responses to second-line chemotherapy was higher. Besides, whereas rituximab in 
the re-induction therapy was randomly assigned in the EORTC20981 trial, most patients 
treated in daily practice received rituximab in the re-induction therapy. As differences in 
patient characteristics between the two groups were observed, we performed match-
ing to correct for possible bias. Thereafter, the ICER of three scenarios was calculated. 
Relying entirely on updated trial results (scenario1) in combination with local cost 
data resulted in ratios of €11,259 per LYG and €12,655 per QALY. For scenario2, consist-
ing of trial efficacy and matched real-world costs, ratios of €21,202 per LYG and €23,821 
per QALY were calculated. Using real-world matched evidence (scenario3) for both 
effectiveness and costs showed ratios of €10,591 per LYG and €11,245 per QALY. While 
results from scenario1 and scenario3 were similar, this should not be interpreted as no 
need for real-world data. First, as most certainly, a cost-effectiveness analysis based on 
real-world or trial data will not always generate similar results. Second, scenario1 and 
scenario3 provide answers to different questions. Due to the randomisation, scenario1 
has the highest internal validity of the treatment effect. However, healthcare decision-
makers are also interested in external valid ICERs. For example, in the Netherlands, policy 
Table 5.5 Results scenario analysis
base case value scenario1 scenario2 scenario3
costs per QALy (€) 12,655 23,821 11,245
Results sensitivity analysis
A) No discounting    
Costs per QALY (€) 12,697 26,228 12,608
B) Unmatched healthcare costs
Costs per QALY (€) - 5,162 -557
C) Unmatched healthcare costs & effects
Costs per QALY (€) -  -6,242
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regulations demanding sufficient relevant evidence on real-world cost-effectiveness 
have been implemented51. Expensive drugs receive conditional reimbursement for 4 
years after which a re-assessment of the available data occurs. The requirements of 
the Dutch government seem to be best fulfilled by option B or C. Scenario3C has the 
highest generalisability because both costs and effects were based on real-world data 
and all patients were included. However, these results are difficult to interpret for the 
government because differences between two incomparable groups cannot be inter-
preted as incremental effects or costs. Scenario2B has the advantages of obtaining the 
incremental treatment effect from an RCT and including all real-world patients in the 
cost analysis. While data synthesis is a common approach to overcome problems due 
to the absence of a randomised design and calculate ICERs of treatment as prescribed 
in daily practice93, our results illustrated that caution is required. First, using matched 
real-world costs but failing to account for the real-world effects (scenario2) results – in 
our case – to ICERs that were too high. Secondly, interpretation and generalisability 
problems arise when RCT effects and real-world costs are combined, that is, to which 
patients the ratios apply. 
Even though existing registries reduce start-up costs, the collection of real-world data 
remains extremely time-consuming and expensive. While registries enabled us to obtain 
real-world data from 3581 non-Hodgkin patients, patient numbers in the rituximab and 
observation group were small, resulting in a considerable level of uncertainty (wider 
confidence intervals). Moreover, although propensity matching is a solid method to 
correct for imbalances in observational studies95, it never substitutes randomisation. In 
addition, it should be noted that the differences in response rate to second-line therapy 
continued to exists. Another limitation of our study is that the registry data did not 
allow us to calculate PFS. As TTNT always exceeds PFS, the average time spent in PFS 
and APS (scenario1 and scenario2) is not directly comparable to the average time spent 
in MOB and NT (scenario3), respectively. Nevertheless, mean OS is comparable. 
Although limitations exist, our results of scenario1 and scenario3 confirmed previ-
ous findings of favourable ICERs for rituximab maintenance of €8,72999 and €12,600100. 
Incremental QALYs were 1.4 in scenario1 and scenario2 and 2.1 for scenario3, and these 
values are close to the 1.61 QALYs found by Demousis101. Real-world costs from our 
study in scenario3 (€88,582 and €64,846) corresponds quite well to the total costs of 
a French observational study, €71,314 and €62,251 for the rituximab and observation 
group, respectively99. The small difference might be explained by the fact that their study 
was conducted from a French perspective, costs were based on expert opinion, and no 
costs associated with death were included. Differences in effects between previously 
published studies were observed as well. Our OS was high in scenario1 and scenario2 
compared with results from previous mentioned studies99,100. However, it should be 
noted that these studies were based on the outcomes of the EORTC20981 trial reported 
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after a median follow-up of 33 months91, while our study used the long-term outcomes 
reported after a median follow-up of 6 years92. Remarkably, our OS based on real-world 
data (scenario3) was higher than the OS as observed in the EORTC20981 trial in spite of 
the older patient population investigated. This might be related to different regimens 
prescribed as first-line or follow-up treatment and a different time of inclusion. Besides, 
treatment with rituximab was an exclusion criterion in the trial, while almost 60% of our 
real-world patients received first-line treatment with rituximab. 
The aim of our study was to provide healthcare decision makers with valid cost-
effectiveness results that were generalisable to the real-world patient population. 
While scenarios B and C most closely match the requirements of Dutch policymakers, 
these options are scientifically less valid. In addition, differences between patients 
included in the trials and registry were observed. Therefore, we recommend healthcare 
decision-makers to reconsider their needs and recognise the importance of calculating 
several scenarios. Our case study illustrated that calculating real-world ratios is possible 
although caution is required with data synthesis and interpretation and generalisability 
of these results.
AcknoWLEDgEmEnTs
PHAROS, the Population-based HAematological Registry for Observational Studies, is a 
cooperation of HOVON (Dutch-Belgian Cooperative Trial Group for Hematology Oncol-
ogy), the Institute of Medical Technology Assessment at Erasmus University Rotterdam 
and the Comprehensive Cancer Centers The Netherlands (IKNL) and South (IKZ). We 
are grateful for the data collection by the various registration teams of the Netherlands 
Cancer Registry. HemoBase is an initiative of the Working party Hematology Friesland. 
We are grateful for the data collected by the haematologist, pathologists and clinical 
chemists in the Frysian hospitals.

Chapter 6
A practical guide for using registry data to inform 
decisions about the cost-effectiveness of new cancer 
drugs: lessons learned from the PHAROS registry
Blommestein HM, Franken MG, Uyl-de Groot CA
PharmacoEconomics (2015): 33(6):551-560
76 Chapter 6
AbsTRAcT
Decision makers increasingly request evidence on the real-world cost effectiveness of 
a new treatment. There is, however, a lack of practical guidance on how to conduct 
an economic evaluation based on registry data and how this evidence can be used in 
actual decision making. This paper explains the required steps on how to perform a 
sound economic evaluation using examples from an economic evaluation conducted 
with real-world data from the Dutch Population based HAematological Registry for 
Observational Studies. There are three main issues related to using registry data: 
confounding by indication, missing data, and insufficient numbers of (comparable) pa-
tients. If encountered, it is crucial to accurately deal with these issues to maximize the 
internal validity and generalisability of the outcomes and their value to decision mak-
ers. Multivariate regression modelling, propensity score matching, and data synthesis 
are well-established methods to deal with confounding. Multiple imputation methods 
should be used in cases where data are missing at random. Furthermore, it is important 
to base the incremental cost-effectiveness ratio of a new treatment compared with its 
alternative on comparable groups of (matched) patients, even if matching results in a 
small analytical population. Unmatched real-world data provide insights into the costs 
and effects of a treatment in a real-world setting. Decision makers should realise that 
real-world evidence provides extremely valuable and relevant policy information, but 
needs to be assessed differently compared with evidence derived from a randomised 
clinical trial. 
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inTRoDucTion
Considerations of costs and cost-effectiveness are increasingly important for decision 
making on healthcare resource allocation. Economic evaluations enable a comparison 
of the cost-effectiveness of alternative treatments, and are thus especially important 
for decision making on reimbursement of new expensive drugs. Until recently, eco-
nomic evaluations mainly consisted of cost-effectiveness analyses (CEAs) modelled 
from randomised controlled trial (RCT) data. RCTs aim to demonstrate the efficacy of 
interventions and ensure internal validity by randomly assigning which patients receive 
the new intervention. The circumstances in especially phase III trials are, however, not 
generalisable (i.e. externally valid) to a more heterogeneous group of patients treated 
in a real-world setting. Therefore, many uncertainties remain regarding the relevance 
of the results of RCTs in a real-world setting. Cost-effectiveness evidence based on RCT 
data may, therefore, not be sufficiently informative for decision makers. In such cases, 
evidence needs to be obtained from other sources, for example patient registries. A 
patient registry enables the evaluation of specified outcomes for a population defined 
by a particular disease, condition, or exposure, and when thoroughly designed and 
performed a patient registry can provide real-world evidence of clinical practice, patient 
outcomes, safety, and comparative effectiveness13. 
Guidelines on conducting and reporting economic evaluations are readily avail-
able4,102,103, as well as questionnaires to assess the relevance and credibility of observa-
tional studies104. However, barriers still exist to use evidence from economic evaluations 
in actual decision making105,106. This necessitates the evaluation of the strengths and 
limitations of different types of evidence12. Moreover, practical guidance on using reg-
istry data for economic evaluations as well as on how these evaluations can be used in 
decision making is currently lacking. 
This paper presents a practical guide on how to use registry data to inform decisions 
about the cost effectiveness of new drugs. We discuss the required steps of conducting 
a sound economic evaluation; the steps are explained by using the Population based 
Haematological Registry for Observational Studies (PHAROS) as an example. Although 
using registry data imposes some challenges, we illustrate that it is feasible to conduct 
an economic evaluation. We also discuss potential issues and limitations of economic 
evaluations based on registry data. The last section highlights the value of real-world 
economic evaluations for decision makers.4
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PhARos AnD iTs conTExT
In the Netherlands, outcomes research requirements were implemented in 2006 for 
new expensive drugs to ensure timely access to promising drugs. If a drug is included 
in this policy, hospitals receive an additional ear-marked budget; however, with the 
obligation to gather data on appropriate drug use and real-world cost-effectiveness12,107. 
A reassessment after 4 years determines whether or not additional financing will con-
tinue. Real-world data are often collected within a patient registry.
One of the first Dutch patient registries was PHAROS. PHAROS is a population-based 
disease registry that started in 2010 with three haematologic malignancies (non-Hodg-
kin lymphoma, multiple myeloma, and chronic lymphatic leukaemia) in three regions; 
these regions cover 40% of the Netherlands21. PHAROS expanded over the years to other 
haematological malignancies (chronic myeloid leukaemia, myelodysplastic syndromes, 
and myelofibrosis) and is currently expanding to a nationwide coverage. Like many 
other registries, PHAROS was created to serve multiple purposes including measuring 
and improving the quality of care and determining the clinical and cost effectiveness 
of treatments used in a real-world setting. This paper uses examples of the economic 
evaluation108 based on data from PHAROS. This economic evaluation was conducted to 
inform the reassessment of rituximab maintenance therapy for patients with follicular 
lymphoma, a subtype of non-Hodgkin lymphoma. A Markov Model was used with a 
20-year time horizon to compare rituximab maintenance therapy in patients who re-
sponded to second-line chemotherapy with best supportive care (i.e. observation after 
a response to second-line chemotherapy). For further details we refer to Blommestein 
et al.108. 
conDucTing sounD Economic EVALuATions 
WiTh REgisTRy DATA
Economic evaluations typically include a number of steps, irrespective of the source 
of data. These steps, comprising existing guidelines in academic literature4,102,103 are 
presented in Table 6.1.
The policy issue 
Above all, it is important to define a clear objective for the economic evaluation and 
ascertain its relevance to healthcare decision making. One of the reasons to initiate 
PHAROS was to support decision making on the reimbursement of expensive drugs 
for three haematologic malignancies. Consequently, PHAROS data should facilitate the 
conduction of economic evaluations with real-world data.
A Practical Guide for Using Registry Data 79
6
Define the research question
It is crucial to determine the main research questions of the economic evaluation before 
setting up a registry that should collect the required data. For example, if a registry 
needs to be able to answer questions about the incremental cost-effectiveness ratio 
(ICER), relevant costs, and effects of at least two groups of patients are to be collected. 
Decision makers in the Netherlands require real-world evidence on appropriate use, ef-
fectiveness, and incremental cost effectiveness of drugs. Based on these requirements, 
the following research questions were defined for PHAROS: i) To whom and how is the 
drug of interest prescribed in daily practice? ii) What is the real-world effectiveness of 
this drug? iii) What is the real-world incremental cost effectiveness of this drug? 
Regarding the first research question, PHAROS needed to include detailed data on 
baseline patient characteristics (including prognostic information) of patients who were 
treated as well as of patients who were not treated with the drug of interest. While 
a registry can be intervention based, PHAROS was set up as a disease-based registry. 
The advantage of using a disease-based registry is that all patients are included who 
meet the disease criteria. Therefore, PHAROS included patients eligible for treatment 
as well as patients ineligible for treatment. This also enabled identifying patients eligible 
for treatment but not treated with the drug of interest; these patients may serve as a 
comparator group. In addition, PHAROS needed to provide evidence on how drugs were 
used in daily practice. PHAROS not only included data on types of treatment, but also 
data on treatment regimens, dosages, dose modifications, treatment interruptions, and 
Table 6.1 Steps of an economic evaluation
step Description
Policy issue Define the objective of the economic evaluation and 
ascertain its relevance for health care decision making 
Research question Determine the main research questions (including what 
is studied for whom)
Perspective Define the perspective of the study
Comparator Identify the relevant alternative treatment(s)
Identify, measure, and value costs Identify the relevant costs and measure these costs and 
value the unit costs
Identify, measure, and value outcomes Identify the relevant outcomes and measure and value 
these outcomes
Calculate the cost-effectiveness ratio Obtain the incremental costs and effects and calculate 
the incremental cost-effectiveness ratio
Sensitivity analyses Analyse the uncertainty of the outcomes using 
deterministic, probabilistic and scenario analysis
Presentation and discussion of results Present the results and discuss all issues of concern
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treatment duration. Furthermore, from a policy perspective, it is important to obtain 
insight into equitable access to (expensive) drugs. Population-based registries can serve 
to obtain evidence on uptake by hospital and region; they may thus serve to reveal 
differences in access to a drug between regions and between university and general 
hospitals. In cases where data are based on a non-population-based registry, it is crucial 
that the selection is representative for the entire patient population as well as that a 
sufficient number of patients is included to ensure generalisability. 
Regarding the second research question, PHAROS had to provide evidence on real-
world effectiveness of the drug of interest. RCTs are the gold standard to demonstrate 
efficacy and assure internal validity by random assigning patients to a treatment strat-
egy. In contrast, registries involve observational data and provide details on patients 
treated in daily practice. Reimbursement decisions may depend on the real-world use, 
effectiveness, and costs; in cases where a drug is not effective or not cost effective in 
daily practice, reimbursement of the drug may be reconsidered. If well designed, a 
registry includes information that enables accounting for heterogeneity in daily prac-
tice patients, physician variation, and the healthcare context. Therefore, effectiveness 
estimates based on registry data assure external validity and are thus generalisable to 
the real-world patient population. Ideally, the data should cover all treatments from 
diagnosis until death. However, this also depends on the length of follow-up and the 
time an analysis is required for policy making. 
Regarding the third research question, PHAROS data needed to be able to demon-
strate incremental real-world cost effectiveness of the drug of interest. Similarly to the 
second research question, a well-designed disease registry enables the estimation of 
incremental real-world effects, costs, and cost effectiveness simultaneously.
Define the perspective of the study 
The perspective of the economic evaluation determines what type of costs and outcomes 
are to be included in the analyses. Most economic evaluations are conducted from a 
third-party payer or societal perspective. A societal perspective implies the inclusion 
of all relevant costs (direct and indirect, medical and non-medical costs) and relevant 
outcomes (quality of life and life-years). In contrast, in a third-party payer perspective 
non-medical costs are not included (e.g., traveling costs, productivity costs). Other 
used perspectives are healthcare, hospital, and patient. Requirements regarding the 
perspective may differ per country. It is, however, best to define the perspective before 
the start of data collection because it determines what costs and outcomes are needed 
for the economic evaluation. The objective of PHAROS was to gather evidence for the 
reassessment of expensive drugs in the Netherlands. Such a reassessment requires a 
societal perspective in the Netherlands. 
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identify the comparator(s)
Economic evaluations involve a ‘‘comparative analysis of alternative courses of action 
in terms of both their costs and consequences’’4. The choice of comparator is crucial 
for the outcomes of the economic evaluation and it may potentially be a source of bias. 
In economic evaluations based on real-world data, it may not always be clear which 
alternative treatment is the most appropriate comparator and it may depend on the 
policy issue at stake. The most relevant alternative for decision makers is usually the 
current standard of treatment, this may also be best supportive care or a wait-and-see 
policy108. The inclusion of control groups to a registry adds to its complexity, time, and 
costs13, but it allows the performance of a sound economic evaluation that compares 
a new treatment with the current standard of care. Collecting data over a long time 
period increases the chance that a registry includes an appropriate comparator group 
and avoids incomparable patient groups because of for example a rapid uptake of a new 
drug. This was, for example, illustrated by a Dutch observational study among patients 
with stage III colon cancer. Patients ineligible for the drug of interest had higher levels 
of unfavourable prognostic factors, i.e. carcinoembryonic antigen levels at baseline109. 
PHAROS included patients diagnosed from 2004 to 2012 and included relatively more 
patients in the comparator group who were included in the earlier years of the registry, 
while the intervention group included more patients who were diagnosed at the later 
years of the registry. 
identify, measure, and value relevant costs
Costs can be identified in the following categories; hospital resources, community care 
resources, patient and family resource use, and resource use in other sectors4. Guide-
lines regarding economic evaluations and valuation of unit costs can differ per country, 
as can the available data. We used Dutch data and the methods as set forward by Dutch 
guidelines110. 
Relevant cost items for inclusion in the registry depend on disease characteristics, the 
patient population, treatment strategies of interest, and the perspective of the study. It 
is usually not efficient to collect all potential cost components and a balance needs to 
be established between the relevance of the cost item relative to the burden of collec-
tion13. This balance can be based on previous research findings and/or determined in 
collaboration with treating physicians and based on professional guidelines. In PHAROS, 
data on hospital resource use were collected for outpatient visits, daycare treatment, 
inpatient days, and intensive care days. In addition, data on drug dosages, treatment 
duration, and supportive care were collected. Data on services provided outside the 
hospital were not collected.
Generally, data on hospital resource use can be collected from electronic hospital 
records and patient files. However, data can only be retrieved if it has been adequately 
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reported by physicians. Adequate reporting may be hampered in daily practice because 
physicians are not dictated by strict criteria as in trials. Patient questionnaires can 
be used to collect data on additional direct medical costs (e.g., healthcare providers 
outside the hospital, concomitant medication), direct non-medical costs (e.g., traveling 
costs), and indirect non-medical costs (e.g., productivity costs). It is important to note, 
however, that the inclusion of cost items other than direct medical may be hampered 
in a registry in which data are retrospectively collected. In PHAROS, we encountered 
several issues. First, information on resource use outside hospitals was expected to be 
extremely fragmented, especially in cases of severe diseases with centralised treatment. 
Patients in the PHAROS registry were often discharged from hospital and referred to dif-
ferent rehabilitation centres. Second, although PHAROS was initiated as a prospective 
registry, clinical and costs data were mainly collected retrospectively at several points 
in time. In other words, we started in 2010 to collect data from patients diagnosed 
from 2004 onwards. Patients were identified using the nationwide Netherlands Cancer 
Registry. This resulted, however, in a delay in the inclusion of patients. 
Regarding productivity costs, PHAROS was supplemented with information from the 
Patient Reported Outcomes Following Initial treatment and Long term Evaluation of 
Survivorship (PROFILES) study. This longitudinal cross-sectional study was conducted to 
obtain insight on amongst others quality of life and productivity losses of patients with 
follicular lymphoma111. However, the reassessment of the drug of interest was bounded 
by a 4-year re-evaluation period. At the time, our economic evaluation needed to be 
conducted for Dutch decision makers, the number of patients included in the longitudi-
nal study was limited and data could not be matched to the disease states in our model. 
Therefore, the economic evaluation did not include productivity costs. We assumed 
that this was a conservative approach because the productivity costs for rituximab 
maintenance are most likely lower compared with the best supportive care group100. 
Furthermore, economic evaluations should only concern costs related to the disease 
and/or its treatment instead of the costs induced by unrelated diseases occurring 
simultaneously. It is important to note, however, that establishing such a relation is 
not always easy or clear-cut when using registry data. For example, admission of older 
patients to a nursing home may either be related to the disease but may also have oc-
curred for other reasons. Moreover, determining which costs are related to the disease 
and/or its treatment is even less straightforward for an older population and in cases 
where comorbidities are present. Therefore, the inclusion of some cost items may be 
debatable. 
The inclusion of cost items in the PHAROS economic evaluation was based on our 
previous experiences and supported by the literature that reported the same main cost 
drivers in treating haematologic patients77,108. Therefore, it was believed that an ap-
propriate balance was achieved between registration burden and relevance of the cost 
A Practical Guide for Using Registry Data 83
6
items. Such an evaluation of assumptions is crucial and depends on the characteristics 
of the patient population and the type of drug of interest. More detailed information 
regarding the included cost items and the unit costs are reported elsewhere108. 
The definition of the policy issue and research questions determines the cost compo-
nents included in a registry. It is possible that researchers who conduct the economic 
evaluation are not yet involved at the start of the registry and must therefore rely on 
available data. In these cases, confirmations from the literature should be obtained to 
ensure that the most important cost components are included in the economic evalu-
ation.
identify, measure, and value outcomes of each alternative
The most preferred effectiveness outcomes for policy makers are overall survival (OS)/
life-years gained (LYG), and quality-adjusted life-years (QALYs) but also other clinical 
objectives linked to improvement in patients’ outcomes can be included110. The follow-
up in registries is generally much longer compared with RCTs and data are collected on 
subsequent treatments. Therefore, registries usually provide more information on OS. 
In addition, if data on life-time follow-up are collected, extrapolation of survival data, 
associated with uncertainty, is no longer necessary. Life-time follow-up is extremely 
valuable for economic evaluations because a lifetime horizon is usually required to in-
corporate all potential differences in effects and costs for the remainder of the patient’s 
life4. However, because economic evaluations should provide timely results, it may be 
necessary to conduct evaluations prior to reaching the ideal follow-up time. 
Regarding other effectiveness outcome measures, it is important to be aware that 
they may differ from the endpoints of an RCT. For example, primary endpoints of RCTs 
in cancer are most often response, time to progression, and progression-free survival; 
OS rarely is a primary endpoint in an RCT. In observational registries, however, data on 
response and progression may be biased because this may not be accurately captured in 
patient files93. Moreover, physicians in daily practice often do not report using standard-
ized response criteria112, whereas RCTs dictate response criteria. This may especially be 
the case when data are retrospectively collected by other individuals than the treating 
physician. The moment at which progression is established may also differ from an RCT 
because there is no strict monitoring scheme; progression could thus be established 
much later than it occurs. Therefore, we advocate using time-to-next-treatment (TTNT) 
as a proxy for progression, additional to survival, in economic evaluations based on 
registry data. Whenever a physician changes to another treatment, there must be a 
reason for doing so; progression can be one of them. In PHAROS, we used TTNT to 
model final outcomes (i.e. LYG and QALYs). 
Regarding the adverse effects of treatments, these should be accounted for in the 
economic evaluation. However, identifying and measuring toxicity data may be ham-
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pered in a registry. Although adverse events and their severity grading were collected in 
PHAROS, we encountered substantial issues establishing causal relations between the 
treatment and the adverse event. 
Regarding the outcome quality of life, these data can be collected in a registry using 
patient-reported outcome measures. As mentioned previously, the number of patients 
included in the PROFILES study was still limited, and we could not match the data to 
the disease states in our model. Therefore, we based the utilities on findings in the 
literature. 
calculate the icER
This step usually involves modelling methods such as Markov modelling or patient-
level simulation modelling177. It is important to carefully select the model that best fits 
the data from the registry185. This step can greatly differ from only using data from an 
RCT. The main issues in calculating the real-world incremental cost effectiveness are 
associated with confounding by indication, missing data, and insufficient numbers of 
(comparable) patients. These issues will be further discussed in the next section. The 
ability to deal with these issues determines whether it is possible to develop a feasible 
model for the economic evaluation and to obtain valid incremental estimates based 
on real-world data only93. We used the methods as set forward by Dutch guidelines. 
Detailed information on the cost-effectiveness calculations performed with PHAROS 
data is reported elsewhere108.
Assessment of uncertainty
The outcomes of an economic evaluation are surrounded with uncertainties, irrespec-
tive of whether the economic evaluation is based on data from an RCT or a registry. 
Therefore, it is important to extensively conduct analyses of the most important uncer-
Table 6.2 Scenario analysis of the PHAROS economic evaluation108
scenarios
Data for effects Data for costs icER per 
QALy
Total costs Total QALys
(cases and 
controls)
(cases and 
controls)
cases controls cases controls
Scenario 1 RCT RCT € 12,655 € 56,608 € 39,182 7.8 6.5
Scenario 2.1 RCT Matched RW € 23,821 € 100,424 € 67,756 7.8 6.4
Scenario 2.2 RCT Unmatched RW € 5,162 € 96,720 € 89,629 7.8 6.4
Scenario 3.1 Matched RW Matched RW € 11,245 € 88,582 € 64,846 8.7 6.5
Scenario 3.2 Matched RW Unmatched RW € -557 € 85,096 € 86,271 8.7 6.5
Scenario 3.3 Unmatched RW Unmatched RW € -6,242 € 81,231 € 95,830 9.4 7.1
RCT: data from randomised clinical trials, RW: data from real-world practice
Table adapted from Blommestein et al.108
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tainties. This information may be crucial for deciding on the adoption of a new drug. 
The uncertainty of input parameters can be analysed by scenario analysis as well as 
probabilistic and univariate sensitivity analyses4. In PHAROS, we observed great patient 
heterogeneity which resulted, in combination with small numbers of eligible patients 
treated with the drug of interest, in wide confidence intervals. In addition, as presented 
in Table 6.2, different scenarios based on different assumptions lead to different cost-
effectiveness ratios (e.g., costs per QALY ranged from €11,499 to €12,789 to €23,919 
in three scenarios108. While information regarding the assumptions for the model and 
appropriate sensitivity analyses on assumptions apply to all economic evaluations, we 
believe this is even more important when using registry data. Assumptions to calculate 
incremental outcomes might be because of the absence of randomisation, which is less 
straightforward. 
Presentation of the results and discussion of all issues of concern to 
users
Presenting and discussing the results in an understandable matter is of utmost impor-
tance for the use of economic evaluations in decision making105. This may even be more 
important when the economic evaluation is based on data from registries because 
registry data are often less straightforward and more prone to bias. Topics that need 
to be reported depend on the conducted economic evaluation but should at least 
include: information on confounders, methods to account for missing values, validity, 
and generalisability of the results. The latter two are extremely important to determine 
usefulness of the results for decision makers4.  It is also important to separately report 
both the effects and costs per alternative. Extremely high ICERs may, for example, in-
dicate large cost differences between alternatives, but they can also result from small 
incremental effects.
ThE mAin issuEs in Economic EVALuATions 
bAsED on REgisTRy DATA
There are three main issues with conducting economic evaluations with real-world data 
from registries: i) confounding by indication; ii) missing data; and iii) insufficient num-
ber of patients. If encountered, it is crucial to appropriately deal with these issues to 
maximize the validity of the results of the economic evaluation and its value to decision 
makers.
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confounding by indication 
One of the main concerns about observational data raised in academic literature is 
the lack of a randomised controlled setting, which results in problems with internal 
validity113-115. Instead of treatment being randomly assigned as in an RCT, the choice of 
treatment is made by the treating physician based on characteristics of the patient. In 
addition, insurance coverage or national guidelines may also influence outcomes12. It is 
important to be aware that confounding by indication is a major challenge for economic 
evaluations based on observational data from registries. PHAROS showed that the real-
world patient population was highly heterogeneous. When baseline patient character-
istics associated with the outcome of interest differ between the treatment groups, the 
results of a study are biased if not appropriately corrected for these differences. We are 
aware that no correction method can substitute randomisation, but there are several 
methods that can be used to increase the validity of the outcomes. 
Methods to deal with confounding by indication are for example multivariable 
regression modelling, propensity score (PS) matching, and data synthesis. Multivari-
able regression modelling has been the conventional method to reduce bias related 
to confounding by indication. Potential confounders are included simultaneously in a 
regression model that estimates final outcomes. Using multivariable regression models 
for registry data requires information on patient and disease characteristics. In the past 
decade, there has been an increasing trend of using PS matching techniques116. This 
technique allows the calculation of the chance of receiving the treatment of interest 
by using observed patient characteristics95. Propensity scores are then used to match 
a treatment group to a comparator group based on patients who have similar chances 
(i.e. propensity scores) of receiving the treatment of interest. Other applications of the 
PS include stratification, covariance adjustment, and weighting95,117. Although PS match-
ing techniques are increasingly and successfully used116,118, these techniques are less 
attractive when multiple treatment strategies are compared simultaneously. A better 
understanding of the benefits and limitations in practical circumstances of PS matching 
vs multivariate risk modelling is still needed116. 
Finally, in case correcting for confounding is hampered (e.g., missing values or a lack 
of a control group), data synthesis can be used to model incremental outcomes. For 
example, it may be a good option to synthesize efficacy data from an RCT with effective-
ness data from daily clinical practice, especially when an appropriate comparator group 
is lacking119. However, it is important to be aware that there was an initial need for data 
from daily practice because patient baseline characteristics may differ between patients 
treated and not treated in an RCT. 
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missing data
Even when a registry is well designed and executed by an active interdisciplinary col-
laborative research group, it is to be expected that missing values on certain variables 
will exist. Therefore, only analysing complete cases is most likely not possible. Although 
imputing mean values might be less of a problem for RCT data, this method is not to 
be recommended because the patient population in daily practice is usually far more 
heterogeneous. We recommend using the multiple imputations method because this 
method not only imputes missing values but also accounts for the uncertainty associ-
ated with the imputed value by creating multiple datasets120. Missing values are imputed 
based on observed variables. To account for the uncertainty of the predicted variables, 
each missing value is imputed multiple times resulting in several complete datasets. 
The analyses of the combined datasets produce overall estimates and standard errors 
that reflect the uncertainty around the imputed variables. However, it is important to 
note that this method can only be used for missing values that depend on known and 
observed variables (i.e. variables missing at random121).
insufficient number of comparable patients
Sufficient numbers of patients and follow-up data are required for conducting a sound 
economic evaluation with registry data. This is, however, sometimes difficult to realise 
in daily practice. A large difference may exist between the actual patient population 
(i.e. the population included in the registry) and the analytic patient population (i.e. 
the population that met the criteria for analysis13). RCTs usually base the number of pa-
tients included on power calculations and continue including patients until the desired 
number has been reached. This is, however, not possible in daily practice; for example, 
if physicians no longer use the alternative treatment, the analytic population will be 
small. The minimal required number of patients also depends on the extensiveness of 
the heterogeneity of the real-world patients, which may not be known in advance. The 
option to actively search for extra patients treated with the drug of interest has to be 
balanced with a potential diminishing generalisability. 
In PHAROS, we faced confounding by indication, missing data, as well as a small 
analytical patient population. First, confounding by indication was present because the 
comparator group included relatively more patients with a worse prognosis compared 
with the treatment group108. We used PS matching methods to correct for observed dif-
ferences in patient and disease characteristics. After matching, both groups were more 
balanced regarding characteristics of re-induction therapy, B symptoms, and disease 
progression. Table 6.2 illustrates the variation on outcomes of our scenario analyses 
in which we used both matched and unmatched data. Second, we encountered a 
small analytical patient population in PHAROS. The actual population included nearly 
700 patients with follicular lymphoma. However, the required analyses were too early 
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for most patients because the patients did not (yet) receive a second line of chemo-
therapy. Therefore, only 14% of the actual population was included in the analytic 
population. To increase the number of patients, data were obtained from Hemobase, a 
multidisciplinary Web-based electronic patient record in the north-eastern part of the 
Netherlands that collected similar data. Although this increased the analytic population 
from 89 to 113 patients, the number of patients remained small. The rather small and 
highly heterogeneous population led to wide confidence intervals for treatment with 
rituximab maintenance (e.g., OS of matched real-world effects ranged from 1.0 to 3.9 
years and costs ranged from -€44,362 to +€105,977). Third, because missing data were 
present for relevant outcomes (e.g., response rates), the number of patients included in 
our analyses reduced even further after applying PS matching (e.g., N = 51 reduced to 
N = 43 in the rituximab group). 
ThE VALuE of REAL-WoRLD Economic 
EVALuATions foR DEcision mAkERs
Decision makers often make limited use of evidence from economic evaluations122,123. 
There is, however, a higher chance that decision makers use such evidence if the evi-
dence is accessible (i.e. timeliness and understandable) and acceptable (i.e. accuracy 
and validity of research methods given institutional requirements)106. Above all, it is 
crucial that decision makers realise that registry data differ from RCT data and that 
the outcomes of their economic evaluations should thus be assessed differently. This 
should, however, not be seen as a drawback, but rather as an important opportunity. 
Both data sources complement each other; they allow balancing internal validity and 
generalisability and answer different questions. 
The economic evaluation based on PHAROS data demonstrated these differences by 
calculating different scenarios. Table 6.2 presents these scenarios as well as their out-
comes. We discuss the value of each scenario for healthcare decision makers regarding 
whether the research methods were accessible and acceptable. 
Scenario 1 was only based on RCT results; no real-world data were included in 
the analyses. Randomisation ensured the internal validity; therefore, the difference 
between the intervention group (i.e. patients who received rituximab maintenance 
therapy) and the control group (i.e. patients who were only observed) could be attrib-
uted to the treatment. In other words, treating patients with rituximab maintenance 
therapy costs €12,655 per QALY gained compared with observation only. This scenario 
used well-known conventional methods (RCT data) and may thus be highly accessible 
and acceptable to decision makers. Accessibility and acceptability is ensured by under-
standable results, i.e. economic evaluations based on trial data are intuitive because 
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conventional methods are used. This is, however, at the cost of generalisability, because 
no data were used from daily practice. The results do not inform decision makers on the 
expected costs and effects in the real-world patient population while this was the policy 
issue at stake. As a consequence, none of the questions raised by decision makers (i.e. 
to whom and how is the drug prescribed and what is the real-world cost effectiveness) 
can be answered with scenario 1. 
In scenarios 2.1 and 2.2, efficacy data from the RCT were combined with matched and 
unmatched real-world cost data, respectively. This resulted in substantial differences in 
the estimated costs per QALY gained (€23,821/ QALY for scenario 2.1 and €5,162/QALY 
for scenario 2.2). Because both scenarios combined RCT data with real-world data, 
the interpretation of the outcomes may be more complicated because it is unclear to 
whom the results apply, i.e. trial, real-world patients, or both. In other words, results 
are less accessible for decision makers. The effectiveness estimates are internally valid 
because they are based on RCT data, but they do not inform decision makers on the 
effectiveness in daily practice. In contrast to scenario 1, both scenarios 2.1 and 2.2 
provide information on real-world costs. It should be noted, however, that the accuracy 
of the incremental costs in scenario 2.2 may be impeded because patients treated and 
not treated with rituximab maintenance therapy were not comparable and we did not 
correct for these differences by using a matching method. Moreover, it is questionable 
for whom the ICER is actually valid (i.e. the efficacy estimates apply to trial patients 
while the cost estimates apply to the real-world patient population). Therefore, both 
ICERs should be carefully interpreted. 
Scenarios 3.1, 3.2, and 3.3 used real-world data for both cost and effectiveness esti-
mates. Consequently, the results are generalisable to the real-world patient population 
and applicable to the policy issue at stake. Because decision makers are less familiar 
with interpreting real-world data, these scenarios may be less accessible for decision 
makers. It is, therefore, crucial that the methods and results are extensively reported 
in an understandable language. Unmatched data as used in scenarios 3.2 and 3.3 in-
form decision makers on the real-world costs and effects, but a major drawback is that 
differences cannot be assessed between cases and controls because the incremental 
estimates are not sufficiently valid. Both scenarios 3.2 and 3.3 show higher total costs 
for the control group while the opposite was expected and shown by the other sce-
narios. Although matching methods reduced the analytical population, we believe that 
scenario 3.1 provides the most accurate and valid results because matching methods 
were used for both costs and effects to reduce bias related to confounding by indication. 
Decision makers were interested in real-world outcomes and, in the Dutch case, re-
quired evidence from daily clinical practice to reduce the uncertainty of both real-world 
costs and effects of rituximab maintenance therapy. We believe that the computed 
ICERs can only be used if the applied methods are accurate and valid. In other words, 
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incremental outcomes of economic evaluations can only be used when cases and con-
trols are comparable or when appropriate methods are used to correct for differences 
in baseline characteristics (scenarios 1 and 3.1). In cases where baseline characteristics 
greatly differ between patient groups and no matching methods have been used, the 
outcomes of an economic evaluation should not be acceptable for decision makers 
because the incremental outcomes are not accurate and not valid. We believe that 
scenario 3.1 is most valuable to decision makers because this scenario achieves an 
appropriate balance between generalisability and internal validity. The estimated cost-
effectiveness ratio (€11,245) also provides reassurance to decision makers that efficacy 
from the trial can be realised at favourable costs in the real-world patient population. 
However, because a formal decision has not yet been made, it is currently unknown 
how decision makers interpreted and evaluated the outcomes. 
fuRThER REsEARch AREAs foR REgisTRy DATA 
Expensive cancer drugs are increasingly developed for patient populations stratified 
by genetic characteristics and this trend illustrates an increasing role for biochemical, 
histological, and genetic markers to aid treatment decisions124. While the PHAROS 
registry focused on expensive drugs, registries may also be used to collect information 
on biochemical, histological, and genetic markers, which can be used for economic 
evaluations of these markers. This may be an important subject for further research 
using registry data.
finAL REmARks
It is important for decision makers that a drug provides sufficient value in relation to 
its costs in daily practice. Economic evaluations based on real-world data can provide 
extremely valuable insights into real-world incremental cost effectiveness108,119,125. In 
PHAROS, both matched and unmatched outcomes seem favourable for the decision to 
adopt rituximab maintenance therapy. In other cases, the variation in outcomes can be 
much greater and less favourable than in PHAROS, which necessitates a careful evalu-
ation of the causes of the conflicting results between RCT and real-world data. More-
over, it may not always be possible to develop a feasible model with real-world data 
to calculate incremental estimates93. We advocate that incremental estimates (ICERs) 
should always be based on matched patients in case patient groups are incomparable. 
However, unmatched real-world data are still valuable for decision makers because they 
provide evidence on costs and effects of a treatment in a real-world setting, although 
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not incremental77,93,123. Real-world evidence can also be used to obtain a certain level 
of reassurance regarding the extent to which the evidence from the RCT is applicable 
to the real-world patient population. It is, however, crucial that decision makers realise 
that the outcomes of an economic evaluation based on registry data should be assessed 
differently compared with the outcomes of an economic evaluation based on RCT data. 
The need for generalisable outcomes has to be balanced with the need for internally 
valid outcomes. While registries are able to provide insight into the use, effectiveness, 
and costs of a therapy in routine clinical practice and therefore offer healthcare deci-
sion makers with realistic expectations for outcomes in real-world patients, it should be 
noted that other solutions exist to balance internal and external validity. For example, 
pragmatic trials can include a broad patient population and can thus also ensure 
generalisability. Pragmatic trials have the major advantage of randomising treatment 
but are on the other hand, however, associated with logistical, ethical, and sample size 
challenges as well as high resource investments126. 
In PHAROS, we demonstrated that it was feasible to conduct a real-world economic 
evaluation using registry data. We believed that we provided decision makers with 
acceptable and accessible information and showed that the real-world outcomes con-
firmed the efficacy of the trial. In our opinion, this provided reassurance to decision 
makers about a drug’s value for money in daily clinical practice. 
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objectives: To study the impact of novel treatments for elderly (≥66 years) patients with 
multiple myeloma (MM) in daily practice by comparing real-world effects (overall 
survival (OS) and quality-adjusted life years (QALYs)) and costs over time. Also, we 
calculate cost-effectiveness of treatment sequences commonly prescribed to predict 
effects and costs if patients had received a different treatment sequence. 
methods: Real-world data including patient and disease characteristics, treatment 
information and resource use were collected from 1054 elderly patients with MM. 
Patients received first-line treatment during 2004–2007 (cohort 1) and 2008–2013 
(cohort 2). The two cohorts were compared using a patient-level simulation (PLS) 
model comprising regression models which used patient and disease characteristics 
to estimate time to next treatment and death. Effects and costs from cohort 2 were 
compared to 4 commonly prescribed real-world sequences. 
Results: Utilisation of novel agents was higher for cohort 2 compared to cohort 1. Mod-
elled average OS for cohort 1 was 38 months (median 25) and total costs €44,200. 
OS for cohort 2 was 42 months (median 28) and total costs €69,017. The model 
identified potential OS gains if all patients were to be treated using combinations 
containing thalidomide, lenalidomide and bortezomib in that particular order. This 
sequence had, compared to real-world treatment, the most favourable incremental 
cost-effectiveness ratio, €24,618 per life year gained and €34,875 per QALY. 
conclusions: Our patient-level model enabled to study the effects and costs of entire 
treatment sequences and to compare real-world treatment patterns over time. 
Increased utilisation of novel agents improved survival and increased costs for real-
world patients with MM in the Netherlands.
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inTRoDucTion
Like many cancers, multiple myeloma (MM) is an incurable disease and treatment is 
characterised by sequential treatment lines aiming to prolong progression-free and 
overall survival (OS). MM is the second most common haematological malignancy 
with 20,180127 and 37,200128 newly diagnosed patients in the United States (2010) and 
Europe (2008), respectively. Median age at diagnosis is 70 years and the number of 
patients with MM is expected to increase due to ageing of the population129,130. The 
clinical course of the disease is very heterogeneous with a wide variation in OS131,132. 
While median OS is 3.7 years for all patients, OS decreases steadily with increasing 
age, that is OS is 5.2 years in patients ≤50 and 2.6 years in patients ≥80133. During the 
past decade, improved OS in a real-world setting has been reported initially mostly for 
younger patients134 but recently also for elderly patients135. Improvements in survival 
were linked to advances in treatment, but besides therapy, many patient and tumour 
characteristics contribute to the final outcome136,137. The majority of the patients is 
ineligible for high-dose therapy followed by stem cell transplantation due to age (age 
≥66 yr.) or coexisting conditions130. The introduction of innovative treatments such as 
thalidomide, bortezomib and lenalidomide during the past decade changed treatment 
of MM and improved OS138-141. However, these improvements imply increasing health-
care costs142 emphasising the relevance of studying costs and effects simultaneously in 
cost-effectiveness analysis (CEA). 
Randomised controlled trials (RCTs) are the golden standard for establishing efficacy 
and are frequently used for CEAs143-146. However, generalising data of RCTs to patients 
in daily clinical practice are hampered because MM mainly affects elderly and/or 
heterogeneous patients generally not included in RCTs147. So while data from RCTs are 
available for this patient population and have demonstrated efficacy of, for example, 
thalidomide139, it is unclear whether similar outcomes are achieved among patients 
treated in daily practice. For example, what is the effectiveness of thalidomide treat-
ment in a real-world setting given the patient and disease characteristics of real-world 
patients and the context in which treatment is provided. In addition, RCTs are designed 
to compare treatments covering only a limited time period. Consequently, using RCTs, a 
CEA covering multiple treatment sequences in a row cannot be made. 
While several RCTs and cost-effectiveness studies were conducted for patients with 
MM, these studies provide us only with pieces of information that – even after combin-
ing them – do not represent the complete real-world picture. Hence, a CEA of treatment 
sequences based on real-world data is of utmost importance. The aim of this study was 
twofold: to provide insight into real-world costs and effects over time and to compare 
real-world cost and effects of different sequences for real-world patients. 
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Regarding the first, the novelty of this study is that it provides insight into real-world 
OS and costs. These data on effectiveness provide additional important information to 
the efficacy findings from RCTs currently available. Dutch treatment guidelines recom-
mended thalidomide as first-line treatment from 2008 onwards, and we hypothesised 
that this change influenced both effects and costs of MM treatment. Therefore, results 
were calculated separately for two cohorts; before and after thalidomide was recom-
mended as first-line treatment. 
Regarding the second aim, real-world data enabled us to study treatment sequences, 
that is multiple treatment lines in a row, instead of only covering one line of treat-
ment. We calculated the cost-effectiveness of different treatment sequences to identify 
whether effects and costs for patients would have been better if patients had received 
a different treatment sequence. These sequences included drugs such as thalidomide, 
bortezomib and lenalidomide. Effectiveness of the drugs in these scenarios was ob-
tained from real-world data controlling for patient and disease characteristics.
mEThoD
clinical analysis
Data sources and patients. 
Data were derived from the Netherlands Cancer Registry (NCR) and the Population based 
Haematological Registry for Observational Studies (PHAROS)21,148. In PHAROS, patients 
from three regions in the western and southern part of the Netherlands diagnosed with 
MM between 2004 and 2011 were included. From these patients, we selected those 
patients who actually received treatment for MM and were at least 66 yr. old (N = 1054) 
as these patients were not eligible for a stem cell transplantation. Based on changed 
guidelines, the patients were divided into cohorts: cohort 1 included patients receiving 
first-line treatment between 2004 and 2007, while cohort 2 included patients receiving 
first-line treatment between 2008 and 2013. Missing values were present in the data set 
and imputed using multiple imputations by chained equations for each variable120,149. 
Ethical approval for the study was obtained from the Dutch Medical Ethics Committee. 
Time and events.
For each patient from the PHAROS data set, the duration of first-line treatment (TTE1) 
was calculated. This was the time from first-line to second-line treatment for patients 
receiving more than one line of treatment. For patients who received only first-line 
treatment, the time to death was calculated. The duration of second-line treatment 
(TTE2) was obtained similarly. For patients who received a third-line treatment, the 
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time from third-line treatment to death (TTE3) was calculated. OS was obtained by 
summarising TTE1, TTE2 and TTE3.
Regression models 
Health economic evaluations require data on the costs and benefits of treatments over 
the lifetime of patients, and extrapolation beyond follow-up was performed by fitting 
parametric distributions (i.e. exponential, Weibull, gamma, Gompertz, lognormal and 
log-logistic150) to the observed TTE1, TTE2 and TTE3. Parametric functions were assessed 
for their goodness of fit to the data using Akaike information criteria (AIC), Bayesian 
information criteria (BIC) and visual inspection. After identifying the distribution that 
best fitted the data, potential parameters that could be included in the regression mod-
els were identified from PHAROS151, because this registry included prognostic variables 
for survival or the start of a new treatment. We used a forward selection method to 
decide which variables should be included in the regression models to predict TTE1, 
TTE2 and TTE3. Variables were included if the inclusion resulted in better AIC or BIC 
and significance levels were acceptable (P < 0.1). The types of events were predicted 
with logistic regression models. Variables for the type of event models were selected 
through forward selection and impact on the R2 of the models and significance levels 
(P < 0.1).
simulation study
Model type
Modelling is necessary to calculate life-time costs and effects and the cost-effectiveness 
of several scenarios. To model the cost-effectiveness of MM treatments properly, a flex-
ible modelling method was required. Patient-level simulation (PLS) models (a subcat-
egory of discrete event simulation models) focus on entities (patients) with attributes 
(characteristics) and events and can easily incorporate treatment history and patient 
characteristics152.
Base case and scenario analyses 
Real-world treatments were categorised in five groups including the following regimens: 
melphalan–prednisone (MP), thalidomide-based (Thal), bortezomib-based (Bmib), 
lenalidomide-based (Lena) and other treatments (Other). Base case analysis modelled 
the effects and costs of real-world treatment and showed these outcomes separately 
for cohort 1 and cohort 2 to answer the first research question. Real-world treatment in 
the base case consisted of a mix of therapies prescribed during these time frames, that 
is real-world treatment patterns derived from PHAROS. To answer the second research 
question to see whether real-world treatment could be improved, costs and effects of 
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alternative scenarios were calculated. These scenarios included treatment sequences 
most commonly prescribed during our observation period: MP–Thal–Bmib, MP–Thal–
Lena, Thal–Bmib–Lena and Thal–Lena–Bmib. In the first two scenarios, all patients 
(100%) in the first-line were treated with MP, while in the third and fourth scenario, 
all patients received first-line treatment with Thal. Second- and third-line treatments 
were only assigned to patients who did not die after first- or second-line treatment, 
respectively. The number of patients who received second- and third-line treatment per 
scenario is included in the Supporting information. Costs and effects of the sequences 
were calculated and compared to real-world treatment from the most recent cohort 
(cohort 2). 
Model simulation 
Each model run included the simulation of 1054 patients. As it is a PLS model, each 
patient is simulated individually. The model simulation of one patient consists of a maxi-
mum of three treatment lines (Figure 7.1). The first treatment line included four steps. 
First (1.1), patient and disease characteristics were assigned to the patient by drawing 
figure 7.1 Example of the simulation of one patient
Step Aim Method
1.1 Characteristics Line 1 Predefined distributions real-world data PHAROS
1.2 Treatment Line 1 Scenario based or predefined distributions real-world data PHAROS
1.3 Time to event Line 1 Weibull model [Age1, Sex, WHO1, Albumine1, Haemoglobin1, Platelets1, 
Serum calcium1, Treatment1, Other Haematological malignancies, Study 
treatment]
1.4 Type of event Line 1 Logistic regression model [TTE 1, Age1, WHO1, Treatment1]
                      Death
Event 1
                      Line 2
END of simulation patient X
2.1 Characteristics Line 2 Linear regression real-world data PHAROS line 1 [e.g. linear regression 
Haemoglobin2 including TTE1 and Haemoglobin1]
2.2 Treatment Line 2 Scenario based or predefined distributions real-world data PHAROS
2.3 Time to event Line 2 Weibull model [TTE1, Albumin2, Creatinine2, Haemoglobin2, LDH2, 
Treatment2]
2.4 Type of event Line 2 Logistic model [TTE1, TTE2, Age2, WHO1, Haemoglobin2, Treatment2]
                      Death
Event 2
                      Line 3
END of simulation patient X
3.1 Characteristics Line 3 Linear regression real-world data PHAROS line 1 and/or line 2 [e.g. linear 
regression Haemoglobin3 including Haemoglobin2]
3.2 Treatment Line 3 Scenario based or predefined distributions real-world data PHAROS
3.3 Time to death Weibull model [TTE2, Albumin3, Creatinine3, Platelets3, Treatment3]
END of simulation patient X
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random numbers from predefined distributions based on real-world data. Second, 
treatment was allocated to the patient (1.2). Depending on the scenario, treatment was 
either obtained from predefined distributions based on real-world treatment patterns 
or assigned based on one of the four scenarios. The third step (1.3) calculated the time 
to the first event (TTE1). TTE1 was obtained from individual survival curves based on the 
parametric survival model included in the Supporting Information. The fourth step (1.4) 
determined the type of event (Event 1), next treatment or death. The simulation ends 
after one line of treatment for patients who died. Second-line treatment was simulated 
with four similar steps (2.1, 2.2, 2.3 and 2.4) for patients who received a second-line of 
treatment. Third-line treatment was similar to the previous treatment lines except that 
time to death (TTE3) was modelled. 
Input parameters 
Utility values (necessary to calculate quality-adjusted life years (QALYs)) for MM are 
unavailable for elderly real-world patients in the literature. A population based cross-
sectional study was conducted in the Patient Reported Outcomes Following Initial 
treatment and Long term Evaluation of Survivorship (PROFILES) registry111. In 2009, 101 
MM patients of 66 yr. or older received a questionnaire including – because the official 
5-level version was not available yet – a preliminary version of the EuroQol-5 dimen-
sions 5 level. Based on 61 patients, the average utility vale was 0.76 (SD 0.21, range: 
0.005 to 1.0), calculated with the Dutch EQ-5D-5L Value Set153.
Resource use including outpatient and day care visits, inpatient wards and intensive 
care days per treatment were obtained from PHAROS. Costs of inpatient days (€562), 
day care (€182), outpatient days (€120) and intensive care (€2,377) were obtained from 
Gaultney et al.77 Drug dosages were obtained from guidelines, and prices were derived 
from the official Dutch price list154. For generalisability reasons, the price for thalidomide 
– which is substantially lower in the Netherlands compared to European countries – was 
based on the literature155. Costs were determined for the year 2014, and according to 
Dutch guidelines, discount rates were 1.5% for effects and 4% for costs156. Additionally, 
discount rates were 0% to calculate undiscounted results.
Probabilistic sensitivity analysis 
Probabilistic sensitivity analysis (PSA) was performed to explore the possible outcomes 
and the likeliness of these outcomes. In the PSA, probability distributions for input 
parameters were used instead of point estimates to reflect the uncertainty of these 
parameters. Input parameters were varied simultaneously, and the model was run 1000 
times for 1054 patients. Input parameters for resource use followed gamma distribu-
tions, unit costs normal distributions and utility values beta distributions. Regression 
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models were varied using Cholesky decomposition to retain the correlations between 
the parameters seen in the covariance matrix157.
REsuLTs
First, the clinical analysis based on real-world data will be discussed; these results served 
as input for the simulation study for which the results are discussed in the second part 
of this paragraph. 
clinical analysis
Patient characteristics and treatment patterns 
From PHAROS, we obtained data from 1054 elderly patients with MM. Median follow-
up was 50 months. Table 7.1 shows the patient and disease characteristics at diagnosis 
of the real-world data as well as the characteristics after multiple imputation. Table 7.2 
presents real-world treatment patterns for line 1, line 2 and line 3 per cohort. Different 
treatment patterns were observed for cohort 1 and cohort 2. For example, MP was 
Table 7.1 Patient and disease characteristics at diagnosis and first line treatment of the original 
real-world data, imputed data and the simulated patient population
Patient characteristics at diagnosis 
 
Real-world 
patients
imputed data simulated 
patients*
N=1054 N=1054 N=1054
Age Mean 76 76 76
Median [Range] 75 [66-93] 75 [66-93] 76 [66-93]
Missing 0%
Male sex N(%) 552(52%) 552(52%) 553(52%)
Missing 0%
WHO status 0 298(36%) 378(36%) 377(36%)
1 388(46%) 482(46%) 480(46%)
2 111(13%) 141(13%) 141(13%)
3 30(4%) 41(4%) 45(4%)
4 8(1%) 11(1%) 11(1%)
Missing 21%
ISS¹ 1 191(29%) 292(28%) 287(27%)
2 226(34%) 344(33%) 354(34%)
3 247(37%) 417(40%) 413(39%)
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Table 7.1 Patient and disease characteristics at diagnosis and first line treatment of the original 
real-world data, imputed data and the simulated patient population (continued)
Patient characteristics at diagnosis 
 
Real-world 
patients
imputed data simulated 
patients*
N=1054 N=1054 N=1054
Missing² 37%
Serumß₂ 
Microglobulin Mean 5.8 6.2
6.2
Median (Range) 4.4 [0.41-35] 4.5 [0.03-38] 4 [0.03-38]
Missing 37%
Albumin level Mean 34 35 35
Median (Range) 35.4 [1.9-45] 36 [1.9-45] 36 [1.9-45]
Missing 15%
Haemoglobin Mean 6.7 6.7 6.7
Median (Range) 6.6 [2.8-10.4] 6.6 [2.8-15] 7 [2.8-15]
Missing 0.3%
Creatinine Mean 137 137 138
Median (Range) 98 [3-998] 98 [3-998] 98 [3-998]
Missing 1%
Platelets Mean 243 243 244
Median (Range) 229 [16-1170] 229 [16-1170] 231 [16-1170]
Missing 2%
LDH³ Mean 271 272 272
Median (Range) 238 [17-1083] 239 [17-1083] 240 [17-1083]
Missing 13%
Serum calcium Mean 2.4 2.4 2.4
Median (Range) 2 [1.27-6.3] 2 [1.27-6.3] 2 [1.27-6.3]
Missing 5%
Salmon Durie stage I A/B 160(16%) 165(16%) 165(16%)
II A 185(18%) 191(18%) 190(18%)
II B 53(5%) 54(5%) 53(5%)
III A 487(48%) 506(48%) 513(49%)
III B 131(13%) 138(13%) 133(13%)
Missing 4%
Comorbidity Other malignancy 165(22%) 230(22%) 228(22%)
Missing 28%
Study treatment line 1 147(14%) 147(14%) 151(14%)
¹ISS denotes International Staging System  2 Proportion of missings partly caused by availability of ISS 
since may 2005 3LDH denotes Lactate dehydrogenase 
* Average of ten simulation runs
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the most common (47%) first-line treatment in cohort 1, while Thal was most often 
prescribed as first-line treatment in cohort 2 (70%). In addition, for cohort 2 compared 
to cohort 1, higher prescription rates of Bmib and Lena were observed in both second- 
and third-line treatments. 
Parametric survival models
After identifying the distribution that best fitted the data (i.e. a Weibull distribution) 
and potential predictors that could be included, three multivariate regression models 
were built to estimate time to event for the first, second and third line, respectively. 
Two logistic models were built for the type of event in the first and second line. The 
parameters included in the multivariate survival and event models are presented in 
Figure 7.1. The regression coefficients including standard errors and confidence inter-
vals are included in the Supporting information.
Table 7.2 Real-world treatment patterns per line per cohort
 
cohort 1
first-line treatment 2004-2007
cohort 2
first-line treatment 2008-2013
Line 1   
N 396 658
Melphalan/Prednisone 187 (47%) 43 (7%)
Thalidomide 158 (40%) 460 (70%)
Bortezomib 3 (1%) 73 (11%)
Lenalidomide 2 (1%) 54 (8%)
Other 46 (12%) 28 (4%)
Line 2   
N 213 288
Melphalan/Prednisone 36 (17%) 33 (11%)
Thalidomide 103 (48%) 40 (14%)
Bortezomib 34 (16%) 124 (43%)
Lenalidomide 16 (8%) 79 (27%)
Other 24 (11%) 12 (4%)
Line 3   
N 112 109
Melphalan/Prednisone 10 (9%) 2 (2%)
Thalidomide 29 (26%) 12 (11%)
Bortezomib 33 (29%) 34 (31%)
Lenalidomide 26 (23%) 51 (47%)
Other 14 (13%) 10 (9%)
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simulation study
Using the results of the clinical analysis (i.e. real-world patient characteristics, treatment 
patterns, multivariate parametric survival models for the time to event and logistic re-
gression models for the type of event) combined with the PLS model (Figure 7.1), effects 
and costs of various treatment sequences were calculated. We compared the survival 
as modelled by our PLS model to the observed data, and Figure 7.2A,B shows similar 
observed and modelled OS for cohort 1 (i.e. first-line treatment during 2004–2007) 
and cohort 2 (i.e. first-line treatment between 2008 and 2013) confirming the model’s 
validity. The modelled OS together with the QALYs and costs of real-world treatment 
figure 7.2 Overall survival as observed in real world and according to the model 
(A) Cohort 1 (first-line treatment between 2004 and 2007)
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(B) Cohort 2 (first-line treatment between 2008 and 2013)
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(i.e. cohort 1 and cohort 2) and frequently observed treatment sequences (i.e. scenario 
1–4) are presented in Table 7.3. Median and average OS for cohort 1 were 25 and 38 
months, respectively. Total costs per patient were on average €44,200 and these costs 
show, from a hospital perspective, the average total costs of the disease per patient 
from first-line treatment to death. Outcomes for cohort 2 were higher; median OS and 
average OS were 28 and 42 months, while average total costs were €69,017. Table 7.3 
also presents the costs and effects of the four most commonly prescribed treatment 
sequences in daily practice during our study period. Depending on the treatment 
sequence, average OS ranged from 36 to 44 months for MP–Thal–Bmib and Thal–Lena–
Bmib, respectively.  Average total costs from diagnosis till death ranged from €38,249 
for MP–Thal–Bmib to €75,375 for Thal–Bmib–Lena. Treatment sequences starting with 
first-line Thal had highest OS but also the highest average costs. The sequence Thal–
Lena–Bmib was the most effective scenario with average OS of 44 months and average 
total costs of €73,202. Figure 7.3 presents the results of the PSA for cohort 1, cohort 2 
and Thal–Lena–Bmib (i.e. the most effective scenario). The model was run 1000 times 
and effects (OS in months) and costs (discounted total costs in euro’s) of each model run 
are presented as one observation point in Figure 7.3. The spreading of the observations 
shows the uncertainty around the estimates. Figure 7.3 demonstrates that both effects 
and costs were higher for cohort 2 compared to cohort 1. Compared to real-world treat-
figure 7.3 Results of probabilistic sensitivity analysis: total discounted average effects and costs of 
real-world tretament per cohort and the most-cost-effective treatment sequence
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ment patterns in cohort 2, the scenario where all patients would have been treated with 
Thal–Lena–Bmib yielded better outcomes at higher costs. Average OS increased with 
0.17 yr. (0.12 QALYs) and aver- age costs with €4,185. The incremental cost-effectiveness 
ratio would be €24,618 and €34,875 per life year and QALY gained, respectively.
Discussion
To our knowledge, this is the first study using real-world patient-level data to investigate 
the cost-effectiveness of complete treatment sequences for elderly real-world patients 
with MM. A disease track model was designed to calculate cost and effects of daily 
practice treatment patterns as well as the cost-effectiveness of commonly used treat-
ment sequences, including innovative novel treatments. 
Guidelines changed and different treatment patterns were observed between 
the earlier and the later years of our observation period (i.e. increasing use of novel 
agents). From 2008 onwards, Thal was recommended as part of first-line treatment 
followed by Bmib or Lena in second- or third-line treatment regimens. This change was 
indeed observed in our real-world data, and we illustrated the impact on outcomes by 
calculating the real-world effects and costs separately for cohort 1 (first-line treatment 
between 2004 and 2007) and cohort 2 (first-line treatment between 2008 and 2013). 
While almost 60% of the patients in cohort 1 did not receive first-line treatment with 
a novel agent, almost 90% did receive a novel agent as first-line treatment in cohort 
2. A comparison between these cohorts revealed that both OS (+4 months) and costs 
(+€24,817) have increased for patients treated according to the real-world treatment 
patterns as observed during cohort 2. In other words, the shift from MP to Thal induc-
tion was clearly followed and proved to be effective. Although we performed an obser-
vational study, we are able to relate the improved outcomes to the different treatment 
patterns observed because we modelled similar patient populations for both cohorts, 
that is the only change in our model was treatment patterns as observed for cohort 
1 and cohort 2. It should be noted that due to limited numbers of patients, we based 
treatment effectiveness on all patients instead of distinguishing different effectiveness 
estimates for cohort 1 and cohort 2. We believe this is a conservative approach because 
effectiveness of treatments might improve if physicians gain more experienced with 
treatments over time. This might mean that the observed improvement in OS between 
cohort 1 and cohort 2 might be higher than the 4 months now reported. 
In addition to the cohort comparison, the scenario analyses clearly demonstrated 
improved survival with increasing use of novel treatments. For example, OS was on 
average 5–8 months better (average 43–44 months versus 36–38 months) if all patients 
received first-line treatment with thalidomide, a novel agent, instead of only MP. Costs 
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for patients treated with MP–Thal–Bmib or MP–Thal–Lena were €38,249 and €47,795, 
respectively. Total costs were €73,202 and €75,375 for Thal–Lena–Bmib and Thal–
Bmib–Lena, respectively.
Outcomes of the most effective scenario (Thal-Lena-Bmib) were compared to the 
real-world treatment patterns as observed for cohort 2. Although novel agents were 
already prescribed, the comparison revealed higher OS for the scenarios in which Thal-
Lena-Bmib would have been the standard treatment approach. In this scenario Lena 
and Bmib were only assigned to patients who did not die after either first- or second-
line treatment. Cost-effectiveness ratios were acceptable, €24,618 per life year gained 
and €34,875 per QALY. 
Although Bmib is recommended as first-line treatment in the Netherlands since 
2013158, we did not study treatment sequences that used Bmib as first-line treatment. 
PHAROS included patients diagnosed since 2004–2011. Of these patients, only 7% was 
treated with Bmib in the first-line. 
The internal validity of our model was confirmed by the good correspondence with 
the real-world data with almost overlapping survival curves. Our results confirmed 
previous findings135,139,159 that, in general, elderly patients benefit from novel agents and 
show that OS of real-world patients improves by increasing the proportion of patients 
treated with novel agents. Survival for treatment sequences is unavailable. However, 
the modelled OS can be compared to the OS as reported in the literature. Results from 
a meta-analysis of 1685 patients included in RCTs showed median OS for first-line MP 
treatment was 32.7 months and for first-line thalidomide treatment 39.3 months139. 
This is above the median OS from our model, 24 and 30 months, respectively. Lower OS 
was expected given the age and disease characteristics of our real-world patient group. 
Nevertheless, the improvement in median survival in our study (5 months) is almost as 
high as the effect of first-line thalidomide as established by the meta-analysis of Fay-
ers et al.139 (6 months). Median OS of cohort 1 and cohort 2 in our study was below 
the median OS of 33.6 months for non-high-dose patients as reported by a Swedish 
population based study159. This difference might be related to different prescription of 
treatments or patient characteristics. For example, our study included a higher propor-
tion of patients with International Staging System III, 38% compared to 25%. 
Real-world costs of patients with relapsed/refractory MM were according to Gault-
ney et al.77 €72,968 and this is above the average total costs in our study. However, 
we included newly diagnosed patients instead of only relapsed refractory patients. In 
addition, the study of Gaultney et al. was more detailed on for example concomitant 
medication costs. Evidence on the cost-effectiveness of novel agents for MM is scarce142. 
Only one other CEA, conducted from the US perspective, is available. Garrison et al.143 
showed – depending on subsequent treatments – higher or comparable lifetime costs, 
€46,458 ($63,294, exchange rate $1 = €0.7340) for first-line MP, while costs for first-line 
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Thal were higher €104,560 ($142,452). The total cost for treatment sequences contain-
ing Thal might be higher due to the branded price for thalidomide used by Garrison 
et al.143,160. Information on health-related quality of life in patients with MM treated 
with novel agents is limited and a comparison between different treatments cannot be 
made161. Utility values, necessary to calculate QALYs, are even scarcer and only avail-
able for transplant eligible patients73. Therefore, we relied on a small cross-sectional 
subsample of a real-world patient population and were unable to assign distinctive 
utility values to the treatment strategies. We assume that all treatments have an equal 
impact on the quality of life, that is neglecting the differences in toxicities between the 
treatments. Nevertheless, this is subject for further research. 
Real-world cost-effectiveness can only be calculated with real-world data, as these 
data provide insight into real-world effects. In addition, due to longer follow-up com-
pared to most RCTs, real-world data also provide additional insights into OS. However, 
the absence of a randomised design is an important limitation of real-world data. This 
might be problematic for a disease such as MM, in which many factors inherent to the 
patient and the tumour itself contribute to the final outcome. To correct for imbalances, 
we included a large number of patient and disease characteristics such as age, labora-
tory values and disease stage that are considered to influence OS in MM. 
Although the PHAROS database provided us with information of 1054 elderly 
patients with MM, uncertainty around the model estimates was presented by the 
cost-effectiveness clouds in the sensitivity analysis. Nevertheless, robust estimates 
were obtained from the sensitivity analysis after 1000 model simulations. Due to the 
number of patients, we were not able to make a distinction between patients receiv-
ing maintenance therapy and patients who did not receive maintenance therapy, and 
only the hospital visits for maintenance therapy were accounted for. In addition, the 
number of patients only allowed us to develop a model with three treatment lines and 
we neglected the drug costs of fourth and subsequent treatment lines. Furthermore, 
real-world costs were based on the most important cost drivers, that is hospital visits 
and drug costs. The effectiveness of maintenance therapy and subsequent treatment 
lines as well as detailed real-world cost analysis including laboratory tests and other 
procedures remains subject for further research. 
This study shows that with the advent of newer treatments that have proven effi-
cacy, real-world elderly patients with MM live longer but at an increased cost. A shift 
from MP to Thal has clearly been effective. OS improved with 4 months for patients 
receiving first-line treatment between 2008 and 2013 compared to patients receiving 
first-line treatment between 2004 and 2007, while average costs per patient increased 
with €24,817. Although OS was a little lower, efficacy of novel agents as obtained in 
RCTs was confirmed in Dutch daily clinical practice. By comparing real-world treatment 
to hypothetical scenarios, we identified that real-world treatment in the Netherlands 
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could have been improved further by increasing the utilisation of novel agents. The in-
cremental costs were €24,618 per life year gained and €34,875 per QALY if the sequence 
Thal–Lena–Bmib was standard treatment for all patients. Recommended treatment for 
MM rapidly changes, and therefore, further research is necessary to identify whether 
outcomes could be improved in the future as well by increasing use of novel agents in 
daily clinical practice. 
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supporting information
Regression coefficients to model time-to-event for line 1
Weibull model      
Variable coefficient sE p-value
[95% 
conf. interval]
Constant 3.433 0.544 0.000 2.366 4.500
Age1 -0.018 0.005 0.001 -0.028 -0.007
Sex (Reference category male) 0.195 0.068 0.004 0.062 0.327
WHO status 0 Reference category   
WHO status 1 -0.093 0.079 0.243 -0.249 0.063
WHO status 2 -0.338 0.109 0.002 -0.551 -0.124
WHO status 3 -0.689 0.215 0.002 -1.120 -0.258
WHO status 4 -1.372 0.638 0.049 -2.736 -0.009
Albumine1 0.014 0.005 0.010 0.003 0.024
Haemoglobin1 0.095 0.029 0.001 0.037 0.152
Platelets1 0.001 0.000 0.022 0.000 0.001
Serum calcium1 -0.190 0.093 0.042 -0.374 -0.007
Treatment1 MP Reference category   
Treatment1 Thal 0.342 0.080 0.000 0.186 0.498
Treatment1 Bmib 0.227 0.150 0.130 -0.067 0.520
Treatment1 Lena 0.441 0.203 0.030 0.043 0.838
Treatment1 Other -0.401 0.136 0.003 -0.668 -0.133
Comorbidity (Reference category no 
comorbidity) -0.215 0.092 0.022 -0.398 -0.032
Included in study (Reference category not 
included 0.259 0.118 0.028 0.028 0.490
      
Shape 1.071 0.030  1.014 1.131
Regression coefficients to model type of event line 1
Variable coefficient sE p-value [95% conf. interval]
Constant -8.024 1.068 0.000 -10.118 -5.930
TTE1 (ln) -0.694 0.078 0.000 -0.848 -0.541
Age1 0.115 0.014 0.000 0.089 0.142
WHO status 0 Reference category   
WHO status 1 0.392 0.204 0.057 -0.011 0.795
WHO status 2 0.616 0.273 0.025 0.079 1.154
WHO status 3 0.298 0.438 0.496 -0.562 1.159
WHO status 4 0.295 0.820 0.720 -1.318 1.907
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Regression coefficients to model type of event line 1 (continued)
Variable coefficient sE p-value [95% conf. interval]
Treatment1 MP Reference category   
Treatment1 Thal 0.240 0.192 0.210 -0.135 0.616
Treatment1 Bmib 0.814 0.363 0.025 0.101 1.526
Treatment1 Lena 0.407 0.433 0.347 -0.441 1.255
Treatment1 Other 0.570 0.337 0.090 -0.089 1.230
Regression coefficients to model time-to-event for line 2
Weibull model      
Variable coefficient sE p-value [95% conf. interval]
Constant 1.009 0.428 0.019 0.166 1.853
TTE1 0.008 0.004 0.045 0.000 0.016
Albumine2 0.036 0.010 0.000 0.017 0.055
Creatinine2 -0.002 0.001 0.001 -0.003 -0.001
Haemoglobin2 0.095 0.043 0.028 0.010 0.180
LDH2 -0.001 0.000 0.000 -0.002 -0.001
Treatment2 MP Reference category   
Treatment2 Thal 0.267 0.152 0.080 -0.032 0.566
Treatment2 Bmib 0.025 0.154 0.873 -0.278 0.327
Treatment2 Lena 0.310 0.179 0.083 -0.040 0.660
Treatment2 Other 0.028 0.211 0.896 -0.387 0.442
      
Shape 1.069 0.042  0.989 1.156
Regression coefficients to model type of event line 2
Variable coefficient sE p-value [95% conf. interval]
Constant -4.429 1.789 0.013 -7.935 -0.923
TTE2 (ln) -0.620 0.117 0.000 -0.850 -0.390
TTE1 -0.024 0.011 0.024 -0.046 -0.003
Age2 0.075 0.021 0.000 0.034 0.116
WHO status 0 Reference category   
WHO status 1 0.551 0.267 0.040 0.026 1.075
WHO status 2 0.534 0.415 0.198 -0.281 1.348
WHO status 3-4 0.207 0.647 0.749 -1.069 1.483
Haemoglobin2 -0.201 0.105 0.056 -0.408 0.005
Treatment2 MP Reference category   
Treatment2 Thal 1.128 0.401 0.005 0.342 1.913
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Regression coefficients to model type of event line 2 (continued)
Variable coefficient sE p-value [95% conf. interval]
Treatment2 Bmib 1.291 0.406 0.001 0.496 2.086
Treatment2 Lena 1.758 0.456 0.000 0.863 2.652
Treatment2 Other 1.051 0.538 0.051 -0.003 2.105
Regression coefficients to model time-to-event (death) for line 3
Weibull model      
Variable coefficient sE p-value [95% conf. interval]
Constant 0.595 0.728 0.414 -0.836 2.026
TTE2 (ln) 0.286 0.104 0.006 0.083 0.490
Albumine3 0.042 0.017 0.013 0.009 0.076
Creatinine3 -0.004 0.001 0.000 -0.006 -0.002
Platelets3 0.003 0.001 0.004 0.001 0.004
Treatment3 MP Reference category   
Treatment3 Thal 0.517 0.358 0.148 -0.184 1.218
Treatment3 Bmib 0.178 0.343 0.603 -0.493 0.850
Treatment3 Lena 0.391 0.349 0.263 -0.293 1.075
Treatment3 Other 0.007 0.417 0.987 -0.810 0.824
      
Shape 1.033 0.067  0.909 1.174
number of patients receiving first, second and third-line treatment per scenario*
 Line 1 Line 2 Line 3
scenario1
MP-Thal-Bmib
Treatment MP
N=1054
Treatment Thal
N=658
Treatment Bmib
N=409
scenario2
MP-Thal-Lena
Treatment MP
N=1054
Treatment Thal
N=658
Treatment Lena
N=410
scenario3
Thal-Bmib-Lena
Treatment Thal
N=1054
Treatment Bmib
N=659
Treatment Lena
N=394
scenario4
Thal-Lena-Bmib
Treatment Thal
N=1054
Treatment Lena
N=659
Treatment Bmib
N=358
* Based on 1000 simulations
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AbsTRAcT
objective: Although models comprising multiple treatment lines are increasing in 
importance, experience is scarce and while guidelines for good modelling practices 
are available, they are sometimes too brief to help researchers develop models that 
are valid and credible. This study provides practical recommendations in construct-
ing a discrete event simulation (DES) model to support real-world cost-effectiveness 
analyses of treatment strategies spanning multiple treatment lines.
methods: Based on experiences with two DES models used in cost-effectiveness analy-
ses of treatment strategies in cancer, we discuss how best practices, mainly derived 
from the ISPOR-SMDM Task Force, can best be implemented. Additional recommen-
dations were provided wherever best practices were unavailable or not applicable.
Results: The following steps in constructing DES models were considered particularly 
important: assigning patient characteristics when simulating a patient population, 
estimating time-to-event (i.e. next treatment line or death) and event type for each 
patient, assigning costs and outcomes to all treatment lines, discounting, and con-
ducting sensitivity analyses. Modelling multiple treatment lines using a DES model 
and real-world data imposes several challenges. First, it is necessary to correct ef-
fectiveness and costs for patient characteristics (including previous treatments). This 
could be addressed by including patient characteristics and effectiveness of previous 
treatments in the survival models. Second, when modelling a heterogeneous popula-
tion, valid extrapolation of survival outcomes beyond observation is required. This 
could be achieved by using multiple survival models per treatment line. Third, the 
timing of competing events needs to be estimated appropriately. As recommended by 
the Task Force, one single survival model should be used together with a regression 
technique to determine event type.
conclusions: Developing good-quality models comprising multiple treatment lines 
requires guidance beyond the existing guidelines and practical recommendations are 
currently lacking. The guidance based on hands-on experience with two DES models 
can improve validity and credibility of future disease models and cost-effectiveness 
analyses.
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inTRoDucTion
As more treatments become available (within and beyond treatment lines), traditional 
economic evaluations may not provide sufficient information, since these do not assess 
costs and effects of treatment strategies spanning multiple treatment lines and are not 
able to determine the optimal order (i.e., sequence) in which treatments should be 
provided. 
As a consequence, full disease models comprising multiple treatment lines are ex-
pected to increase in importance, but experience is scarce. Tosh and colleagues162 called 
for a methodological framework for economic evaluations of sequential therapy for 
chronic conditions, since they found that methods have not been consistently applied, 
which has led to varied estimates of cost-effectiveness and uncertainty in respect of the 
most appropriate analytic methods. Although guidelines for good modelling practices 
are available including the series commissioned by the ISPOR-SMDM Task Force163, they 
are sometimes too brief to help researchers develop models that are valid and credible. 
This study provides practical recommendations in constructing a discrete event 
simulation (DES) model to support cost-effectiveness analyses of treatment strategies 
spanning multiple treatment lines. Best practices derived from the ISPOR-SMDM Task 
Force and additional sources are cited, followed by a description of how these were 
implemented in our DES models to estimate the real-world cost-effectiveness of new 
treatments in metastatic renal cell carcinoma (mRCC) and multiple myeloma (MM). 
cAsE sTuDiEs
metastatic Renal cell carcinoma (mRcc)
115,200 patients were diagnosed with kidney cancer in Europe in 2012164. Renal cell 
carcinoma represents 80% of all kidney cancers. Median overall survival (OS) of patients 
with advanced disease is 43, 27 and 8.8 months for patients with a favourable, interme-
diate or poor prognosis, respectively165. Health outcomes are influenced by prognostic 
factors166.
A number of first- and second-line targeted therapies (e.g. sunitinib, sorafenib and 
everolimus) for mRCC have been introduced since 2006165. These therapies improve 
health outcomes, such as progression-free survival (PFS) and OS167-172. However, a Dutch 
population-based registry showed that almost half of the patients presenting with 
mRCC did not receive any targeted therapy173. A DES model was developed to study the 
real-world cost-effectiveness of several treatment strategies applied in patients with 
mRCC comprising one or more sequentially administered drugs. Potential health out-
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comes and costs of hypothetical treatment scenarios were calculated by assuming that 
all treatment-eligible patients were treated according to a particular treatment strategy.
multiple myeloma (mm)
In 2012, 38,900 patients were diagnosed with MM in Europe164. MM is a heterogeneous 
disease with a wide variation in OS131,132. Depending on the stage of the disease, median 
OS ranges from 29-62 months174. 
Like for many cancers, treatment of MM is characterised by sequential treatment 
lines aiming to prolong PFS and OS. In the past decade, several treatment options have 
become available including the thalidomide-, bortezomib- and lenalidomide-based 
regimens. While most of these treatments were first recommended as treatment for 
third or subsequent lines, they are now recommended as induction therapy. Health 
outcomes are also influenced by prognostic factors, mainly patient and disease char-
acteristics136,137. A DES model was developed to study the real-world cost-effectiveness 
of sequential use of novel agents for elderly MM patients148. Furthermore, by studying 
treatment sequences, we aimed to identify the optimal treatment strategy.
Comprehensive data on patient and disease characteristics of patients with mRCC and 
MM, as well as data on treatments and outcomes were collected in two population-
based registries, the mRCC registry (PERCEPTION) and the MM registry (PHAROS)21,151.
moDEL sTRucTuRE AnD DEsign
Best practice:
“If, (…), a valid representation of any aspect of the decision problem would lead 
to an unmanageable number of states, then an individual-level state-transition 
model is recommended.”176
“DES is an attractive option in nonconstrained models (…) when individual 
pathways through the model are influenced by multiple characteristics of the 
entity; and when recording individual entity experience is desirable.”175
The first stage in developing a decision model involves choosing an appropriate model 
structure. According to the best practice commissioned by the ISPOR-SMDM Task Force, 
DES is the preferred modelling method if it is difficult to model the disease course of 
the average patient, and when the course of the disease, including its treatment, would 
require too many health states. As stated in the previous paragraph, patients with mRCC 
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and MM in daily practice represent a heterogeneous population, and characteristics of 
these patients have a large impact on the costs and effects of treatment. In order to 
incorporate individual patients and allow for variability between patients, a DES model 
was developed to calculate the cost-effectiveness of various treatment scenarios as rec-
ommended by the ISPOR-SMDM Task Force175,176. DES models allow individual patients 
to have their own characteristics, such as age and health state, which may also change 
over time177. 
Furthermore, treatment of both mRCC and MM is characterised by sequentially 
administered drugs. Instead of modelling single treatment options, a comparison of 
complete treatment strategies was needed. DES models can easily include the effect of 
previous therapies, in contrast to Markov models, which cannot incorporate history of 
patients without constructing a large amount of health states. Therefore, a DES model 
seemed a better choice for modelling treatment strategies spanning multiple treatment 
lines for mRCC and MM176. Caro et al.163 also argued that a DES provides an alternative, 
more natural, way to simulate clinical reality, whereas a Markov model requires all 
aspects of a disease including patient and disease characteristics and treatment history 
to be captured in a health state. Although various methods exist which can include 
memory in Markov models (e.g. tracker variables), the required number of tracking 
variables would have been quite large in a model of sequential therapies. 
In addition, data from the mRCC registry and MM registry revealed that some patients 
died very soon after treatment was initiated while some patients survived much longer. 
In a micro simulation Markov model, patients can only experience one transition per 
cycle and this would require many cycles with a small cycle length, which favoured a DES 
model allowing to include time continuously.
The DES models for mRCC and MM comprised entities (i.e. patients), attributes as-
signed to the entities, and events. Attributes were obtained from patient-level data 
from either the mRCC or MM registry by selecting clinical factors, biochemical and hae-
matological factors known to impact mRCC or MM outcomes, respectively. Events were 
either second-line treatment, third-line treatment (in the MM model only) or death. 
The time horizon of the models spanned the patients’ lifetime. The structures of the 
mRCC and MM model are presented in Figure 8.1. Characteristics and sources for input 
parameters of both models are presented in Table 8.1.
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figure 8.1 model structure of the full disease models spanning multiple treatment lines
a) mRCC model
A
Time to event 1 (TTE 1)
(until 12 months)
Type of event 1
(second-line treatment 
or death)
Time to event 2
(TTE 2)
Type of event 2
(death)
Logistic model with the following covariates:
age, (sex), (prior nephrectomy), (nr of metastatic sites), (WHO 
performance status), (lung metastases), (liver metastases), (bone 
metastases), (haemoglobin), (neutrophil count), platelet count, albumin, 
(corrected serum calcium), (alkaline phosphatase), (lactate 
dehydrogenase), (first-line treatment), TTE 1
Loglogistic model with the following covariates:
(Age), sex, (prior nephrectomy), (nr of metastatic sites), (WHO 
performance status), (lung metastases), (liver metastases), (bone 
metastases), (haemoglobin), neutrophil count, (platelet count), albumin, 
(corrected serum calcium), (alkaline phosphatase), (lactate 
dehydrogenase), (first-line treatment), (TTE 1), (second-line treatment) 
Costs: Costs of therapy and resource 
utilisation costs, such as hospitalisations, 
outpatient visits and medical imaging 
services
Effects: Life years and Quality Adjusted Life 
Years
Costs: Costs of therapy and resource 
utilisation costs, such as hospitalisations, 
outpatient visits and medical imaging 
services
Effects: Life years and Quality Adjusted Life 
Years
Input parameters OutcomesModel structure
Time to event 1 (TTE 1)
(> 12 months)
Costs: Costs of therapy and resource 
utilisation costs, such as hospitalisations, 
outpatient visits and medical imaging 
services
Effects: Life years and Quality Adjusted Life 
Years
Loglogistic model with the following covariates: 
age, (sex), prior nephrectomy, nr of metastatic sites, WHO performance 
status, (lung metastases), liver metastases, bone metastases, 
haemoglobin, neutrophil count, (platelet count), albumin, (corrected 
serum calcium), alkaline phosphatase, (lactate dehydrogenase), first-line 
treatment 
Input parameters utcomesMode  tructure
Exponential model with the following covariates: 
age, (sex), prior nephrectomy, (nr of metastatic sites), WHO performance 
status, (lung metastases), (liver metastases), (bone metastases), 
(haemoglobin), (neutrophil count), (platelet count), (albumin), (corrected 
serum calcium), (alkaline phosphatase), (lactate dehydrogenase), first-
line treatment 
b) MM model
B
Time to event 1 
(TTE 1)
Weibull model with the following covariates: 
Age1, Sex, WHO1, Albumine1, Haemoglobin1, Platelets1, Serum 
calcium1, Treatment1, Other Haematological malignancies, Study 
treatment
Logistic regression model with the following covariates: 
TTE 1, Age1, WHO1, Treatment1
Time to event 3
(TTE3)
Type of event 1
(second-line treatment 
or death)
Costs: Costs of therapy and resource 
utilisation costs, such as hospitalisations and 
outpatient visits
Effects: Life years and Quality Adjusted Life 
Years
Time to event 2
(TTE 2)
Weibull model with the following covariates:
TTE1, Albumin2, Creatinine2, Haemoglobin2, LDH2, Treatment2
Logistic model with the following covariates:
TTE1, TTE2, Age2, WHO1, Haemoglobin2, Treatment2
Input parameters OutcomesModel structure
Costs: Costs of therapy and resource 
utilisation costs, such as hospitalisations and 
outpatient visits 
Effects: Life years and Quality Adjusted Life 
Years
Weibull model with the following covariates: 
TTE 1, Age1, WHO1, Treatment1
Costs: Costs of therapy and resource 
utilisation costs, such as hospitalisations and 
outpatient visits
Effects: Life years and Quality Adjusted Life 
Years
Type of event 2
(third-line treatment or 
death)
Type of event 3
(death)
NOTE. Covariates between brackets were considered for inclusion in the survival models and logistic 
regression model, but excluded through backward and/or forward selection.
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Table 8.1. model characteristics and sources for input parameters of the DEs models
 metastatic renal cell carcinoma multiple myeloma
model characteristics
Aim Model real-world cost-
effectiveness for patients with 
metastatic renal cell carcinoma
Model real-world cost-
effectiveness for elderly patients 
with multiple myeloma
Perspective Health care Health care
Patients Patients with metastatic renal cell 
carcinoma
Elderly patients with multiple 
myeloma
Outcomes Effects (OS and QALYs) and costs 
(€)
Effects (OS and QALYs) and costs 
(€)
Model type Discrete event simulation Discrete event simulation
Time horizon Lifetime Lifetime
Parametric distribution Loglogistic and exponential 
distribution (line one) and 
loglogistic distribution (line two)
Weibull distribution for all lines
Disease pathways (Base 
case)
Real-world treatment including 
two subsequent lines
Real-world treatment including 
three subsequent lines
Disease pathways 
(scenarios)
Hypothetical pathways including 
two lines of treatment
Hypothetical pathways including 
three lines of treatment
No targeted therapy MP-thalidomide-bortezomib
Sunitinib - Sorafenib MP-thalidomide-lenalidomide
Sunitinib - Everolimus Thalidomide-bortezomib-
lenalidomide
Sunitinib - Other Thalidomide-lenalidomide-
bortezomib
Sensitivity analysis Univariate and probabilistic 
sensitivity analyses (1000 
simulations)
Univariate and probabilistic 
sensitivity analyses (1000 
simulations)
sources for input parameters
Data
(Patient and disease 
characteristics, 
treatment effects and 
patterns, health care 
utilisation)
Real-world data from the mRCC 
registry (PERCEPTION)
Real-world data from the MM 
registry 
(PHAROS)
Unit prices Dutch reference price lists and 
literature
Dutch reference price lists and 
literature
Discount rates Dutch guidelines (effects 1.5%, 
costs 4%)
Dutch guidelines (effects 1.5%, 
costs 4%)
Utilities Literature Cross-sectional study
OS: overall survival QALYs: Quality-adjusted life years MP: melphalan prednison
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TimE-To-EVEnT 
Best practice:
“It is (...)  very important to justify the particular extrapolation approach 
chosen, to demonstrate that extrapolation has been undertaken appropriately 
and so that decision makers can be confident in the results of the associated 
economic analysis.”178
As survival data is often not fully observed, extrapolation beyond the observation period 
is needed. The method to extrapolate this data should be chosen in a systematic way 
in order to ensure valid and clinical plausible extrapolation. Time-to-event data derived 
from either the mRCC or MM registry were extrapolated using a range of parametric 
models (Exponential, Weibull, Log-logistic, Log-normal, Gamma and Gompertz). These 
models were assessed for their goodness of fit to the data using the Akaike Information 
Criterion (AIC) and Bayesian Information Criterion (BIC). Furthermore, each parametric 
function was assessed graphically as recommended by Latimer178.
For the mRCC model, a loglogistic distribution best fitted the time to the first event 
(TTE1) and the time to the second event (TTE2). Nevertheless, visual inspection showed 
that TTE1 was underestimated after 12 months. Additionally, as a consequence of the 
functional form of this distribution, mean TTE1 was highly influenced by a small propor-
tion of the population with very long TTE1 estimates. Therefore, an alternative model 
(i.e. exponential) was chosen for TTE1 after 12 months, based on the AIC and BIC. This 
approach was also conducted by Leunis et al., who specified different survival models 
for different time periods179. For the MM model, a Weibull distribution best fitted the 
time to the first, second and third event. A Weibull distribution had the best goodness 
of fit based on the AIC/BIC and was also considered appropriate based on visual inspec-
tion.
comPETing EVEnTs
Best practice:
“Where feasible, when estimating times to competing events, methods of 
analysis that estimate the timing of competing events jointly are preferred to 
approaches that estimate separate time to event curves for each event.” 178
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In survival analysis, competing events are present when an individual is at risk of several 
different types of events but can have only one event at a time150,175. For the mRCC and 
MM models, time to next treatment was calculated from patient level data. Since some 
patients died before a new treatment was initiated, next treatment and death were 
competing events. Generally, there are two approaches to analyse competing events175. 
The first approach is to perform separate survival analysis for each event where the 
other event is treated as censored. Then, for each event a time is sampled, with the 
patient moving to the event with the shortest time. The second approach is to perform 
one single survival analysis but make no distinction between the competing events; a 
separate sampling process in the model determines which event a patient will experi-
ence.  
The second approach was adopted in the mRCC and MM models, as recommended 
by the ISPOR-SMDM Modelling Good Research Practices Task Force175. Whereas survival 
analysis assumes that censoring is non-informative, we hypothesised that death was 
mostly treatment-related and, as a consequence, that censoring the patients who died 
might have altered the probability of experiencing a next treatment. Furthermore, the 
graphic presentation and interpretation of the single survival analysis are straightfor-
ward whereas the interpretation of the two separate survival curves is less intuitive. 
While the second approach was adopted in the mRCC and MM models, we applied 
the first approach to validate our results and hypothesis. Interestingly, both methods 
yielded very similar results in the models. Since there is no difference between the two 
methods in terms of ease or speed (i.e. both methods require the estimation of two 
statistical models), we decided to align with current guidelines.
Assigning PATiEnT AnD DisEAsE 
chARAcTERisTics
Best practice: 
“The expected costs and benefits across the sampled group [..] provide an 
unbiased estimate provided that a sufficiently large sample is simulated and 
any covariance between the different patient characteristics is correctly taken 
into account.”180 
While the mRCC and MM registries provided patient level data, simulation of the popula-
tion including patient and disease characteristics was needed to study what would have 
happened to a patient if that patient had been treated differently. No recommendations 
were made by the ISPOR-SMDM Task Force about simulating a population. However, 
124 Chapter 8 
Davis et al. emphasises the need to account for the covariance between patient and 
disease characteristics180. 
In the mRCC and MM models, patient and disease characteristics were simulated 
similarly; random numbers were drawn from predefined distributions. These distribu-
tions were derived from patient-level data from the mRCC registry or the MM registry, 
respectively.
To account for the covariance between characteristics, different distributions were 
used for patients with a different prognosis. For example in the mRCC model, first WHO 
performance status before treatment was simulated by drawing random numbers from 
a predefined distribution as obtained from the PERCEPTION registry. In simulating addi-
tional patient and disease characteristics; for each characteristic, a different distribution 
was used for patients with a WHO performance status of 0-1, and for patients with a 
WHO performance status of 2-4. This method was adopted to increase the likelihood 
that the combination of patient and disease characteristics per individual matched the 
original data.
Besides patient and disease characteristics, treatment needed to be assigned to 
each patient. Two multinomial logistic regression models (i.e. one to assign first-line 
treatment and one to assign second-line treatment) were used, including patient and 
disease characteristics as well as treatment history as covariates, to assign real-world 
treatment patterns to the patients in the mRCC model. This process guaranteed that 
the patients who received the treatments in the model were similar to the patients 
who received these treatments in daily clinical practice. This method was not feasible 
in the MM model, since some novel agents (i.e. bortezomib and lenalidomide) were 
prescribed to very few patients during the follow-up period. These numbers were too 
small to run a multinomial logistic regression model. Treatment in the MM model was 
therefore simulated in the same way as patient and disease characteristics; the prob-
ability of receiving a certain treatment was based on the distribution of treatments as 
observed in daily clinical practice using different distributions for patients with a differ-
ent WHO performance status. Having simulated patient and disease characteristics, and 
treatment for all patients, the patient’s time to an event (either TTE1, TTE2 and TTE3) 
was estimated taking these characteristics into account. 
AccounTing foR PREVious ThERAPiEs
The mRCC and MM model aimed to calculate the cost-effectiveness of several treatment 
strategies comprising one or more sequentially administered treatments. Therefore, it 
was important to correct for the effectiveness of previous treatments when estimating 
the effectiveness of second- and third-line treatments. In addition, the effectiveness of 
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subsequent therapies should be taken into account when estimating overall survival of 
first- and second-line treatments. Ideally, the effectiveness of, for example, bortezomib 
after thalidomide is solely based on patients treated with thalidomide followed by 
treatment with bortezomib. Although the registries included a substantial number of 
patients, these were not adequate to provide a stable estimate of the effectiveness of 
all treatment sequences. Recommendations to account for previous therapies in full 
disease models do not exist.
Therefore, we chose to correct for the effectiveness of previous therapies by including 
the TTE of the previous line in estimating the TTE of the subsequent therapy. For exam-
ple, TTE1 was included in the parametric survival model estimating TTE2. This allowed 
us to obtain the effectiveness of second-line treatment accounting for the effectiveness 
of first-line treatment given the patient’s characteristics. In the MM model TTE1 had 
a significant association with TTE2 as well as with the type of event. The coefficient 
corresponding to TTE1 was not treatment specific, i.e. a TTE1 of 2 months obtained 
by treatment with thalidomide is similar to a TTE1 of 2 months obtained by treatment 
with bortezomib. Since adding type of treatment to the model did not improve it’s 
explanatory value, we believe this method can be used to correct for the effectiveness 
of previous therapies.
cosTs AnD ouTcomEs
Best practice:
“Costs and quality of life weights are attached to events and time spent with 
different health conditions to estimate long term costs and health outcomes.”175
According to this guideline, health outcomes and costs depend on events and time 
and this practice was adopted in both models. Total life years (i.e., OS) were calculated 
by summing TTE1, TTE2 (and TTE3). Besides total life years, total quality adjusted life 
years (QALYs) were calculated by weighting LYs for the quality of life during these years 
using utility weights. In the mRCC model, various utility weights were used for patients 
with a favourable or intermediate prognosis, and patients with a poor prognosis before 
either first-line therapy or second-line therapy since their quality of life was expected to 
differ. Treatment-specific (including the effect of adverse events) or utility weights for 
different risk groups (or disease stages) were unavailable for elderly patients with MM. 
Therefore, an average utility weight was used in the MM model, obtained from a Dutch 
population-based cross-sectional study in MM. 
Based on real-world data, average treatment-specific resource use per month was ob-
tained in order to calculate total costs per month. For example the number of outpatient 
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visits per month for mRCC patients treated with sunitinib or the number of hospital days 
per month for MM patients treated with thalidomide. Average total costs per patient 
were calculated by multiplying treatment specific total costs per month with TTE. 
DiscounTing
Best practice
“A (common) real discount rate should be applied to future costs and, when 
used in a cost-effectiveness analysis, to future outcomes.”184
“Discounting methods should accord with general guidelines for economic 
evaluation.”185
Future effects and costs should be converted to their present value in order to account 
for factors such as time preferences and uncertainty. As recommended, future costs 
and effects in the mRCC and MM model were discounted to their present value using 
discount rates based on the Dutch guideline for pharmacoeconomic research181.   
While a Markov model with a fixed cycle length provides a convenient structure to 
discount future costs and effects, discounting future costs and effects in a DES model 
including treatment strategies comprising one or more sequentially administered treat-
ments is more challenging. First, a DES model produces individual TTE estimates, and 
as a consequence LYs and QALYs need to be discounted for each patient separately. 
Furthermore, different utility values were assigned to the treatment lines in the mRCC 
model and therefore, total QALYs needed to be discounted for each treatment line sepa-
rately. Second, unit costs per month differed between treatment lines. For example, a 
patient with MM treated with melphalan-prednisone, followed by a bortezomib-based 
regimen, and then followed by a lenalidomide-based regimen, incurs different hospital 
and drug costs per month during first-, second- and third-line treatment. As a conse-
quence, total costs need to be discounted for each treatment line separately.
Since total costs per treatment line were obtained by multiplying unit costs per 
month by the corresponding TTE, it was decided to discount TTE and multiply unit costs 
per month by the discounted TTE. The same approach was adopted to discount future 
QALYs in the mRCC model. While discounting time was a convenient approach in our 
models, this is not possible for DES models where costs are obtained from multivariable 
regression models. Since these models include undiscounted time as an explanatory 
variable, it is not possible to calculate and discount the total costs per line. Instead, 
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costs should be calculated and discounted for different time frames, e.g. per year, which 
adds both complexity and computational burden to the model.
PRobAbiLisTic sEnsiTiViTy AnALysis
Best practice
“The inner loop evaluates the outcomes across the simulated population for the 
given parameter values, and the outer loop samples those parameter values to 
reflect uncertainty in the model inputs. In a cohort-level model, only the outer 
loop is required, thus PSA computation time for a cohort-level model is likely to 
be lower than for an equivalent patient-level model.”180
In other words, the inner loop aims to calculate costs and effects for one simulated 
population (with constant patient and disease characteristics), whereas the outer loop 
changes all input parameters according to their probability distributions to examine 
the impact of the joint uncertainty across all input parameters. In the model for 
mRCC and MM, the values of input parameters varied across simulations. Due to the 
probabilistic structure of the models, the values of input parameters could also vary 
within one simulation. For example, an inpatient day could cost €402 while calculating 
costs of treatment scenario A and €646 while calculating costs of treatment scenario 
B. Furthermore, patient and disease characteristics could vary within one simulation. 
For instance, 26% of the population could be assigned a WHO performance status 
of 2-4 while calculating costs and effects of treatment scenario A and 35% could be 
assigned a WHO performance status of 2-4 while calculating costs and effects of treat-
ment scenario B. However, in each single simulation, parameters that are not related 
to a certain treatment scenario should have the same values in all treatment scenarios. 
This approach reduces the ‘noise’ or random variation that is introduced by setting unit 
costs and patient and disease characteristics twice in each simulation, once for Scenario 
A and once again for scenario B. It also increases the model’s efficiency, since fewer 
simulations are needed to get a stable estimate of the ICER. 
Apart from probabilistic sensitivity analysis, univariate sensitivity analyses can be 
performed to examine the impact of alternative input parameters on the incremental 
cost-effectiveness ratios (ICERs) as illustrated in the mRCC model. 
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Economic evaluations mostly require a lifetime time horizon in order to capture all 
health and economic consequences4. Such a time horizon makes a full disease model in-
cluding treatment strategies spanning multiple treatment lines inevitable. However, the 
development of the full disease models for mRCC and MM revealed several challenges, 
including the optimal ways to correct effectiveness and costs for patient characteristics 
(including the effectiveness of previous treatments), extrapolate survival outcomes 
beyond observation for a heterogeneous patient population, and estimate the timing 
of competing events. Best practices, including solutions to these challenges, were not 
always found in the literature. Also, existing disease models did not often provide suit-
able solutions to these challenges since these models differed in aim, characteristics of 
the disease or treatment varied and comprehensive data was unavailable. Therefore, 
guidance beyond the existing guidelines and practical recommendations are necessary 
to improve validity and credibility of future disease models.
Based on hands on experiences with two DES models the following recommenda-
tions can be made in constructing a DES model to support real-world cost-effectiveness 
analyses of treatment strategies spanning multiple treatment lines. 
First, the inclusion of patient characteristics (including the effectiveness of previous 
treatments) as covariates in survival models, makes it possible to derive more valid 
estimates of costs and effectiveness. Second, using multiple survival models per treat-
ment line ensures valid extrapolation of survival outcomes beyond observation for a 
heterogeneous population. Third, as recommended by the ISPOR-SMDM Task Force, 
when competing events exist, one single survival model should be used together with a 
regression technique to determine which event type will occur.
Although the mRCC and MM models enabled the estimation of the cost-effectiveness 
of several treatment strategies comprising one or more sequentially administered 
drugs,148,173 these models could have been improved further. Based on our experiences, 
the following recommendations can be made to improve future models of treatment 
strategies spanning multiple treatment lines. First, in our models, patient and disease 
characteristics were simulated by drawing random numbers from predefined distribu-
tions. Covariance between characteristics was accounted for by using different distribu-
tions for patients with a different prognosis. This method does, however, not guarantee 
valid relationships between all patient and disease characteristics. Multivariable regres-
sion models could overcome this problem as illustrated by Goossens et al. in a study on 
propensity score matching182. This method generated patient and disease character-
istics based on a set of regression models; one for each characteristic. While the first 
characteristic was defined using a predefined distribution, all other characteristics were 
simulated using regression models that included as covariates all of the characteristics 
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already assigned to the patient; this preserved the covariance between the different 
characteristics that was observed in the original data. 
Second, in the mRCC and MM models, total costs per patient were derived by multi-
plying mean monthly costs (per treatment) by the individual patient’s time to an event. 
However, the distribution of cost data is skewed which means that a limited number 
of patients is responsible for a high proportion of the costs4. As a consequence, by 
multiplying mean monthly costs by the individual patient’s time to an event, total costs 
per patient might be overestimated. Again multivariable regression models could solve 
this problem. Besides type of treatment and time to event, these models could include 
patient and disease characteristics as covariates to estimate total costs per patient. In 
this way, overestimation of costs will be prevented. 
This practical guide is a first attempt to document how best practices in modelling, 
derived from the ISPOR-SMDM Task Force and additional sources, can be interpreted 
and implemented. Experiences in implementing best practices were based on two stud-
ies only; these studies had rather similar aims, they both focussed on treatment strate-
gies in cancer, and the available data was comparable. Although, treatment strategies 
spanning multiple treatment lines are common in other disease areas (e.g., rheumatoid 
arthritis), we recommend further research to be done to ascertain whether this practi-
cal guide helps others with different goals working in other disease areas with different 
data sources. We therefore recommend them to share their findings from constructing 
and using a DES model including treatment strategies spanning multiple treatment lines. 
It should be clear that a DES model is not necessarily the best choice when con-
structing a full disease model.  While a DES model was a feasible option to study the 
cost-effectiveness of several treatment strategies comprising one or more sequentially 
administered drugs for patients with mRCC and MM, disadvantages of this model struc-
ture may include the type and amount of required data as well as the time needed for 
model building and simulation183. Data for the mRCC and MM model were derived from 
population based registries. In these registries comprehensive data were collected on 
patient and disease characteristics. In addition, compared to randomised trials, both 
registries had a long follow-up duration. This enabled us to study the impact of multiple 
treatment lines on overall survival. If comprehensive data is not available, a different 
model structure might be more appropriate. Additionally, the time needed for model 
building and simulation should be balanced against the benefits of modelling patients 
individually in a DES model.
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concLusion
In order to secure the validity and credibility of models, guidelines were developed sum-
marising best practices in modelling175,176,178,180,184,185. Unfortunately, these guidelines are 
sometimes too brief to be used in constructing full disease models comprising multiple 
treatment line. Extra instruction is therefore needed. This study aimed to help filling this 
gap by providing practical guidance on constructing a DES model. Specifically, it explores 
how to apply the guidelines by describing how they were actually implemented in two 
DES models, and it provides additional recommendations which may help to further 
improve the validity of full disease models. 
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bAckgRounD
Health care expenditures are increasing1 and trigger intense debate regarding the 
extent to which new developments should be publicly reimbursed with scarce (pub-
lic) resources4. Health technology assessment (HTA) examines the consequences of 
adopting or using a new technology in a transparent manner by examining clinical, 
organisational, economic and patient-related aspects6. From the beginning, HTA was 
based on evidence from randomised controlled trials186 (RCTs) which are conducted to 
establish the efficacy and safety of treatments. However, results from RCTs are often 
not generalisable to patients treated in daily clinical practice for many reasons, e.g. due 
to differences in patient characteristics and differences in the context of health care 
delivery. Therefore, there is globally an increasing interest in real-world data7,12,187. This 
thesis evaluated the added value of real-world data for health care decision makers 
regarding organisational, clinical and economic aspects of HTA using haematological 
malignancies as a case study.
In the introduction of this thesis, three research questions (RQs) have been formu-
lated;
1. What are the shortcomings of data from RCTs for health care decision makers?
2. What is the added value of real-world data for health care decision makers regarding 
A) organisational aspects of health technology assessment?
 B) clinical aspects of health technology assessment?
 C) economic aspects of health technology assessment?
3. What are the methodological challenges for using real-world data to inform health 
care decision makers?
This chapter discusses the main findings, evaluates, the impact of real-world data on 
health outcomes and describes recommendations for further research. 
RQ1 WhAT ARE ThE shoRTcomings of DATA 
fRom RcTs foR hEALTh cARE DEcision mAkERs?
RCTs aim to establish the efficacy and safety of treatments compared to placebo or 
another active treatment. To estimate efficacy most accurately, bias should be reduced 
as much as possible. Treatment is randomly assigned to ensure similarity between the 
groups for observed and unobserved patient and disease characteristics. Strict in- and 
exclusion criteria are used and the circumstances of care delivery are controlled by 
stringent treatment protocols to reduce the chances that contextual factors influence 
efficacy and safety estimates. The strict criteria and controlled circumstances increase 
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the likeliness of finding an unbiased treatment effect. For that reason, RCTs are consid-
ered the golden standard and the rigidity of RCT protocols ensure high internal validity. 
However, this also leads to severe limitations of the external validity of the information 
regarding organisational, clinical and economic aspects of HTA for health care decision 
makers. 
organisational aspects
Organisational aspects of HTA include the uptake, accessibility and utilisation of new 
treatments (see Figure 1.1, Chapter 1). RCT data are unable to provide generalisable 
insights in organisational aspects of new treatments. The uptake includes whether a 
technology is adopted by physicians in daily practice and accessibility refers to availabil-
ity for patients who may benefit from the drug. Utilisation includes how many patients 
received the drug and by which treatment regimens and in what time schedule. The 
uptake, accessibility and utilisation of a technology in daily clinical practice is, however, 
influenced by characteristics of the patient, technology and physicians, and by the con-
text of care delivery. For example, recommendations from the professional group and 
financing conditions set by the government can have a major impact on organisational 
aspects. In reverse, the same characteristics that enable a description of organisational 
aspects of HTA (e.g. the context of care delivery) are potential sources of bias for finding 
a treatment effect and are therefore eliminated in RCTs. As RCTs lack data regarding 
organisational aspects of HTA, information cannot be derived on the uptake, accessibil-
ity and utilisation in daily practice.
clinical aspects
Clinical aspects of HTA include amongst others efficacy, effectiveness and safety. RCTs 
compare a new treatment to, usually, one other treatment and aim to ensure internal 
validity. Therefore, RCTs are seen as the golden standard for demonstrating the efficacy 
of a treatment. However, the generalisability (external validity) of RCT results is ham-
pered. Due to the strict inclusion criteria, patients included in the RCT are not likely rep-
resentative for patients treated in daily clinical practice. When real-world patients are 
different, RCT data do not reflect the true effectiveness of a technology in daily practice. 
Furthermore, the efficacy of a treatment is most often not measured by overall survival 
but by using intermediate outcomes such as laboratory or biomedical end-points (e.g. 
progression-free survival). In the study described in Chapter 2 efficacy was measured 
by the proportion of patients that became transfusion independent after treatment. 
Impact on final outcomes (i.e. OS) could not be obtained due to cross-over, the small 
number of patients included and the short follow-up. Due to the aim of RCTs, follow-up 
is often limited especially for patients who discontinue treatment. As a consequence, 
impact on overall survival is often difficult to establish from RCT data. Moreover, as 
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follow-up is shorter, (rare) long-term adverse events cannot be observed187. Limited 
follow-up is especially a problem for diseases which have a large likelihood to progress 
(e.g. haematological malignancies). Furthermore, RCTs are designed to compare treat-
ments during a limited period of time and are not designed to estimate the effectiveness 
of treatment sequences including multiple lines of treatment. 
RCTs compare a new treatment to usually one and occasionally two other treatments. 
Chapter 2 and Chapter 5 illustrated that placebo and best supportive care can be the 
most relevant comparators in case there is no (other) active treatment option avail-
able. However, this is not necessarily the case and treatment in daily practice is often 
more diverse. Since the number of comparator treatments that can be included in an 
RCT is limited, the comparator in the RCT may, therefore, not reflect treatment in daily 
practice, especially when treatment developments are rapidly evolving. 
Economic aspects
Performing economic analyses, including cost-effectiveness analyses (see Figure 1.1, 
Chapter 1), is not the main goal of most RCTs. Although piggyback analyses alongside 
RCTs are conducted, most RCTs do not collect health resource use data. Because find-
ings from RCT data are not sufficiently generalisable to real-world patient populations, 
RCT data do not provide the information for studying the economic aspects of HTA. 
If the controlled circumstances from RCTs differ from treatment in daily practice, cost 
calculations based on resource use in RCTs are not representative. For example, due 
to the strict inclusion criteria, patients in RCTs may be fit and therefore have on aver-
age lower resource use (i.e. less hospital admissions) than less or unfit patients. As a 
consequence, RCT data may underestimate costs. In contrast, it is also possible that RCT 
data overestimate costs for instance due to extensive monitoring or diagnostic testing. 
Our study showed that governmental agencies are often uncertain about the costs in 
daily practice in case only RCT data are available. Chapter 2 illustrates that the ICER was 
significantly influenced by the proportion of patients receiving long-term treatment. 
It was questionable whether or not the proportion of patients that receive long-term 
treatment was generalisable to the daily practice patient population. As a consequence, 
the cost-effectiveness of the technology was highly uncertain.
In conclusion, insights in organisational, clinical and economic aspects of HTA that rep-
resent daily practice cannot be derived from RCT data. RCT data lack generalisability; 
usually focus on intermediate outcomes, and have a relatively short follow-up. The 
comparator treatment may not reflect treatment in daily practice and RCTs are not 
designed to study treatment sequences. 
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RQ2A WhAT is ThE ADDED VALuE of REAL-
WoRLD DATA REgARDing oRgAnisATionAL 
AsPEcTs of hEALTh TEchnoLogy 
AssEssmEnT?
Real-world data allow studying the uptake, accessibility and utilisation of an innovative 
treatment in daily clinical practice. Time may pass before a new drug is regularly pre-
scribed and real-world data provide insight in the uptake process. For example, Chapter 
3 revealed that it took two years before the innovative treatment was regularly pre-
scribed. Furthermore, our data showed that utilisation substantially increased after ad-
ditional financing was provided for using this treatment. This illustrates that contextual 
factors that are eliminated in RCTs have an impact on uptake and accessibility in daily 
practice. 
Uptake and accessibility at the national and regional level can be described with real-
world data. This information can be used to study whether equal access per region 
is guaranteed. In the Netherlands, different utilisation patterns between regions were 
identified which could not be explained by differences in incidence rates, guidelines or 
reimbursement188. These findings illustrate that although professional guidelines were 
available, treatment prescription in daily practice may be diverse, possibly influenced 
by organisational (most likely financial) aspects. However, it should be noted that ag-
gregated real-world data, such as the sales data used in Chapter 3, also have limitations. 
Aggregated real-world data are not able to show whether patients were appropriately 
treated because they do not describe which patients were treated. Moreover, it is not 
possible to define in which treatment line the drug was prescribed, in which regimen, 
for how many cycles and what the clinical benefit was. 
Whether the technology is used appropriately (i.e. the right patient, dosage, fre-
quency and combination regimen) is especially relevant if the drug is used for several 
indications and administration is not limited to one single patient population. Providing 
insight in appropriate use requires more detailed real-world data which can be obtained 
from a population based registry such as the PHAROS-registry20,21. This registry included 
information on patient and disease characteristics as well as detailed data on treat-
ments and resource use. Such detailed real-world data allow comparing utilisation 
in daily clinical practice to prescription in the RCT or clinical guidelines. First of all, it 
is possible to describe which patients are treated in daily practice. A treatment may 
receive approval for a subpopulation, however, patients who do not meet the criteria 
of the subpopulation may also receive the treatment in daily practice.  For example, 
maintenance therapy was licensed for patients with a response to previous therapy, 
but in daily practice maintenance was also prescribed to patients with stable disease108. 
Second, detailed real-world data provide insight in the utilisation including dosages, 
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frequencies and combination regimens. While lower dosages might be expected in case 
patients are less fit, experience with the treatment over years may also increase dosing 
or prescription for different indications. Chapter 5 illustrated that average dosages and 
total number of cycles can be similar to RCT protocol, however, that patients can receive 
the drug with shorter intervals, i.e. more frequently, in daily practice. Deviations from 
the RCT protocol in daily practice may have an impact on real-world effectiveness. 
While most new treatments are initially recommended to relapsing or refractory 
patients, over time, treatments may be recommended to newly diagnosed patients. 
For example thalidomide, lenalidomide and bortezomib, were initially prescribed as 
third-line treatment. However, these treatments were later also recommended in clini-
cal guidelines as second- or first-line treatments. Uptake of new guidelines can only be 
studied with real-world data spanning multiple lines of treatment. Furthermore, in case 
several treatments are available, a full disease model including multiple treatments per 
line and covering multiple lines of treatment becomes a necessity to determine the 
optimal treatment sequence. We investigated the uptake of innovative treatments for 
multiple myeloma in the first, second and third line148. Our results in Chapter 7, showed 
that treatment guidelines, recommending thalidomide as first-line treatment, were 
followed and the uptake of the new guideline proved to be rather rapid. This might be 
related to the fact that the treatment (thalidomide) was not a new novel treatment as 
it was previously used in subsequent treatment lines. 
In conclusion, aggregated real-world data provide insight in the uptake, utilisation and 
accessibility of health technologies in daily practice. More detailed real-world data 
are necessary to establish whether the technology is used appropriately (i.e. the right 
patients, dosage, frequency and combination regimen).
RQ2b WhAT is ThE ADDED VALuE of REAL-
WoRLD DATA REgARDing cLinicAL AsPEcTs of 
hEALTh TEchnoLogy AssEssmEnT? 
Real-world data enable to study clinical aspects of HTA including effectiveness in daily 
practice, final outcome measures,  all relevant comparators and the full disease course. 
Effectiveness
This thesis showed that effectiveness of treatments can be estimated in daily practice 
for the real-world patient population with real-world data. Real-world analyses can 
confirm that technologies are not only effective for patients included in RCTs but also 
for the patient population of interest in daily practice. That may lead to new findings. In 
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Chapter 5, real-world patients with non-Hodgkin lymphoma were generally older and 
had better response rates to the earlier chemotherapy regimens compared to the RCT 
population. Effectiveness in daily practice is not only influenced by different patient 
characteristics, the real-world utilisation, including dosing and frequencies, also influ-
ence effectiveness. 
final outcome measures
Since the follow-up of real-world data is usually much longer, real-world data provide 
insight in both intermediate and final outcome measures such as OS. Furthermore, 
longer follow-up increases the chance of revealing rare adverse events of treatments. 
However, establishing the causality of adverse events is much more complicated in daily 
practice. Especially for haematological malignancies where treatment regimens consist 
of several drugs and adverse events (e.g. anaemia) can be both an adverse event and a 
symptom of the disease189. 
comparators
All relevant comparator treatments are included in case real-world data are population 
and disease based. Incremental effectiveness of a technology can then be compared 
to the most relevant comparator. The most relevant comparator is not necessarily one 
treatment, such as in RCTs, but can be a diverse spectrum of treatments or even be 
different over time. 
Treatment sequences
In case real-world data is collected from diagnosis till death, information is included 
on all lines of therapy which provides insight in treatment sequences and their effec-
tiveness of them. For many diseases, such as in haematological malignancies, multiple 
treatment options are available. This not only facilitates establishing the effectiveness 
of a treatment, but also determining the optimal treatment order. To study the effec-
tiveness of treatment sequences, it is necessary to account for previous and subsequent 
lines of therapy.  As shown in Chapter 7 and 8, a micro level simulation model including 
multiple lines of treatment can be developed with detailed patient level real-world data 
for diseases with multiple treatment options. Such a simulation model can calculate 
intermediate (i.e. time-till-next treatment) and final outcomes (overall survival) of dif-
ferent real-world treatments over time. Furthermore, full disease models can identify 
and estimate potential health gains. Our developed micro level simulation model for 
multiple myeloma included five treatment options per line and three lines of treat-
ment148. Treatment sequence models help to identify the optimal sequence and to 
facilitate an improvement of outcomes. Chapter 7 showed that an increase in the use of 
novel agents, would improve health outcomes. 
Discussion 141
9
In conclusion, real-world data can establish effectiveness of treatments in daily practice 
for real-world patient populations. They provide insight in long-term and final outcomes 
and all relevant comparators can be included in the comparison. Furthermore, real-
world data enable to develop full disease models spanning multiple lines of treatment. 
These models provide insight in the optimal treatment sequence.
RQ2c WhAT is ThE ADDED VALuE of REAL-
WoRLD DATA REgARDing Economic AsPEcTs 
of hEALTh TEchnoLogy AssEssmEnT? 
Real-world data provide insight in the economic aspects of technologies in daily 
practice. Chapter 4 illustrates that real-world data, from hospital registration systems 
and medical files, can be used to study the costs of treatments in daily practice. Cost 
estimates based on real-world data provide generalisable insight in the costs and cost 
drivers in daily practice since they represent costs of patients who were treated under 
real-world circumstances. Real-world data enable reliable estimates of budget impact 
while identifying cost drivers may indicate potential strategies to reduce the total costs 
of specific treatment. 
Detailed real-world data including patient and disease characteristics, treatment 
prescription and resource use, as used in Chapter 5 and Chapter 7, allow simultane-
ously studying effects and costs and enable conducting real-world cost-effectiveness 
analyses. The cost-effectiveness estimates will be generalisable to patients treated in 
daily practice. Real-world cost-effectiveness analyses can be focused on one treatment 
such as in Chapter 5 where the cost-effectiveness was evaluated of one specific treat-
ment (rituximab). However, in case real-world data are collected from diagnosis till 
death, analyses can also calculate the cost-effectiveness of treatment sequences. This 
was illustrated in Chapter 7, cost-effectiveness was calculated for real-world treatment 
sequences in multiple myeloma. Furthermore, a disease model facilitates a comparison 
of the cost-effectiveness of commonly used treatment sequences. Moreover, a micro 
level simulation model enables an assessment regarding the extent to which effects 
and costs for patients would have been better in case patients had received a different 
treatment sequence. Potential health gains can be identified and the incremental cost-
effectiveness ratio can be calculated by comparing treatment strategies. 
In conclusion, real-world data not only provide insight in the real-world costs and 
cost-effectiveness of all treatments independently but also provide insight into costs 
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and cost-effectiveness of treatment sequences and insight into the optimal order of 
treatments.
RQ3 WhAT ARE ThE mEThoDoLogicAL 
chALLEngEs foR using REAL-WoRLD DATA To 
infoRm hEALTh cARE DEcision mAkERs?
Although real-world data have much added value and high potential, several challenges 
remain to exist for comprehensively studying the organisational, clinical and economic 
aspects of HTA. This thesis addressed three main methodological challenges: confound-
ing, missing data and sufficient number of patients. 
correcting for confounders
Correcting for confounders is the first main challenge. The effect of confounders is not 
eliminated in daily practice since circumstances are not strictly controlled and treatment 
is not randomly assigned as in RCTs. The population in daily practice is often far more 
heterogeneous and as a consequence, differences between the treatment and compara-
tor group may exist that hamper the internal validity of results obtained from real-world 
data113-115. For example in Chapter 5, differences observed between the characteristics 
of the patients treated with the technology of interest compared to patients treated 
with the comparative treatment regarding prior treatments and disease progression. 
This would result in bias in case effectiveness would have been directly derived from the 
difference between the two groups. Propensity score matching (PSM) and multivariate 
regression are two often used methods to correct for observed confounders187,190. 
Propensity score matching
In Chapter 5, we illustrated that PSM, can be used to control for observed differences in 
patient and disease characteristics. A propensity score is calculated based on observed 
characteristics and represents the probability that a patient would have been in the 
treatment group of interest95.  This propensity score can then be used to match patients 
that receive the treatment of interest to control patients. After matching, effectiveness 
estimates of the treatment can be retrieved from the difference between the matched 
groups. Although PSM enables a more reliable comparison between patients treated 
and the control group, it should be noted that this method also has several limitations. 
First, while randomisation ensures a balance between both observed and unobserved 
characteristics between the groups, PSM can only match patients based on observed 
characteristics. Differences can remain to exist in unobserved characteristics after 
matching (i.e. residual confounding).
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Second, there are certain requirements for using PSM. Ideally, the sample size should 
be large, the data should include many covariates and the circumstances for the two 
groups should be similar191. Similar circumstances ensure that observed differences 
between the two groups can be attributed to the treatment. However, such conditions 
are often not fulfilled for real-world data. As illustrated in Chapter 5, the number of 
patients in two groups can be limited even when real-world data were collected of 
many patients. Furthermore, including many covariates in the dataset does not nec-
essarily ensure the inclusion of many covariates in the matching. For example, when 
certain parameters cannot be retrieved from hospital registrations, they are missing 
and cannot be included in the matching. Moreover, comparing real-world effectiveness 
and utilisation implies that organisational circumstances influence outcomes and thus 
that circumstances can be different. Nevertheless, population based disease registries 
ensure that data are obtained in a similar manner and from similar sources. While PSM 
is a feasible option to correct for imbalances for analyses that compare two treatments, 
Chapter 7 and 8 showed PSM was not feasible for the calculation of the effectiveness of 
treatment sequences. PSM can compare two treatment options, however, the number 
of treatment options is much larger when several different treatment options are avail-
able in the first-, second- and third-line. In Chapter 7 for example, first-line treatment 
consists of five different regimens. Furthermore, PSM assumes that it is sufficient to 
account for the baseline characteristics. However, to study treatment sequences it is 
necessary to account for characteristics at the start of second and third-line treatment 
as well, especially since characteristics may change over time and can influence or bias 
treatment effects.
Multivariate regression 
Multivariate regression is another method to correct for confounders187. All covariates 
that potentially influence the outcome of interest can be included in the regression 
model. Chapter 8 shows that the main challenges in calculating the cost-effectiveness 
of treatment sequences are challenges including to correct effectiveness and costs for 
patient characteristics (including previous treatments), to extrapolate survival out-
comes beyond observation for a heterogeneous patient population, and to estimate the 
timing of competing events. It is possible to account for (changing) characteristics over 
time with multivariate regression models per treatment line. In Chapter 7, time to next 
treatment in the first line was estimated with a Weibull survival model including age, 
sex, WHO performance status, laboratory parameters, comorbidities, inclusion in RCT, 
and treatment. In the second-line, the Weibull survival model also included laboratory 
parameters, but these were based on values at the start of second-line treatment. Nev-
ertheless, as opposed to strictly controlled randomisation, regression models can still 
not account for unobserved variables and do not create balance between groups. This 
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is especially important in case certain characteristics are only present among patients 
who receive similar treatment since this may bias the regression coefficients. 
missing data
Missing data are the second main methodological challenge for using real-world data. 
The more variables included in the analysis, the higher the chance that the number of 
missing values is substantial. In contrast to Chapter 5, it was not possible to analyse 
complete cases only in Chapter 7. The regression models for time to next treatment in-
cluded many variables and the proportion of patients who had missing data on at least 
one of these parameters was simply too large. Multiple imputations by chained equa-
tions can be used to impute missing values accounting for the uncertainty associated 
with the imputed value120,121. Uncertainty is accounted for by imputing missing values 
multiple times where the imputed value may deviate. As a result, multiple datasets are 
available and analyses of the combined datasets produce estimates and standard errors 
that account for the uncertainty associated with the imputed values. Chapter 7 uses 
multiple imputation by chained equations and illustrates that this method can be used 
to analyse the complete dataset. However, multiple imputations assume that missing 
values are at random and can be estimated from observed variables. Since missing val-
ues are unavailable, this can never be tested. Furthermore, the complexity of analyses 
significantly increases since all analyses have to be performed on the combined dataset. 
Adequate patient numbers
The third challenge of real-world data is a limited number of patients in the control 
group and/or treatment group. In daily practice, treatment is not randomly assigned 
and the uptake of newly introduced treatments may be rapid. As a consequence, the 
number of patients in a defined control group can be limited. Data collection during a 
longer time frame allows using a historical control group and this increases the chance 
of identifying appropriate and sufficient patients who can serve as comparator. How-
ever, a historical control group should be treated under the same circumstances. As 
illustrated in Chapter 5, even when data of many real-world patients are collected and 
when uptake occurs as expected, the number of patients in both groups can be limited 
due to the moment real-world data collection started. Many of the patients in the real-
world datasets had not yet received two lines of therapy at the moment of the analyses. 
Therefore, most patients were ineligible for inclusion in this study. Continuous data 
collection of all potential necessary variables increases the chance of having sufficient 
eligible patients in a dataset for real-world data analysis. However, this may not always 
be feasible. The studies included in this thesis were performed for haematological 
malignancies where incidence and prevalence of the diseases is relatively low. Hence, 
continuous data collection is necessary to have an adequate number of patients but 
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also feasible. However, if the incidence and prevalence of diseases is much larger such 
as in colon cancer or lung cancer, data collection would be extremely time consuming 
and most likely cost-inefficiently.
Timeliness
Another challenge is timely providing relevant results for decision makers. In case the 
uptake is slow or when the follow-up is not sufficiently long, analyses can be postponed. 
However, postponing analyses may reduce the relevance of studying real-world data 
for health care decisions makers. This is especially relevant for a disease area such as 
haematological malignancies since new treatments are rapidly introduced and treat-
ments shift from later lines to first-line treatment. As a consequence, the initial research 
question may no longer be relevant. The challenge for real-world data to provide results 
in a timely matter was also highlighted in Chapter 7. Effectiveness was estimated on 
real-world treatment data; however, the moment the results were presented, guide-
lines for first-line treatment had already been revised. Consequently, the relevance of 
a comparison between real-world treatment patterns and guidelines was diminished. 
Health care decision makers are more interested in adherence to current guidelines 
than adherence to past guidelines. Furthermore, since current treatment patterns were 
most likely already changed, the identified potential health gains were less relevant. 
Providing insight in the latest treatment patterns was not possible since the number 
of patients receiving these treatments were still limited.  Providing relevant results in 
a timely manner is crucial. However, a balance needs to be established between time-
liness and relevance of the results and sufficient follow-up in order to estimate final 
outcomes and adequate numbers of treated patients.
In conclusion, using real-world data imposes several methodological challenges includ-
ing confounding, missing data and sufficient number of patients. PSM, multivariate re-
gression analysis multiple imputation are methods to overcome some of the challenges. 
Nevertheless, a sufficient number of comparable patients and timely providing results, 
remain important challenges.
imPAcT AnD PoTEnTiAL usE of REAL-WoRLD 
DATA foR hEALTh cARE DEcision mAkERs 
Real-world data provide generalisable results for organisational, economic and clinical 
aspects of HTA for health care decision makers. Although patient related aspects, such 
as quality of life were not studied in this thesis, previous studies showed that real-world 
data are also able to describe patient-related aspects192-197. Nevertheless, the impact of 
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real-world data on health care decision making and ultimately, health care outcomes, 
is less straightforward. 
According to Stryer et al.198, there is a hierarchical order where four levels of impact 
can be distinguished; i) impact on further research including research on methods, ii) 
impact on policies, iii) impact on clinical practice and, iv) impact on health care out-
comes. According to the hierarchical order, impact on health care outcomes can only be 
realised if studies have an impact on policies and clinical practice.
The real-world studies included in this thesis did have an impact on further research 
and methods. Insights were provided in areas in which scientific data were previously 
lacking. For example, while RCT data established the efficacy of treatments, the effec-
tiveness in real-world practice was unknown for rituximab, thalidomide, lenalidomide 
and bortezomib. Furthermore, methodological guidance was provided for conducting 
cost-effectiveness analysis using real-world data and constructing full disease models. 
These practical guides facilitate future research with real-world data. Finally, our results 
showed that accessibility in daily practice can best be studied using both quantitative 
and qualitative methods. 
Our studies also illustrate that real-world data influence the second level of impact 
(impact on policies). Cost estimates based on real-world data provided decision mak-
ers with representative results and, as a result, reimbursement rates (of treatment 
with stem cell transplantations) were revised based on our generated evidence. Our 
real-world cost-effectiveness studies provided policy makers and clinicians with gen-
eralisable insights in the cost-effectiveness of treatments in daily practice. However, 
the extent to which they had an impact on reimbursement decision remains to be 
seen. For most expensive drugs, including our real-world cost-effectiveness analysis of 
rituximab maintenance, a formal decision regarding continuous reimbursement has not 
been made123. Nevertheless, real-world cost-effectiveness data served as input for price 
negotiations and financial arrangements.
While our generated real-world evidence had an impact on the first two levels (i.e. 
impact on further research and policies), so far, impact on clinical practice or health care 
outcomes is negligible. Potentially, the identified major cost drivers from real-world 
studies could be used to improve the efficiency of health care delivery. However, if costs 
and effects are not studied simultaneously, it is not possible to illustrate whether reduc-
ing costs influences health outcomes. If negative influences on health outcomes cannot 
be ruled out, the impact of cost data on clinical practice remains limited. It should be 
noted that even when costs and effects are studied simultaneously, time passes before 
results from real-world data are available. During this time period, new uncertainties 
may have arisen, for example new treatment options may have become available. 
Relevant results should be provided in a timely manner to influence clinical practice and 
ultimately improve health outcomes. 
Discussion 147
9
Regarding the fourth level of impact, our real-world evidence did not yet have an impact 
on health outcomes. It should be noted that impact on health outcomes depends on 
many factors. For example, results of real-world data should be accessible (i.e. avail-
able and understandable) and acceptable (i.e. scientific, institutional appropriate and 
ethical)105. Timely access to real-world data is a major challenge especially in diseases 
where patients progress fast to new lines of therapy. In those circumstances, real-world 
analysis might soon be outdated if they are not directly available. 
An online system with direct access may help to improve accessibility and timely ac-
cess of real-world data. For example, the Dutch Institute for Clinical Auditing fortnightly 
provides physicians with benchmarked feedback, which allows physicians to compare 
their performance with national performances199. However, extreme caution is required 
regarding interpretation of results considering potential biases associated with real-
world data. Another potential use of real-world data that may improve accessibility 
and may have an impact on clinical decision making is the use of real-world data for 
validating and creating nomograms. Nomograms provide, based on patient and disease 
characteristics, individual estimates for recurrence, cancer-specific and overall survival 
and benefit of therapies200. When nomograms are easily accessible, e.g. the nomogram 
for gallbladder cancer201 or breastcancer202, they can provide a convenient structure to 
make real-world data more accessible for physicians and hence, may better facilitate 
improving health outcomes. Nevertheless further research regarding the potential of 
real-world data for nomograms is necessary. 
Future research could also investigate whether it is possible to improve acceptability 
of real-world results for policy makers and clinicians. The studies included in this thesis 
illustrated that there are several challenges associated with real-world analyses and 
these challenges may influence the acceptability of real-world results. Methods, 
including multiple imputation, propensity score matching and modelling are available 
to overcome some of the challenges. However, an insufficient number of comparable 
patients is a serious problem that cannot be resolved easily. Furthermore, real-world 
data will never reach the same level of internal validity as RCT data. Therefore, if RCT 
and real-world data show contrasting results, it is important to carefully evaluate the 
validity of the results of both sources.
This thesis used haematological malignancies as case study and therefore further 
research may be necessary to confirm conclusions. However, it should be noted that 
haematological malignancies have characteristics that are applicable to other disease 
areas. For example, treatment consist of subsequent lines with multiple treatment op-
tions available per line creating a need for a full disease model. Chapter 8 illustrated 
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that although other diseases may have different characteristics, modelling approaches 
can be more or less similar. 
concLuDing REmARks
This thesis discusses the added value of data obtained from population based, real-
world studies encompassing patients with haematological malignancies, in comparison 
with data obtained from RCTs. Although we only used real-world data on haematological 
malignancies, we believe that our findings are important and relevant for other disease 
areas in which multiple treatments are available in subsequent lines of treatment. 
Our study shows that insights in organisational, clinical and economic aspects of HTA 
that represent daily practice cannot be derived from RCT data. RCT data lack generalis-
ability, usually focus on intermediate outcomes, have difficulties detecting rare adverse 
events, the comparator treatment hardly ever reflects treatment in daily practice and 
studying treatment sequences is not possible. Real-world data provide generalisable 
results for organisational, economic and clinical aspects of HTA for health care decision 
makers. Nevertheless, using real-world data impose several challenges including cor-
recting for confounders, missing data and limited number of patients. Although there 
are methods to overcome these challenges, the impact of real-world studies on health 
care policy and outcome has been limited so far. Impact on health outcomes can only be 
realised by improving the accessibility and acceptability of real-world evidence, which is 
the main challenge for future research. 
The most valid conclusion from this thesis is that both types of data are necessary for 
HTA of new technologies for patients at large. The most important step forward is that 
(cost-)effectiveness can be analysed of treatment sequences spanning multiple lines of 
treatment.
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153Summary
inTRoDucTion
Health technology assessment (HTA) is a policy approach that examines the short- and 
long-term social consequences of the application or use of a health technology. The 
main dimensions of HTA include organisational, clinical, economic, and patient-related 
aspects. For a long time, HTA was mainly based on evidence from randomised con-
trolled trials (RCTs). However, more recently, there is growing interest in HTA based on 
real-world data. RCTs are considered the golden standard for establishing efficacy since 
they demonstrate whether the treatment works and is safe under optimal and highly 
controlled circumstances. Although RCTs ensure internal validity, the results are not 
generalisable to the context of care in daily practice (i.e. external validity). Technologies 
may not be adopted, adopted under different circumstances or applied to patients who 
do not fulfil the inclusion criteria of studies. As a consequence, results from RCTs might 
not be sufficient for making decisions in daily clinical practice. Therefore, real-world evi-
dence is increasingly requested.  Real-world data are not collected through conventional 
RCTs, but from real-world clinical practice (i.e. not under controlled circumstances). 
While findings from real-world data are of more practical value to health care decision 
makers, using real-world data also imposes methodological challenges due to the un-
controlled circumstances and absence of random treatment assignment. The evidence 
base regarding the actual added value of real-world data compared to RCTs is currently 
inconclusive. This thesis evaluates the added value of real-world evidence for health 
care decision makers using haematological diseases as case study. 
PART onE: LimiTATions of EViDEncE fRom 
RAnDomisED conTRoLLED TRiALs
chapter 2 reports on the single technology appraisal of lenalidomide, a treatment for 
patients with myelodysplastic syndromes. Evidence regarding outcomes and costs was 
primarily obtained from a randomised trial. However, with only RCT data available, 
several uncertainties remained regarding the effectiveness and costs in daily practice as 
well as long-term outcomes. The appraisal committee accepted a commitment from the 
manufacturer to publish, once available, real-world data. This was believed to provide 
reassurance regarding the value for money. 
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PART TWo: oRgAnisATionAL, cLinicAL AnD 
Economic AsPEcTs of hEALTh TEchnoLogy 
AssEssmEnT
To obtain insight in the organisational aspects of HTA, chapter 3 reports on the utilisa-
tion and accessibility of an expensive drug (i.e. bortezomib) for patients with multiple 
myeloma. The accessibility to bortezomib treatment was investigated at national and 
regional levels using real-world data (i.e. interviews and sales data from 2004-2009). 
Interviews with stakeholders revealed awareness of the high treatment costs, although 
prescription barriers were not encountered. Sales data revealed that utilisation in-
creased slowly, indicating a long adjustment period. Furthermore, utilisation remains 
below the rate estimated by the professional association of haematologists and regional 
differences were observed. Based on our results, we concluded that utilisation and ac-
cessibility can best be studied with both qualitative and quantitative real-world data. 
Providing these real-world insights can enhance evidence-based decision making and 
improve appropriate and efficient utilisation of expensive drugs.
In chapter 4, we describe how economic aspects of HTA can be studied with real-world 
data. The real-world costs for stem cell transplantations (SCTs) were calculated and ma-
jor cost drivers were identified. Real-world data were obtained from patients, treated 
at three university hospitals, who underwent an autologous (auto) SCT or allogeneic 
(allo) SCT in 2007, 2008 or 2009. Allo-SCT included sibling donors, matched unrelated 
donors (MUD) and umbilical cord blood (UCB). Resource use was collected from the 
hospital registration systems and medical files. The average total costs per patient were 
€45,670 for auto-SCT and €101,919 for sibling allo-SCT. The costs of transplantations 
from unrelated donors were much higher: €171,478 for allo-SCT-MUD and €254,689 
for allo-SCT-UCB. Hospital inpatient days together with laboratory and other activities 
were the main cost drivers across all types of SCT. Besides, donor search costs were 
a large cost component in allo-SCT-sib (18%) and allo-SCT-MUD (12%). We concluded 
that real-world costs were above routine reimbursement and appropriate financing is 
necessary to guarantee the continuation of SCT. 
Economic aspects of HTA were further addressed in chapter 5. The real-world cost-
effectiveness of rituximab maintenance compared with observation in relapsed or 
refractory follicular lymphoma patients was calculated. Data were obtained from a trial 
and from population based registries. A Markov model was developed to calculate cost 
per life year gained (LYG) and quality-adjusted life years (QALYs) for different scenarios. 
Using real-world data as well as results from long-term trial follow-up showed favourable 
incremental cost-effectiveness ratios for rituximab maintenance. Nevertheless, results 
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showed that caution is required with data synthesis, interpretation and generalisability 
of results. 
PART ThREE: PRAcTicAL guiDAncE AnD 
mEThoDoLogicAL chALLEngEs
Practical guidance on using real-world data was provided in chapter 6. This chapter 
describes the required steps necessary to perform a sound economic evaluation using 
an economic evaluation conducted with real-world data as example. Methodological 
challenges for using real-world data were identified as well and included three main is-
sues: confounding by indication, missing data, and insufficient numbers of (comparable) 
patients. If encountered, it is crucial to accurately deal with these issues to maximise 
the internal validity and generalisability of the outcomes and their value to decision 
makers. Multivariate regression modelling, propensity score matching, and data syn-
thesis are well-established methods to deal with confounding. Multiple imputation 
methods should be used in cases where data are missing at random. We concluded that 
decision makers should realise that real-world evidence provides extremely valuable 
and relevant policy information, but needs to be assessed differently compared with 
evidence derived from an RCT. 
Calculating real-world cost-effectiveness of strategies spanning multiple lines is one 
of the main potentials of real-world data. This was illustrated in chapter 7 where the 
cost-effectiveness of real-world treatment sequences for elderly patients with multiple 
myeloma were calculated. Using real-world data, a patient-level simulation model was 
designed comprising three treatment lines. The model enabled to study the impact of 
novel treatments in daily practice and revealed that utilisation of novel agents increased 
over the years. This improved survival and increased costs. Real-world treatment pat-
terns were also compared to the optimal treatment strategy. This comparison showed 
that outcomes could be improved at favourable incremental cost-effectiveness ratios.
Although models comprising multiple treatment lines are increasing in importance, ex-
perience is scarce. In chapter 8, guidance is provided in constructing a model to support 
cost-effectiveness analyses of treatment strategies spanning multiple treatment lines. 
Based on experiences with two models used in cost-effectiveness analyses of treatment 
strategies in cancer, we discuss how best practices can best be implemented. Additional 
recommendations were provided wherever best practices were unavailable or not ap-
plicable. Guidance based on hands-on experience with two models can improve the 
validity of future disease models and cost-effectiveness analyses.
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Discussion
This thesis discusses the added value of evidence obtained from real-world stud-
ies encompassing patients with haematological malignancies, in comparison with 
evidence obtained from RCTs. Our study shows that insights in organisational, clinical 
and economic aspects of HTA that represent daily practice cannot be derived from RCT 
data. Real-world data provide generalisable results for organisational, economic and 
clinical aspects of HTA for health care decision makers. Furthermore, real-world cost-
effectiveness of treatment sequences can be calculated. Nevertheless, using real-world 
data impose several challenges including correcting for confounders, missing data and 
limited number of patients. Although there are methods to overcome these challenges, 
the impact of real-world studies on health care policy and outcome has been limited so 
far. Impact on health outcomes can only be realised by improving the accessibility and 
acceptability of real-world evidence, which is the main challenge for future research. 
The most valid conclusion from this thesis is that both types of data are necessary for 
HTA of new technologies.  The most important step forward is that real-world (cost-)
effectiveness can be analysed of treatment sequences spanning multiple lines of treat-
ment.
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inTRoDucTiE
Health Technology Assessment (HTA ) is een beleidsaanpak die de korte en lange termijn 
effecten onderzoekt van het toepassen van een gezondheidstechnologie. De belangrijk-
ste onderdelen van HTA omvatten organisatorische, klinische, economische en patiënt 
gerelateerde aspecten. Oorspronkelijk was HTA voornamelijk gebaseerd op gegevens 
uit gerandomiseerde gecontroleerde studies (RCTs). RCTs laten zien of een behandeling 
effectief en veilig is onder optimale en gecontroleerde omstandigheden. Hierdoor wor-
den RCTs gezien als de gouden standaard voor het vaststellen van de effectiviteit van 
een technologie. De interne validiteit van de resultaten is groot maar dit gaat ten koste 
van de generaliseerbaarheid (externe validiteit) voor de dagelijkse praktijk. In de dage-
lijkse praktijk worden technologieën mogelijk niet geïmplementeerd, geïmplementeerd 
onder andere omstandigheden of toegepast bij patiënten met andere karakteristieken 
dan de patiënten in de RCTs. Hierdoor zijn de resultaten van RCTs mogelijk niet vol-
doende om beslissingen te nemen en neemt de vraag naar gegevens uit de dagelijkse 
praktijk toe. Deze gegevens kunnen niet verkregen worden via de traditionele RCTs. 
Hoewel resultaten uit de dagelijkse praktijk van praktische waarde zijn voor het nemen 
van beslissingen in de dagelijkse praktijk, brengt het analyseren van deze gegevens ook 
methodologische problemen mee vanwege de niet gecontroleerde omstandigheden en 
de afwezigheid van randomisatie. De daadwerkelijke toegevoegde waarde van resul-
taten uit de dagelijkse praktijk ten opzichte van gegevens uit RCTs is op dit moment 
niet eenduidig. Dit proefschrift evalueert de toegevoegde waarde van resultaten uit de 
dagelijkse praktijk voor het nemen van beslissingen in de gezondheidszorg. Hematologi-
sche ziekten worden hierbij gebruikt als casus. 
DEEL één: bEPERkingEn VAn REsuLTATEn uiT 
gERAnDomisEERDE sTuDiEs
In hoofdstuk 2 wordt de behoordeling beschreven van lenalidomide, een behandeling 
voor patiënten met myelodysplastische syndromen. De effecten en kosten waren voor-
namelijk gebaseerd op een gerandomiseerde studie. Hierdoor was er onzekerheid over 
de effectiviteit en kosten in de dagelijkse praktijk, alsmede de lange termijn uitkom-
sten. Er werd besloten de behandeling te vergoeden, maar onder de voorwaarde dat 
de fabrikant resultaten uit de dagelijkse praktijk zou verzamelen waarmee een latere 
herevaluatie mogelijk zou zijn. 
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DEEL TWEE: oRgAnisAToRischE, kLinischE 
En EconomischE AsPEcTEn VAn hEALTh 
TEchnoLogy AssEssmEnT
In hoofdstuk 3 wordt inzicht verkregen in de waarde van gegevens uit de dagelijkse 
praktijk voor de organisatorische aspecten van HTA. Het gebruik en de toegankelijkheid 
voor een duur geneesmiddel (i.e. bortezomib) voor patiënten met multiple myeloom 
is onderzocht op nationaal en regionaal niveau met behulp van interviews en verkoop-
cijfers over 2004-2009. Uit interviews bleken stakeholders op de hoogte van de hoge 
behandelkosten, maar barrières om het dure geneesmiddel voor te schrijven werden 
niet ervaren. De verkoopcijfers lieten zien dat het gebruik langzaam toenam en dit 
duidde op een lange aanpassingsperiode voordat het geneesmiddel regulier werd voor-
geschreven. Het daadwerkelijke gebruik bleef lager dan het verwachte gebruik door de 
beroepsgroep en daarnaast was het gebruik tussen de regio’s niet evenredig aan het 
aantal myeloom patiënten per regio. Op basis van de gevonden resultaten concluderen 
we dat het gebruik en de toegankelijkheid van een behandeling het beste bestudeerd 
kan worden met kwantitatieve en kwalitatieve gegevens uit de dagelijkse praktijk. Het 
bestuderen van deze gegevens kan gepast en efficiënt gebruik van dure geneesmid-
delen verbeteren. 
In hoofdstuk 4, beschrijven we hoe de economische aspecten van HTA bestudeerd 
kunnen worden met behulp van gegevens uit de klinische praktijk. De kosten van 
stamceltransplantaties (SCTs) zijn berekend en de belangrijkste kostenposten zijn 
geïdentificeerd. Gegevens uit de dagelijkse praktijk zijn verzameld uit ziekenhuis in-
formatiesystemen en medische dossiers. Patiënten uit drie universitaire ziekenhuizen 
werden geïncludeerd indien ze in 2007, 2008 of 2009 een transplantatie ondergingen 
van een autologe (auto) of allogene (allo) donor. Allo-SCTs konden SCTs van verwante 
donoren, niet verwante donoren (MUD) of navelstrengbloed (UCB) zijn. De totale kos-
ten per patiënt voor een auto-SCT waren €45,670. De kosten voor een allo-SCT van een 
verwante donor waren €101,919. De kosten van een SCT via een niet verwante donor 
of navelstrengbloed waren een stuk hoger, respectievelijk €171,478 en €254,689. Op-
namedagen in het ziekenhuis en ziekenhuisactiviteiten, zoals laboratorium bepalingen 
en beeldvormende diagnostiek, waren de grootste kosten posten bij alle type transplan-
taties. Voor de allo-SCTs van niet verwante donoren of navelstrengbloed vormden de 
kosten voor het zoeken van een donor ook een grote kostenpost, 18% bij niet verwante 
en 12% bij navelstrengbloed SCTs. Gegevens uit de dagelijkse praktijk lieten zien dat de 
daadwerkelijke kosten hoger waren dan de huidige vergoedingstarieven. 
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Economische aspecten van HTA werden ook bestudeerd in hoofdstuk 5. In dit hoofd-
stuk is de kosten-effectiviteit in de dagelijkse praktijk berekend van rituximab als on-
derhoudsbehandeling in vergelijking met geen onderhoudsbehandeling voor patiënten 
met gerecidiveerd of refractair folliculair lymfoom. Gegevens werden verkregen via 
de registratie trial en registers. Een Markov model werd ontwikkeld om de kosten te 
berekenen per gewonnen levensjaar en per voor kwaliteit gecorrigeerd levensjaar voor 
verschillende scenario’s. De incrementele kosten-effectiviteit van rituximab was gun-
stig, zowel op basis van resultaten uit de dagelijkse praktijk als op basis van langdurige 
opvolging van de patiënten in de registratie studie. Echter, de resultaten lieten ook zien 
dat we voorzichtig moeten zijn met het samenvoegen van verschillende gegevensbron-
nen, de interpretatie en de generaliseerbaarheid van verschillende scenario’s. 
DEEL DRiE: PRAkTischE AAnbEVELingEn En 
mEThoDoLogischE uiTDAgingEn  
In hoofdstuk 6 worden er praktische aanbevelingen gegeven voor het gebruik van 
klinische praktijk gegevens. Dit hoofdstuk bespreekt de noodzakelijke stappen voor het 
uitvoeren van een goede economische evaluatie en gebruikt hierbij een praktisch voor-
beeld van een economische evaluatie op basis van gegevens uit de dagelijkse praktijk. 
Er worden methodologische uitdagingen geïdentificeerd waarvan de afwezigheid van 
randomisatie, het ontbreken van gegevens, en onvoldoende vergelijkbare patiënten de 
belangrijkste drie zijn.
Het is belangrijk om deze uitdagingen op de juiste manier te adresseren om de in-
terne validiteit en generaliseerbaarheid van resultaten zo goed mogelijk te waarborgen. 
Multivariate regressie modellen, propensity score matching en het combineren van 
meerdere databronnen zijn erkende methoden om de problemen aan te pakken die 
voortvloeien uit het niet randomiseren van behandelingen. Meervoudige imputatie kan 
gebruikt worden wanneer de missende gegevens willekeurig zijn. Resultaten gebaseerd 
op gegevens uit de dagelijkse praktijk zijn zeer waardevol bij het nemen van beslis-
singen in de gezondheidszorg en bij het maken van beleid. Echter, de resultaten moeten 
wel anders beoordeeld worden dan resultaten die afkomstig zijn uit RCTs.
Eén van de belangrijkste mogelijkheden van klinische praktijk gegevens is het berekenen 
van de kosten-effectiviteit van complete behandelstrategieën die bestaan uit meerdere 
behandellijnen. Dit wordt geïllustreerd in hoofdstuk 7 waarin de kosten-effectiviteit 
wordt omschreven van behandelstrategieën in de dagelijkse praktijk voor oudere pa-
tiënten met multiple myeloom. Met behulp van gegevens uit de dagelijkse praktijk is 
een microsimulatie model gebouwd bestaande uit drie behandellijnen. Met behulp van 
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het model kan het effect van nieuwe behandel mogelijkheden in de dagelijkse praktijk 
bestudeerd worden. Daarnaast lieten klinische praktijk gegevens zien dat het gebruik 
van nieuwe behandelingen steeg over de jaren. Deze stijging verbeterde de overleving, 
maar zorgde ook voor hogere kosten. Behandelstrategieën in de dagelijkse praktijk 
werden ook vergeleken met de optimale behandelstrategie. Deze vergelijking liet zien 
dat uitkomsten in de dagelijkse praktijk verder verbeterd konden worden tegenover 
gunstige kosten-effectiviteitratio’s. 
Ondanks dat modellen voor complete behandelstrategieën steeds belangrijker wor-
den, is de ervaring op dit moment beperkt. In hoofdstuk 8 worden er aanbevelingen 
gegeven voor het construeren van een model om de kosten-effectiviteit te berekenen 
van behandelstrategieën. Op basis van twee ziektemodellen wordt er beschreven hoe 
de huidige richtlijnen geïmplementeerd kunnen worden bij het ontwikkelen van een 
ziektemodel voor behandelstrategieën. Additionele aanbevelingen voor het ontwikke-
len van een ziektemodel worden gegeven wanneer de huidige richtlijnen onvoldoende 
van toepassing zijn of houvast bieden. Deze aanbevelingen kunnen de validiteit van 
toekomstige ziektemodellen en kosten-effectiviteitsanalyses van behandelstrategieën 
verbeteren. 
DiscussiE
In dit proefschrift wordt de toegevoegde waarde van gegevens uit de dagelijkse praktijk 
omschreven op basis van studies naar hematologische ziektes. Deze studies laten zien 
dat resultaten op basis van RCTs beperkt generaliseerbaar zijn. Met gegevens uit de da-
gelijkse praktijk is het mogelijk de organisatorische, klinische en economische aspecten 
van HTA te bestuderen. Dit geeft resultaten die generaliseerbaar zijn en niet verkregen 
kunnen worden uit de reguliere RCTs.
Echter, het gebruik van klinische praktijk gegevens brengt ook uitdagingen met 
zich mee zoals het corrigeren van verstorende variabelen, missende gegevens en een 
beperkt aantal patiënten. Ondanks dat er methoden beschikbaar zijn om met deze 
uitdagingen om te gaan, is de invloed van resultaten uit de dagelijkse praktijk op het 
nemen van beslissingen in de gezondheidszorg tot nu toe beperkt. Invloed kan alleen 
gerealiseerd worden door de toegankelijkheid en acceptatie van resultaten uit de 
dagelijkse praktijk te verbeteren en dit is de belangrijkste uitdaging voor toekomstig 
onderzoek. De belangrijkste conclusie op dit moment over de waarde van gegevens 
uit de dagelijkse praktijk is dat voor HTA zowel gegevens uit RCTs als uit de dagelijkse 
praktijk noodzakelijk zijn. De belangrijkste stap voorwaarts is dat de kosten-effectiviteit 
van volledige behandelstrategieën in de dagelijkse praktijk berekend kan worden.
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Mijn proefschrift is klaar! Ik heb dit zeker niet alleen gedaan en wil graag iedereen 
bedanken voor zijn of haar bijdrage.
Een aantal mensen wil ik in het bijzonder bedanken. Allereerst mijn twee promoteren. 
Carin, vanaf de eerste dag heb je me de kans en het vertrouwen gegeven om als een 
zelfstandig onderzoeker aan de slag te gaan. Ik bewonder en waardeer jouw enorme 
enthousiasme voor het onderzoek, grote hoeveelheid kennis en optimisme. In combi-
natie met je belangstelling voor mij en de mensen om me heen, had ik me geen fijnere 
promotor kunnen wensen. 
Peter, zoals jij, is er maar één. Je bent enorm gedreven en je energie en kennis lijken 
oneindig. Wat is het fijn om daar gebruik van te mogen maken. Ik wil je bedanken voor 
alle kansen die je mij de afgelopen jaren geboden hebt en ook nu nog biedt. 
Naast mijn promotoren wil ik de commissieleden bedanken voor het lezen van mijn 
proefschrift en het opponeren tijdens de verdediging.
De artikelen uit dit proefschrift zouden niet tot stand gekomen zijn zonder coauteurs. 
Allemaal bedankt voor jullie input! Maiwenn, jou wil ik in het bijzonder bedanken voor 
de ontzettend leerzame en hele fijne samenwerking. Margreet, zonder jou had ik mis-
schien niet eens bij BMG gewerkt! Vanaf dag één ben je zo behulpzaam geweest en 
heb je altijd het beste met me voorgehad. Bedankt voor je enorme bijdrage aan de 
artikelen en de introductie en discussie van dit proefschrift. Cobi, je bent weliswaar 
geen coauteur maar wat zouden we zonder jou moeten!
Het merendeel van de hoofdstukken is gebaseerd op data uit PHAROS. Graag wil ik alle 
datamanagers, de deelnemende patiënten, de ziekenhuizen, de projectleden en andere 
betrokkenen bedanken voor hun onmisbare bijdrage. Zonder jullie zou het niet mogelijk 
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Marieke Koelink, jouw bijdrage wil ik nadrukkelijk benoemen. Bedankt voor je inzet en 
persoonlijke aandacht op het juiste moment. Het Integraal Kankercentrum Nederland 
wil ik verder graag bedanken voor de mogelijkheid om het onderzoek met real-world 
data voort te zetten. 
Heel veel uren heb ik de afgelopen jaren doorgebracht bij het iBMG. Uren die echt 
omgevlogen zijn dankzij alle fijne collega’s. Bedankt! Eén van de hoogtepunten die ik in 
het bijzonder wil noemen is onze deelname aan de Roparun van Parijs naar Rotterdam. 
Team 179! Een unieke ervaring waar ik nog heel vaak aan terugdenk. 
182 Dankwoord
Apo, Matthijs, Pieter en Tim, samen met de meiden vormen jullie voor mij een uniek 
collectief. Inhoudelijke discussies hebben we de afgelopen jaren afgewisseld met kort 
even buurten en vele feestjes op of buiten het werk, #onmisbaar! 
Lieve Laura, we hebben een hoop uren samen op de kamer doorgebracht. Ik wil je 
allereerst bedanken voor al het meedenken de afgelopen jaren. Daarnaast hebben je 
aanstekelijke vrolijkheid (de voorpret voor kerst begon altijd ruim van tevoren!) en 
razendsnelle humor ervoor gezorgd dat we de afgelopen jaren ontzettend veel gelachen 
hebben.
Lieve Igna, wat was het fijn om samen met jou aan dit promotietraject te beginnen. 
Ik heb zoveel aan je gehad en niet alleen als mede trouwe bezoeker bij de lunch of een 
andere BMG-bijeenkomst. Wanneer er iets niet lekker liep had je het altijd direct door 
en er samen over praten, vaak aan het einde van de dag, zorgde altijd voor nieuwe 
energie. Wat fijn dat je mijn paranimf wilt zijn.
Lieve Saskia, wat is het fijn om zo’n lieve vriendin iedere dag om je heen te hebben 
en een echte luxe om daar ook op zo’n prettige manier samen mee te werken. Ik ben 
enorm trots op wat we samen ontdekt en geleerd hebben. Zonder jou was ik echt niet 
tot hier gekomen en daarom ben ik erg blij dat je vandaag mijn paranimf wilt zijn.
Lieve familie en vrienden, er is door jullie allemaal altijd met zoveel belangstelling 
geïnformeerd naar dit proefschrift. Ik wil jullie allemaal bedanken voor de interesse en 
aanmoedigingen. Ik hoop dat jullie het mooi vinden.
Lieve Renske, je bent altijd belangstellend en geïnteresseerd, ook in mijn werk. Onze 
trip naar Rusland was superleuk en zo welkom na het inleveren van mijn proefschrift 
bij de kleine commissie. Lieve Maja, Anneloes en Janine, als BMG vriendinnetjes heb-
ben we de basis gelegd voor dit proefschrift maar ook voor heel veel leuke tripjes en 
etentjes. Ik vind het fijn dat we lekker over BMG onderwerpen kunnen kletsen maar nog 
leuker om met jullie feestjes te bouwen. 
Van mijn familie wil ik in het bijzonder mijn broers, zwager, schoonzussen, opa’s en 
oma’s, schoonouders en ouders bedanken. Allemaal hebben jullie altijd, met alles wat 
mij bezighoudt, enorm meegeleefd.  Echt uniek en wat fijn dat ik jullie dit nu kan laten 
zien!
Lieve broers, Arjan, wat is het fijn als jij een weekendje bij ons in Rotterdam bent. 
René, wat hebben we een fijne tijd gehad op de Blaardorpstraat tijdens onze studie en 
recent in Australië.
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Lieve Ed en Marijke, ik kan me geen fijnere schoonouders wensen. Ed, nog voordat ik 
wist wat het was, zei jij dat ik “lekker moest gaan promoveren”. Dat zou goed voor mijn 
CV zijn. Bedankt voor de tip! Graag wil ik jullie allebei bedanken voor de noodzakelijke 
ontspanning tijdens heerlijke etentjes en fijne vakanties.
Lieve pap en mam, ik wil jullie bedanken voor alle steun en interesse. Wat is het fijn om 
zulke trotse ouders te hebben die altijd achter je staan. Niets is jullie ooit teveel en ik wil 
jullie bedanken voor echt alles wat jullie voor mij doen op ieder vlak.
Allerliefste Michael, in al je bescheidenheid zal je onterecht jouw aandeel in dit proef-
schrift weten te bagatelliseren. Je heerlijke gevoel voor humor, relativeringsvermogen 
en liefde zijn voor mij echter onmisbaar, en waren dat ook bij het schrijven van mijn 
proefschrift. Ik word blij als ik aan je denk, intens gelukkig als ik bij je ben. Zonder jou 
had ik hier nooit op deze manier kunnen staan. Ik ben ontzettend blij om dit traject te 
kunnen afronden en kijk uit naar alle mooie dingen, groot en nu nog heel klein, die we 
samen (zullen) delen.
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